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Polypharmacy: Patterns And Policy Propositions 
Abstract 
Sixty percent of U.S. adults report frequent use of prescription medications, a prevalence that is higher 
than ever before. Although medications are lifesaving when used properly, they can produce side effects 
ranging from minor problems like dizziness to severe events such as an increased risk of cancer. 
Polypharmacy – a phenomenon typically defined as concurrent use of multiple medications – may 
present unique risks for medication side effects, amplifying the effects of each of the medication in a set. 
Given the growing medication use across the country, this dissertation examined the causes of 
polypharmacy and the consequences of concurrent use of medications with side effects on population 
health and health care use. The first chapter provided background information on polypharmacy and 
medication side effects. The second chapter used the National Health and Nutrition Examination Survey 
(NHANES) to investigate whether and how the introduction of Medicare Part D, a large and sudden 
change to health care financing for Medicare beneficiaries, affected medication use for older adults. 
While Part D increased the use of lifesaving medications, it also increased polypharmacy. The third 
chapter used the NHANES to show that concurrent use of three or more medications with cognitive 
impairment side effects among U.S. older adults increased three-fold in the past two decades. Individuals 
who used three or more such medications experienced increased risks of cognitive deficits compared to 
non-users. The fourth chapter used the Medical Expenditure Panel Survey (MEPS) to document a growth 
of 36% in the concurrent use of at least three medications with mental health side effects among U.S. 
adults in the past two decades. Concurrent use of these medications was associated with an increase in 
psychiatric symptoms and the use/costs of mental health services. In the fifth chapter, I discussed how 
the processes of medicalization and pharmaceuticalization contributed to rising medication use and 
disparities in such use, which in turn had implications for population-level health disparities. Collectively, 
these findings shed light on patterns and disparities in population health associated with polypharmacy 
and speak directly to the role of broader social, economic, cultural, and institutional inequalities in 
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POLYPHARMACY: PATTERNS AND POLICY PROPOSITIONS 
Duy Do 
Jason Schnittker 
Sixty percent of U.S. adults report frequent use of prescription medications, a prevalence 
that is higher than ever before. Although medications are lifesaving when used properly, 
they can produce side effects ranging from minor problems like dizziness to severe 
events such as an increased risk of cancer. Polypharmacy – a phenomenon typically 
defined as concurrent use of multiple medications – may present unique risks for 
medication side effects, amplifying the effects of each of the medication in a set. Given 
the growing medication use across the country, this dissertation examined the causes of 
polypharmacy and the consequences of concurrent use of medications with side effects 
on population health and health care use. The first chapter provided background 
information on polypharmacy and medication side effects. The second chapter used the 
National Health and Nutrition Examination Survey (NHANES) to investigate whether 
and how the introduction of Medicare Part D, a large and sudden change to health care 
financing for Medicare beneficiaries, affected medication use for older adults. While Part 
D increased the use of lifesaving medications, it also increased polypharmacy. The third 
chapter used the NHANES to show that concurrent use of three or more medications with 
cognitive impairment side effects among U.S. older adults increased three-fold in the past 
two decades. Individuals who used three or more such medications experienced increased 
risks of cognitive deficits compared to non-users. The fourth chapter used the Medical 
Expenditure Panel Survey (MEPS) to document a growth of 36% in the concurrent use of 
at least three medications with mental health side effects among U.S. adults in the past 
two decades. Concurrent use of these medications was associated with an increase in 
psychiatric symptoms and the use/costs of mental health services. In the fifth chapter, I 
discussed how the processes of medicalization and pharmaceuticalization contributed to 
rising medication use and disparities in such use, which in turn had implications for 
population-level health disparities. Collectively, these findings shed light on patterns and 
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disparities in population health associated with polypharmacy and speak directly to the 
role of broader social, economic, cultural, and institutional inequalities in generating and 
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CHAPTER 1:  
Introduction 
Polypharmacy 
Almost 60 percent of U.S. adults report frequent use of prescription medications, a 
prevalence that is higher than ever before (Kantor et al., 2015). The use of medications 
varies significantly by demographic characteristics. Adults over 65 years of age, non-
Hispanic Whites, women, and U.S. born citizens are more likely to consume prescription 
medications than their counterparts. Much of the increase in medication use between 
1999 and 2012 could be attributed to growing use of certain drug classes such as 
antihyperlipidemic agents (6.9% to 17%), antidepressants (6.8% to 13%), prescription 
proton-pump inhibitors (3.9% to 7.8%), and muscle relaxants (1.2% to 2.5%) (Kantor et 
al., 2015). The growth in popularity of these drug classes in part reflected the increasing 
availability of medications, as well as rising occurrences of disease such as high 
cholesterol (Superko et al., 2019), depression (Weinberger et al., 2018), gastroesophageal 
reflux diseases (El–Serag, 2007), and chronic pain (Nahin et al., 2019). 
 
While the use of at least one medication increased by almost 18% between 1999 and 
2012 among community-dwelling adults, the use of five or more medications increased 
by nearly 83% – a phenomenon typically referred to as polypharmacy (Kantor et al., 
2015). Although there is no scientific consensus or clinical definition for polypharmacy, 
this term is typically used interchangeably to describe multiple, concurrent, excessive, 
unnecessary, or unindicated medication consumption. A handful of studies defined 
polypharmacy as consuming at least five medications concurrently for older adults and at 
2 
 
least two medications for young adults, because researchers typically detected adverse 
effects of medications at these thresholds in various health care settings (Mortazavi et al., 
2016). Given that the prevalence of polypharmacy is likely to increase even more in the 
future, it is important to examine the causes of polypharmacy and its potential 
consequences on health. 
 
Causes of polypharmacy 
Causes of polypharmacy are multifactorial. Potential risk factors for polypharmacy 
include the rise in chronic conditions and comorbidity, failure to consider comorbidity in 
clinical practice guidelines, health care fragmentation, and the use of medications to treat 
adverse drug reactions. 
 
Chronic conditions and comorbidity. The rise in chronic conditions in the United States 
may partly explain for growing prevalence of polypharmacy. In 2010, approximately half 
of U.S. adults had at least one chronic condition1 (Ward & Schiller, 2013). When one 
condition occurs, more conditions await backstage. Therefore, among individuals with at 
any chronic conditions, half had at least two conditions (Ward & Schiller, 2013). The 
proportion of U.S. adults having multiple chronic conditions is not only high and 
alarming, but it has also been increasing over time. The prevalence of having at least two 
chronic conditions in 2001 was 21.8%, while it was 25% in 2010 (Ward & Schiller, 
 
1 Chronic conditions in the study by Ward and Schiller (2013) included hypertension, coronary heart 
disease, stroke, diabetes, cancer, arthritis, hepatitis, weak or failing kidneys, chronic obstructive pulmonary 
disease, and current asthma. 
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2013). The growth in comorbidity has also been observed across various demographic 
subgroups, such as men (19.1% to 24%), women (24.3% to 27.7%), adults aged 45-64 
(30.7% to 33.8%), adults aged 65+ (56.2% to 62.1%), and non-Hispanic Whited (23.4% 
to 28.1%) (Ward & Schiller, 2013). An increase in comorbidity, combined with rapid 
pharmaceutical advancements and an overconfidence in medicine as a solution to disease, 
may have given rise to polypharmacy.  
 
Failure to consider comorbidity in clinical practice guidelines. Clinical practice 
guidelines help manage chronic conditions. However, most guidelines only address a 
single disease outcome in accordance with modern medicine’s practice and fail to 
acknowledge the presence of comorbidity, especially among older patients. Take an 
example of a hypothetical patient that has hypertension, diabetes mellitus, osteoporosis, 
osteoarthritis, and chronic obstructive pulmonary disease. Strict adherence to the national 
guidelines for these conditions easily results in 12 prescriptions that require 19 doses 
taken five times per day (Boyd et al., 2005). Under the recent pay-for-performance 
initiative in the health care system, which rewards physicians who follow interventions 
that reflect national clinical guidelines, one should expect that polypharmacy may 
increase as a result. 
 
Health care fragmentation. Medical care delivery in the U.S. often involves multiple 
providers and organizations, without a single entity that effectively coordinates all 
aspects of care (Elhauge, 2010). Although the ideal physician-to-patient ratio is one, 
many patients may see several physicians to manage the same medical condition (Cebul 
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et al., 2008). Marked variation in physicians’ practice styles may contribute to various 
treatment plans for patients. It has been well-established that health care delivery varies 
across small geographical areas, or even within the same hospital or health care system 
(Keating et al., 2006; Zhang et al., 2012). Cutler, Skinner, Stern, & Wennberg (2019) 
found that although patients’ characteristics and preferences fail to explain for the 
geographical variation in end-of-life care delivery, 35% of the variation is explained by 
physician beliefs. Similarly, Zhang, Baicker, & Newhouse (2010) found a substantial 
variation in the quality of prescribing – defined as prescribing medications that are 
potentially high-risk for older adults – among local hospital markets even after 
controlling for patients’ characteristics. The lack of care coordination across providers 
who have different beliefs, training, and knowledge about a patient’s medical history may 
result in polypharmacy and adverse outcomes associated with polypharmacy. In fact, Col, 
Fanale, & Kronholm (1990) found that the number of physicians seen regularly is 
positively associated with the likelihood of being admitted to hospital for drug-related 
illnesses.  
 
Adverse drug reactions. All medications have adverse side effects. Although 
pharmaceutical therapies are typically lifesaving when used correctly, consuming a 
medication that has adverse side effects may lead to the onset of another condition for 
which the medication was not intended. Symptoms that are due to adverse drug reactions 
are often mistakenly diagnosed as a new disease. As a result, 80% of drug adverse 




Consequences of polypharmacy 
Although medications are critical for disease management and prevention, growing 
concerns have emphasized the consequences of polypharmacy on adverse drug reactions, 
drug-drug interactions, medication nonadherence, and excessive medical interventions 
that do more harm than good for patients’ health. Previous studies have documented 
adverse medical outcomes of polypharmacy on health in various settings. Among 
outpatients of all ages, using at least five medications is associated with an increase of 
88% in experiencing adverse drug events (Bourgeois et al., 2010). For nursing home 
residents, the bar is higher. Using at least nine medications is associated with an 
increased risk of adverse drug reactions by 2.33 times (Nguyen et al., 2006). Concurrent 
use of medications can also lead to drug-drug interactions when the effectiveness or 
toxicity of a medication is altered by the other. Lindblad et al. (2005) found that the risk 
drug-drug interaction increased 4 times and 9 times among elderly veterans who 
consumed 5-8 medications and at least 9 medications simultaneously, compared to 
nonusers. Polypharmacy also has direct impacts on health: those who consumed at least 
five medications are more likely to experience cognitive impairment and falls, and these 
associations have been observed across all age groups (Huang et al., 2010; Jyrkkä et al., 
2011; Kool et al., 2012). Adverse medical outcomes associated with polypharmacy may 






Causes of polypharmacy. While a handful of previous studies has documented medical 
outcomes associated with polypharmacy, we know little about causes of this 
phenomenon. Even though the current literature has suggested some potential causes of 
polypharmacy – such as the rise in chronic conditions and comorbidity, failure to address 
comorbidity in clinical practice guidelines, health care fragmentation, and adverse drug 
reactions – many of these causes are suggestive and they lack adequate empirical 
evidence. Moreover, there are other causes that have not been frequently discussed in the 
literature, such as the role of health insurance expansion and increased access to medical 
services. From the late 1990s until the mid-2010s, the U.S. health care system witnessed 
multiple significant health care expansions. Examples include the Children’s Health 
Insurance Program (CHIP) in 1997 that expanded Medicaid to cover uninsured low-
income children; the Medicare Prescription Drug, Improvement and Modernization Act 
of 2003 that, for the first time, covered outpatient prescription medications for Medicare 
beneficiaries; and most recently the Affordable Care Act that allowed young adults under 
the age of 26 to remain as dependents on their parents’ insurance plans and expanded 
Medicaid eligibility to cover more than 15.5 million uninsured low-income adults (Gates 
et al., 2016). Although these expansions significantly eliminated financial burdens and 
provided access to medical treatments that were otherwise unaffordable to some of the 
most vulnerable segments of population (Committee on Child Health Financing, 2014; 
Engelhardt & Gruber, 2011; Mazurenko et al., 2018), little is known about their 




Consequences of polypharmacy. Although the literature on adverse consequences of 
polypharmacy is relatively more extensive than that of the causes of polypharmacy, 
further investigation of this topic is warranted due to two main reasons. First, studies that 
investigated the consequences of polypharmacy on health and health care utilization 
failed to address a possibility that not all medications result in adverse reactions, even 
when consumed in a set. It is possible that some groups of medications are more harmful 
when combined with others. For example, Qato, Ozenberger, & Olfson (2018) provided 
evidence that concurrent consumption of multiple medications with depression as a 
potential side effect was significantly associated with an increased risk of depressive 
symptoms. The authors also found a dose-response relationship, such that the association 
increased for every additional medication consumed that has depression as a potential 
side effect. In contrast, using medications without known depression side effect was not 
harmful to mental health, even when consuming multiple simultaneously. As such, 
policies that aim to address polypharmacy should target the simultaneous use of multiple 
medications with serious side effects, instead of reducing the use of all medications. It is 
possible that medications without side effects are indeed beneficial for disease 
management, and that reducing the use of these medications may be harmful to patients. 
 
Second, the literature on polypharmacy typically focuses on older adults because they are 
at higher risks of adverse drug reactions due to biological and medical reasons, such as 
decreases in hepatic metabolism and renal clearance (Leon, 2011; Shi & Klotz, 2011), the 
presence of comorbidity (Ward & Schiller, 2013), and the use of multiple medications 
simultaneously (Kantor et al., 2015). Regardless, the consequences of polypharmacy 
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among young adults are also of important policy and clinical concerns. For young and 
healthy adults, the selection into using multiple medications simultaneously may be 
attributed to the early onset of chronic conditions that can be more debilitating to health 
than those that occur at older ages. Moreover, the threshold at which polypharmacy 
results in negative consequences for young adults may be even lower than that for older 
adults. Huang et al. (2010) found that using four to five medications simultaneously 
increased the risk of falls among young adults with diabetes compared to those using one 
or no medications. For older adults with diabetes, the authors did not observe a 
significant relationship between polypharmacy and falls until patients consumed six to 
seven medications. From an economic perspective, experiencing adverse effects of 
medications at young ages not only have cumulative effects on health, but also on 
productivity, human capital, and income throughout the lifetime. While the prevalence of 
polypharmacy among young adults is much lower than that among older adults (3.1% vs. 
39% in 2011-2012), the significantly increasing trend in polypharmacy over time among 
young adults prompts further investigation into this population (Kantor et al., 2015).  
 
Given the limitations in the literature, this dissertation aims to address the following 
questions: 
Chapter 2:  
• What is the impact of expanding the Medicare Part D prescription medication 
insurance on polypharmacy among older adults? 
• Did polypharmacy increase significantly more for some socio-demographic sub-




• What are the trends in the using medications with cognitive impairment side 
effects from 1999 to 2016 among adults aged 60 and older? 
• What is the relationship between cognitive function and concurrent use of 
medications with and without cognitive side effects for older adults? 
• Does the relationship vary by subgroups? 
Chapter 4: 
• What are the trends in using medications that have insomnia, depression, suicide, 
and anxiety as potential side effects among U.S. adults? 
• What is the association between concurrent use of medications with and without 
these side effects and nonspecific psychological distress, as well as utilization and 
costs of mental health services? 
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The Impact of Medicare Part D on Polypharmacy 
 
Objective: To investigate whether and how the introduction of Medicare Part D 
increased polypharmacy – the concurrent use of five or more medications – among older 
adults. 
Data source: Nationally representative sample of adults aged 55-74 from the National 
Health and Nutrition Examination Survey (NHANES) in 1999-2016 without public 
health insurance. 
Study design: I used a difference-in-differences approach to compare medication use and 
polypharmacy between Medicare eligible adults (aged 65-74) and Medicare ineligible 
adults (aged 55-64) before and after Part D was introduced in 2006, while controlling for 
socio-demographic characteristics, health insurance coverage, health conditions, and 
secular trends. 
Principal findings: Among Medicare-ineligible respondents (aged 55-64), the number of 
prescription medications consumed was not significantly different before and after Part D 
took effect (2.30 medications and 16.6% for polypharmacy before 2006 vs. 2.36 
medications and 16.1% for polypharmacy after 2006). In contrast, prescription 
medication use increased considerably among Medicare-eligible respondents (aged 65-
74) after Part D (3.24 medications and 26.6% for polypharmacy before 2006 vs. 3.77 
medications and 32.4% for polypharmacy after 2006). The implementation of Part D was 
associated with an increase in the odds of polypharmacy by 1.57 times (p < 0.01). In 
multiple sensitivity and placebo analyses, Part D did not have any effects on the use of 
dietary supplements or poly-supplementation (the concurrent use of five or more dietary 
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supplements), which were not covered under standard Part D plans. In addition, Part D 
did not alter the use of prescription medications among publicly insured respondents who 
already received some prescription medication benefits prior to Part D. The results were 
also robust to the unobserved impacts of the Great Recession and different definitions of 
medication use and polypharmacy. 
Conclusion: Although prescription medications are lifesaving when used properly, using 
five or more medications simultaneously has been linked to adverse medical outcomes 
for older adults, including mortality, drug-drug interactions, adverse drug events, medical 
nonadherence, falls, and cognitive impairment. While the benefits of gaining access to 
life-saving prescription medications as a result of Medicare Part D may outweigh the 
unintended effects of polypharmacy, efforts that focus on addressing the adverse effects 
of polypharmacy may generate additional health benefits for Medicare beneficiaries. 
Using Medicare Part D as a case study, I demonstrated that other health insurance 
program expansions might have similar effects on polypharmacy (i.e. the Medicaid 












Understanding the effects of health insurance on health and health behavior is a central 
question in every debate on the U.S. health care reform. On the one hand, health 
insurance may improve health by improving access to medical services and financial 
security (Currie & Gruber, 1996; Engelhardt & Gruber, 2011; Goldin et al., 2019; 
Hanratty, 1996; F. Lichtenberg, 2002). On the other hand, receiving additional medical 
care as a result of gaining health insurance may provide few clinical benefits at the 
margin (Baicker et al., 2013; Brook et al., 1983). One of the most heated public policy 
debates in recent U.S. presidential elections is whether a Medicare-for-all initiative 
improves the well-being of Americans. Since its inception, Medicare is a national health 
insurance program that primarily provides coverage to Americans aged 65 and older, 
young adults with disability, and individuals with end-stage renal disease. The original 
Medicare program covered most medical expenditures, such as hospital and doctor costs, 
but it excluded prescription medications. Public concern about rising medication prices 
and the potential consequences of medication unaffordability on health of older adults in 
the U.S. drove efforts to provide prescription medication coverage to Medicare 
beneficiaries. This resulted in the introduction of Medicare Part D in January 2006, which 
for the first time expanded the Medicare program to include coverage for outpatient 
medications. 
 
The current paper revisits the implementation of Part D and examines its effects around a 
previously understudied margin: whether and how the program resulted in polypharmacy 
– the use of five or more medications simultaneously – among older adults. Although 
18 
 
there is no scientific consensus or clinical definition for polypharmacy, this term is 
typically used interchangeably to describe multiple, concurrent, excessive, unnecessary, 
or unindicated medication consumption (Mortazavi et al., 2016). Previous research has 
shown that expanding prescription medication coverage under Part D increased access to 
lifesaving medications that were otherwise unaffordable to older adults (Ayyagari & 
Shane, 2015; Engelhardt & Gruber, 2011; Ghosh et al., 2019), but coverage expansion 
might also increase the risk of polypharmacy, which has more ambiguous effects on 
health. Prior studies have documented the negative health consequences of polypharmacy 
for older adults, including adverse drug events, drug-drug interactions, medication 
nonadherence, falls, and cognitive impairment (Bourgeois et al., 2010; Hovstadius & 
Petersson, 2013; Huang et al., 2010; Jyrkkä et al., 2011; Lindblad et al., 2005; Maher et 
al., 2014; Marcum & Gellad, 2012; Sergi et al., 2011). The causes of polypharmacy are 
multifactorial. Potential risk factors for polypharmacy include the rise in chronic 
conditions and comorbidity (Ward & Schiller, 2013), failure to consider comorbidity in 
clinical practice guidelines (Boyd et al., 2005), and visiting multiple physicians or filling 
medications at multiple pharmacies (Col et al., 1990). Regardless, little is known about 
the role of health insurance expansion in the rising prevalence of polypharmacy. 
 
I add to the existing literature by using the introduction of Medicare Part D in 2006, a 
large and sudden change to health care financing for Medicare beneficiaries, to study the 
relationship between health insurance expansion and polypharmacy. Part D benefits are 
provided by private stand-alone prescription medication plans or Medicare Advantage 
plans that offer both prescription medication and health care coverage. Although benefits 
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varied across plans, beneficiaries were typically entitled to the following coverage for 
prescription medication in 2006: no coverage for the first $250 in medication spending 
each year, coverage of 75% of the next $2,250, no coverage for the next $3,600, then 
coverage of 95% of costs above $5,100. Before Part D, Medicare beneficiaries had access 
to prescription medication coverage through employer-sponsored retirement health 
benefits, Medicare managed care plans, or through dual eligibility with Medicaid or other 
public insurance programs. Only two-thirds of Medicare enrollees had prescription drug 
coverage (Safran et al., 2005; Schneeweiss et al., 2009). While enrollment in Part D was 
voluntary, any Medicare beneficiaries who enrolled in the program after May 15, 2016 
were subjected to a financial penalty to alleviate adverse selection into the program. In 
the first year after Part D took effect, 67% of Medicare beneficiaries without prescription 
medication insurance gained coverage through a stand-alone prescription medication 
plan, a Medicare Advantage plan, or through their current employer’s plan provided that 
the benefits were as generous as those of standard Part D plans (Levy & Weir, 2009). 
Before Part D, 90% of Medicare beneficiaries reported taking prescription medication 
and almost half of them used five or more medications concurrently (Safran et al., 2005). 
Given a high prevalence of medication use, 30% of Medicare enrollees spent over $100 
per month on prescription medications in 2003 (Safran et al., 2005). Out-of-pocket 
medication expenditures also increased with age: individuals aged 50-64 paid on average 
$237 annually for prescription medication in 1998 while those aged 65-79 paid $456 and 




Prior research found a modest reduction in out-of-pocket medication spending as a result 
of gaining Part D benefits (Khan & Kaestner, 2009; Lichtenberg & Sun, 2007; Yin et al., 
2008). The cost reduction mainly concentrated among high-spending beneficiaries who 
often required long-term pharmaceutical therapies (Engelhardt & Gruber, 2011). Other 
studies demonstrated that Part D increased the consumption of prescription medications 
(Kaestner & Nasreen Khan, 2012), improved mental health (Ayyagari & Shane, 2015), 
reduced hospitalization and emergency department visits (Afendulis et al., 2011; 
Ayyagari et al., 2017), and reduced medication nonadherence (Madden et al., 2008). 
However, little is known about whether increased access to prescription medications 
under Medicare Part D gave rise to polypharmacy. While prescription medications are 
lifesaving when used properly, polypharmacy may increase the risk of adverse medical 
outcomes and medical costs associated with these outcomes (Sergi et al., 2011). To the 
extent that the results are generalizable to other health insurance programs, this paper 
speaks directly to the potentially unintended impact of health insurance expansion on 




I used the 1999-2016 National Health and Nutrition Examination Survey (NHANES), a 
nationally representative two-year cycle survey of the civilian noninstitutionalized U.S. 
population. NHANES was obtained using a multistage probability sampling design to 
represent the general population but with an oversampling of Black, Hispanic, and adults 
aged 60 and older. The average non-response rate was 22%. All analyses used survey 
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weight to produce nationally representative estimates and to avoid non-response bias. I 
removed respondents interviewed in 2005-2006 because this survey cycle overlapped 
with the introduction of Medicare Part D in January 2006. I also dropped respondents 
interviewed in the 2013-2014 and 2015-2016 survey cycles to avoid spillover effect of 
the Medicaid expansion in 2014 onto the analysis. Previous studies suggested that the 
Medicaid expansion in 2014 influenced physicians’ prescribing practice and medication 
use (Ghosh et al., 2019; Saloner et al., 2018). Since many physicians treat both Medicaid 
and non-Medicaid patients, changes in prescribing practice as a result of Medicaid 
expansion may have a spillover effect to Medicare beneficiaries. I selected respondents 
aged 55 to 74 because their ages were close to the Medicare’s age eligibility of 65 (N = 
9,319). I classified respondents into two distinct groups based on the likelihood that the 
introduction of Part D affected their prescription drug coverage. Medicare eligible 
respondents aged 65-74 qualified for Medicare Part D at the time of the survey interview, 
while ineligible respondents aged 55-64 did not qualify. I excluded respondents aged 55-
64 who received Medicare benefits (N = 529) and respondents who had public health 
insurance – including Medicaid, military insurance, Indian health service programs, 
Children's Health Insurance Program, and other state-sponsored or government health 
plans (N = 1,464). The former mainly consisted of individuals with disability whose 
unobservable characteristics might be different from those of their peers. The latter 
included individuals with public insurance who already received some prescription drug 
coverage before Part D. I excluded respondents who had missing information on 
medication use and control covariates (N = 1,271). I imputed missing data for control 
covariates using multiple imputation with chained equations, but the results were similar 
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to when not using imputation. As such, the results were restricted to a final sample of 
6,055 respondents without missing data. 
 
Prescription medications were collected during the prescription medication interviews. 
Interviewers asked respondents to show the containers of all prescription medications 
they had taken in the past 30 days. Respondents who could not show a container were 
asked to verbally report the medication’s name. When interviewers entered the 
medication names into a computer, more than 95% of entries resulted in exact or similar 
matches with an existing drug. The drug database used for the match was obtained from 
Lexicon Plus, a proprietary database of Cerner Multum that provided, on an annual basis, 
a comprehensive list of all prescription and some non-prescription medications available 
in the U.S. market. Using reported use of medications in the past month, I constructed 
two main outcomes: the number of medications used last month, and whether a 
respondent used at least five medications last month (polypharmacy). 
 
Covariates in this paper included demographic characteristics, health insurance, income, 
and health conditions. Demographic covariates were age, age squared, race (non-
Hispanic Whites: reference category, non-Hispanic Blacks, non-Hispanic others, 
Hispanic), gender, marital status (married or cohabiting: reference category, 
widowed/divorced/separated, never married), education (less than high school graduate: 
reference category, high school graduate, some college, college graduate or above), and 
nativity/citizenship status (U.S. citizen born in the U.S. or its territories: reference 
category, U.S. citizen born abroad, not a citizen). Health insurance covariate indicated 
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whether a person had any type of health insurance. Income covariates included household 
poverty level as a series of dummy variables (less than 100%: reference category, 100-
199%, 200-299%, 300-399%, 400-499%, 500% or more). Health covariates included the 
number of chronic conditions (none: reference category, one or two, three or more 
conditions), whether a person was overweight or obese (BMI of at least 25), and self-
reported health status (excellent: reference category, very good, good, fair, poor). Chronic 
conditions in this study included a series of self-reported diagnoses of asthma, arthritis, 
cancer, congestive health failure, coronary heart disease, heart attack, angina, 
emphysema, bronchitis, stroke, hypertension, and diabetes. 
 
I assessed the impact of Medicare Part D on medication use using a difference-in-
differences approach:  
 
RxUseit = α0 + α1Eligibleit*Post2006it + α2Eligibleit + α3Post2006it + α4Xit + ɛit 
 
where RxUseit was either the number of prescription medications consumed in the last 30 
days by person i at time t, or whether the person used at least five medications in the last 
30 days (polypharmacy). Eligibleit took the value of 1 if the person qualified for Medicare 
(ages 65-74), and 0 if the person was 55-64 years of age. Post2006it indicated if the 
person was interviewed after Part D took effect. Eligibleit*Post2006it is the variable of 
interest, and α1 reflected the reduced-form effect of Part D on medication use. Xit 
included a set of demographic characteristics, health insurance, income, and health 
covariates, as described earlier. I controlled for time trends in the outcomes by including 
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the year fixed effect. The main assumption of the difference-in-differences method, 
referred to as the parallel assumption, is that any differences in medication use between 
Medicare eligible and ineligible adults are constant over time prior to Part D. This 
assumption is empirically tested and presented in the result section.  
 
I conducted multiple additional sensitivity analyses. First, I assessed the impact of Part D 
on the number of dietary supplements consumed and whether a respondent used at least 
five supplements (“poly-supplementation” hereafter) last month. Part D did not subsidize 
dietary supplements, thus there should be no impact of Part D on such use. Similar to the 
prescription medications interview section, respondents reported all dietary supplements2 
and non-prescription antacids3 that they consumed in the past 30 days. Second, I 
investigated whether Part D affected the use of prescription medication for publicly 
insured individuals. Most public insurance programs provided their beneficiaries with 
some prescription medication benefits prior to Part D. Therefore, there should be no 
impact of Part D on medication use among the publicly insured population (Basu et al., 
2010; Millett et al., 2010). Third, I included in the analysis survey cycles from 2013 to 
2016 that were previously removed because they overlapped with the Medicaid 
 
2 Dietary supplements included vitamins or minerals (i.e. Calcium, Vitamin C, Calcium and Iron, Vitamin 
E, Magnesium, Zinc, Calcium plus Vitamin D), multi-vitamins or multi-minerals (i.e. Flintstones, One a 
Day, Prenatals, Tri-Vi-Flor, B-Complex, Centrum), herbs and botanicals (i.e. Echinacea, garlic, Saw 
Palmetto, Ginkgo, Ginseng), fiber (i.e. Metamucil, Fibercon, Benefiber), amino acids (i.e. Lysine, 
Methionine, Tryptophan), and others (i.e. fish oil, Chondrotin, Glucosamine). 




expansion in 2014. Fourth, the post-Part-D period coincided with the recession from 
2007 to 2009, which might have affected Medicare eligible and ineligible respondents in 
systematic ways. While Medicare eligible adults were relatively insulated from the 
recession due to their access to Social Security benefits, Medicare ineligible adults were 
heavily affected by unemployment and the loss of private health insurance associated 
with their jobs. The lack of health insurance in turn affected medication use among 
Medicare ineligible adults. To address this possibility, I propose two sets of sensitivity 
analyses, including (1) removing survey cycles in 2007-2008 and 2009-2010 that 
overlapped with the recession and (2) excluding all uninsured individuals who might 
have lost health insurance due to the recession. The interpretation of the results should be 
similar to that of the main analysis if the use of medication was not driven by unobserved 
heterogeneity during the recession. Fifth, I propose a stricter definition of polypharmacy. 
In previous analyses, I counted all prescription medications that a person used in the past 
month. Nevertheless, although a respondent reported taking at least five medications last 
month, the simultaneous consumption of these medications might not have occurred 
daily, as the definition of polypharmacy implies. I reconstructed the outcome variables 
and only included prescription medications that a person consumed every day in the last 
month and repeated the analysis in equation (1). I also repeated the same analysis for 
daily use of dietary supplements. Finally, I relaxed the numerical threshold of 
polypharmacy. While there is no clinical definition of polypharmacy, previous studies 
typically defined polypharmacy as concurrent use of five or more medications. In a set of 
sensitivity analyses, I created ten outcome variables, ranging from whether a respondent 
used at least one prescription medication in the last month to whether a respondent used 
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Figure 1 presents the gender and age adjusted average number of outpatient prescription 
medications (Panel A) and dietary supplements (Panel B) consumed by Medicare eligible 
and ineligible adults from 1999 to 2016. Prior to Part D, Medicare eligible adults 
consumed more prescription medications than ineligible adults (Panel A). Regardless, the 
difference in medication consumption of two groups was relatively constant over time 
before Part D. After Part D took effect, prescription medication use increased 
significantly among Medicare eligible adults, although it leveled off and declined during 
the 2007-2009 recession. In contrast, the trend in prescription medication use among 
Medicare ineligible adults was relatively stable after Part D took effect. Medication use 
slightly declined during the recession for the ineligible group, possibly because they were 
affected by unemployment and the loss of health insurance during this period. In Panel B, 
the use of dietary supplements was not significantly different between Medicare eligible 
and ineligible adults in all survey cycles. There was no evidence that Part D affected the 
use of dietary supplements for Medicare eligible adults, mainly because Part D did not 
subsidize dietary supplements.  
 
-Insert Figure 1 About Here- 
 
Figure 2 demonstrates the gender and age adjusted prevalence of polypharmacy (Panel A) 
and poly-supplementation (Panel B). The results mirror those observed in Figure 1. In 
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Panel A, the prevalence of polypharmacy was relatively parallel between two groups 
before 2006, then diverged after Part D took effect. In contrast, Part D did not have any 
effect on poly-supplementation (Panel B). 
 
-Insert Figure 2 About Here- 
 
Table 1 compares descriptive statistics of medication use and control variables between 
Medicare eligible and ineligible respondents, before and after Part D. Among ineligible 
respondents (aged 55-64), prescription medications consumed was not significantly 
different before and after Part D (2.30 medications and 16.6% for polypharmacy before 
2006 vs. 2.36 medications and 16.1% for polypharmacy after 2006). In contrast, 
prescription medication use increased considerably among eligible respondents (aged 65-
74) after Part D (3.24 medications and 26.6% for polypharmacy before 2006 vs. 3.77 
medications and 32.4% for polypharmacy after 2006). In contrast, the use of dietary 
supplements among Medicare eligible and ineligible adults remained relatively 
unchanged before and after Part D.  
 
Overall, Medicare ineligible respondents tend to be more racially and ethnically diverse, 
less likely to be female, more likely to be married, are more educated, less likely to have 
been born in the U.S., less likely to have health insurance, have higher household income, 
have fewer chronic conditions, less likely to be overweight or obese, and more likely to 
report excellent or very good health than Medicare eligible respondents. This is 
potentially due to the cohort effect and mortality selection in older ages. Regardless, I did 
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not detect any significant differences between Medicare eligible and ineligible 
respondents before and after Part D for all control variables after controlling for age.  
 
-Insert Table 1 About Here- 
 
Panel A of Table 2 presents difference-in-difference results for the impact of Part D on 
medication use and polypharmacy. In the unadjusted model 1, being eligible for Part D 
after the program took effect resulted in an increase of 0.467 medications used in the last 
30 days, compared to Medicare ineligible adults before and after Part D and Medicare 
eligible adults before Part D (p<0.05). Adjusted for socio-demographic characteristics, 
health insurance, income, health conditions, and time trends (model 5) did not 
significantly alter the impact of Part D on medication use (coefficient = 0.460, p < 0.01). 
I observed similar patterns for polypharmacy. Medicare Part D resulted in an increase of 
1.368 times the odds of polypharmacy in the past month (p < 0.05, model 1). Adjusting 
for all covariates in model 5 increased the estimate (OR = 1.572, p < 0.01), although two 
estimates were not significantly different from one another. 
 
In Panel B of Table 2, I presented the difference-in-differences results with year fixed-
effect interactions. Results in models 1 to 5 indicate that the number of medications used 
did not increase until 2007 after Part D was introduced. There were no statistically 
significant differences in medication use between eligible and ineligible respondents 
before 2006, implying that the parallel assumption for the difference-in-difference model 
was valid. Any changes in medication use in 2006 onward were potentially due to the 
introduction of Part D. The results for polypharmacy were quite similar. However, the 
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difference-in-difference models with year fixed-effect did not detect significant 
differences in polypharmacy between Medicare eligible and ineligible adults in each year, 
both before and after the implementation of Part D. Regardless, when pooling all years 
before and after Part D, I detected an increase in polypharmacy as a result of the program 
implementation. 
 
-Insert Table 2 About Here- 
 
Figures 3 to 11 present the heterogeneous effects of Part D on polypharmacy by 
race/ethnicity, gender, marital status, educational attainment, nativity and citizenship 
status, household income, comorbidity, obesity status, and self-reported health status. 
Overall, the effect of Part D on polypharmacy was particularly large for subgroups that 
had limited access to prescription drug insurance prior to Part D. The introduction of Part 
D was associated with an increase in polypharmacy for non-Hispanic Whites, non-
Hispanic Blacks, and Hispanic respondents (Figure 3). Regardless, the effect of Part D 
was larger for non-Hispanic Black and Hispanic respondents compared to that of non-
Hispanic Whites, potentially because racial/ethnic minorities were less likely to have 
access to prescription medication insurance prior to Part D, such as employer-sponsored 
coverage or Medicare Advantage plans (Briesacher et al., 2003). Similarly, married and 
widowed/divorced/separated respondents were more likely to experience polypharmacy 
than their non-married peers as a result of Part D (Figure 5), in part because they were 
less likely to have prescription medication insurance prior to Part D (Poisal et al., 1999). I 
found that the effects of Part D on polypharmacy were particularly large and statistically 
significant among respondents who were college educated (Figure 6), native-born 
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citizens (Figure 7), and middle-class (Figure 8), compared to their peers. While high-
income respondents may purchase private prescription medication insurance and non-
college-educated individuals, naturalized citizens, migrants, and low-income respondents 
may qualify for government programs that help pay for prescription medication costs 
such as Medicaid or Low-Income Subsidy4 (Stuart et al., 2012), college educated, native-
born, and middle-class respondents typically did not qualify for low-income government 
programs before Part D. This lack of coverage in part explained why gaining Part D 
benefits had a particularly large impact on polypharmacy among college educated, 
native-born, and middle-class respondents. Finally, respondents who had at least three 
chronic conditions (Figure 9), who were not obese (Figure 10), and who reported 
excellent or very good health (Figure 11) were more likely to experience polypharmacy 
due to the implementation of Part D. Respondents who were obese or who reported poor 
or fair health often required extensive pharmaceutical treatments and had high out-of-
pocket medication expenditures (Jackson et al., 2004; Kit et al., 2012, pp. 2005–2008), 
and might have already had prescription medication coverage through public insurance or 
the Low-Income Subsidy program before Part D, which explained why Part D did not 
significantly affect their prevalence of polypharmacy.  
 
-Insert Figures 3 to 11 About Here- 
 
 
4 Although I excluded respondents with public health insurance because they already had some prescription 
medication benefits prior to Part D, I wasn’t able exclude respondents who received other forms of 




I conducted multiple additional sensitivity analyses. First, I assessed the impact of Part D 
on the use of dietary supplements and poly-supplementation. Since Medicare did not 
cover non-prescription medications, there should be no impact of Part D on the use of 
dietary supplements. In Table 3, results from unadjusted and adjust models indicated that 
there was no impact of Medicare Part D on the number of dietary supplements used and 
poly-supplementation. This sensitivity analysis reinforced my findings in Table 2: that 
Medicare Part D only affected the use of prescription medications. 
 
-Insert Table 3 About Here- 
 
Second, I repeated the analyses in Table 2 for publicly insured respondents who already 
received some prescription medication benefits prior to Part D. I hypothesized that Part D 
did not affect prescription medication use among this population. As demonstrated in 
Table 4, there was no effect of Part D on prescription medication use, and in some cases, 
medication use and polypharmacy even declined for Medicare eligible respondents after 
Part D compared to the control group.  
 
-Insert Table 4 About Here- 
 
Third, I included in my analysis the 2013-2016 survey cycles that were previously 
excluded to avoid the spillover effect of the Medicaid expansion in 2014 onto the 
analyses. In Panel A of Table 5, I replicated results in Table 2 using all survey cycles 
(1999-2016). The inclusion of data in 2013 onward did not significantly alter the results.  
 




Fourth, I assessed whether the 2007-2009 Great Recession affected the results. The 
recession might have had differential consequences for Medicare eligible and ineligible 
adults that in turn influenced their use of prescription medications in systematic ways that 
confounded the effects of Part D. For instance, Medicare ineligible adults might have 
been more affected by unemployment during the recession than Medicare eligible adults, 
which reduced their ability to obtain health insurance and to purchase prescription 
medications. Thus, an increase in medication use after 2006 among Medicare eligible 
adults compared to those who were ineligible might have been attributed to the loss of 
health insurance among Medicare ineligible adults, rather than Part D per se. In Panel B 
of Table 5, I included in the analysis all survey cycles, except for those in 2007-2008 and 
2009-2010 that overlapped with the recession. Exclusion of such survey cycles did not 
significantly alter the interpretation of the results. In Panel C of Table 5, I repeated the 
main analysis in Table 2 for all survey cycles in 1999-2016, but I excluded all uninsured 
individuals who might have lost their health insurance due to the recession. I found that 
the interpretation of the results remained relatively unchanged. Collectively, while the 
Great Recession might have affected Medicare eligible and ineligible adults differently, it 
did not affect the results in this paper.  
 
Fifth, I proposed a stricter definition of polypharmacy. In previous analyses, I defined 
polypharmacy as the use of five or more medications in the past month. However, even 
though respondents consumed at least five medications, it was unclear whether they 
consumed those medications simultaneously. I repeated the analyses using a revised 
measure of polypharmacy that indicated polypharmacy on a daily rather than monthly 
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basis. I did the same for poly-supplementation. In Table 6, I found that Part D 
significantly increased the number of medications consumed daily and polypharmacy for 
Medicare eligible adults, compared to control groups (Panel A). In contrast, I did not 
detect any effects of Part D on the use of dietary supplements (Panel B). 
 
-Insert Table 6 About Here- 
 
Finally, I estimated the impact of Part D on polypharmacy using different numerical 
thresholds for polypharmacy. I created ten outcome variables, ranging from whether a 
respondent used at least one prescription medication in the last month to whether a 
respondent used at least ten prescription medications. Results in Panel A of Table 7 
suggested that Part D affected the use of multiple medications more than single 
medications, starting at four or more prescription medications to at least ten medications 
in the past month. As before, I did not find any significant impacts of Part D on the use of 
dietary supplements, regardless of which cutoff points that were used to define poly-
supplementation (Panel B).  
 
-Insert Table 7 About Here- 
 
Discussion 
Medicare Part D was one of the most expensive health insurance expansion programs in 
the United States since the inception of Medicare. Federal spending in 2019 on the 
program is expected to be more than $95 billion (Centers for Medicare and Medicaid 
Services, 2019). However, evidence as to the extent to which Part D improves health 




To my knowledge, this paper is the first to provide evidence that health insurance 
expansion is associated with an increase in polypharmacy. While Part D might have 
increased the use of prescription medications that were otherwise unaffordable to older 
adults, it had a more substantial impact on polypharmacy. In various placebo analyses, I 
found that Part D did not have any effects on the use of dietary supplements, which were 
not covered under standard Part D plans. In addition, Part D did not alter the use of 
prescription medications among publicly insured respondents who already received some 
prescription medication benefits before Part D. The results were also robust to the 
unobserved impacts of the Great Recession and different definitions of medication use 
and polypharmacy.  
 
Results in this paper are within the range of estimates from prior studies. In Table 2, I 
found that Part D was associated with an increase of 16.3% in the number of prescription 
medication consumed last month. Using Walgreen’s 2004-2007 claims data and a similar 
difference-in-differences approach, prior studies found that Part D led to an increase of 
6%-13% in prescription fills (F. R. Lichtenberg & Sun, 2007; Yin et al., 2008). Using 
pharmacy data in 2005-2006, another study suggested an increase of 11%-37% in 
medication use as a result of Part D (Schneeweiss et al., 2009). In contrast to these 
studies, I used a nationally representative sample of older adults and a longer post-Part-D 
period. Although claims data provide detailed information on medication fills and 
alleviate recall bias, they are not representative of the population and typically exclude 
uninsured individuals – one of the population segments that benefited the most from the 
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introduction of Part D. In addition, the effect of Part D on medication use was likely 
accumulated over time as more Medicare beneficiaries gained coverage and Part D 
coverage became more generous over time (Cubanski et al., 2018), which might explain 
why the estimate in this study was slightly higher than some estimates in prior studies.  
 
Although the benefits of gaining access to life-saving prescription medications as a result 
of Part D may outweigh the unintended effects on polypharmacy, efforts that focus on 
addressing polypharmacy may improve health for Medicare beneficiaries. In 2006, the 
Center for Medicare and Medicaid Services required that all Part D plans included 
Medication Therapy Management (MTM) services. The MTM program is free for Part D 
beneficiaries who meet three eligibility criteria: enrollees must have at least two chronic 
conditions, they must use multiple medications covered under their Part D plan, and they 
must be at risk at spending more on annual Part D covered medication costs than a certain 
cost threshold. Through the MTM program, eligible beneficiaries meet with a health 
professional annually to conduct a comprehensive review of their medications. Health 
professionals then inform beneficiaries if their medications have any potential side 
effects, if there are any potentially serious drug-drug interactions among their 
medications, and if their medication costs can be lowered. The program can potentially 
address the issue of polypharmacy, but it is significantly underused. A study in Maryland 
and Delaware found that 60% of Medicare respondents were unaware of the MTM 
program, and 80% had never received a medication therapy review (Truong et al., 2009). 
In addition, program eligibility is not universal, but rather varies across plans (Touchette 
et al., 2006). Private Part D plans can select their own MTM criteria within the general 
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guidelines from the government: they can select the types of chronic conditions on which 
they want to focus, the number of chronic conditions that a beneficiary has, or the 
number of Part D medications required for the beneficiary to be eligible for the program. 
In 2008, half of Part D plans opened enrollment to their MTM program for beneficiaries 
who had two chronic conditions, while the other half restricted enrollment to 
beneficiaries with a minimum of three to five chronic conditions (Wang et al., 2015). In 
2010 and onward, approximately 80% of Part D plans required beneficiaries to have three 
or more chronic conditions to enroll in the MTM program (Wang et al., 2015). Such 
variation across plans can prevent beneficiaries who are at risk of polypharmacy from 
receiving a comprehensive review of their medications. Given the benefits of MTM 
programs on reducing drug-related adverse outcomes (Perlroth et al., 2013; Welch et al., 
2009), more efforts should focus on increasing enrollment in the MTM program in order 
to address the adverse consequences of polypharmacy. 
 
Other program expansions might have similar effects. For example, the Medicaid 
expansion in 2014 expanded enrollment eligibility to nonelderly adults with family 
incomes at or below 138% of the federal poverty level. The expansion resulted in an 
increase of 15.5 million new enrollees two years following its implementation (Gates et 
al., 2016). Prior research found that Medicaid expansion improved access to medical 
care, medical affordability, and health outcomes (Mazurenko et al., 2018; Mulcahy et al., 
2016). Since Medicaid covers most major pharmacological therapy, expanding coverage 




Although this paper has several strengths, including the use of Medicare ineligible group 
to control for secular trends and a longer post-Part-D period, it faces some limitations. 
First, Medicare ineligible adults may differ from eligible adults in terms of employment, 
health, health insurance’s coverage generosity, and preferences toward medical care. 
Such unobserved heterogeneity may result in marked differences in medication use 
between Medicare ineligible and eligible adults, which can bias the estimates towards the 
null. Regardless, Table 1 provides evidence that there were no significant differences in 
medication use and other characteristics between two groups before and after Part D. 
Second, I may underreport the prevalence of polypharmacy since NHANES lacks 
information on medications administered to inpatients. However, many inpatient 
medications were already covered under the traditional Medicare program prior to Part D. 
Thus, missing data on inpatient medications was unlikely to affect the estimates of the 
impact of Part D on polypharmacy.  
 
Conclusion 
This study presents a strong relationship between expanding public health insurance and 
polypharmacy among older adults. Despite the well-documented negative consequences 
of polypharmacy, little is known about the role of health insurance programs in overusing 
prescription medications. Efforts that address polypharmacy among Medicare 
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Figure 1: Gender and Age Adjusted Weighted Average Number of Prescription 
Medications and Dietary Supplements Consumed Last Month by Medicare Eligible 
(Aged 65-74) and Ineligible (Aged 55-64) Adults, with 95% Confidence Intervals. 










Figure 2: Gender and Age Adjusted Weighted Prevalence of Medicare Eligible 
(Aged 65-74) and Ineligible (Aged 55-64) Adults Consuming At Least Five 
Prescription Medications and Dietary Supplements Last Month, with 95% 









Table 1: Descriptive Statistics of Medication Use and Characteristics of Medicare Eligible (Aged 65-74) and Ineligible (Aged 
55-64) Adults Before and After Medicare Part D Took Effect. Data Source: NHANES 1999-2012. 
 
Medicare ineligible (ages 55-64)  Medicare eligible (ages 65-74)   
  
Before Part D              
(1999-2004) 
After Part D                             
(2007-2012) 
  
Before Part D             
(1999-2004) 
After Part D                             
(2007-2012) 
  p-value a 
Outcomes                       
Number of prescription medications used 
last 30 days, meanb (SE) 
2.30 (0.08) 2.36 (0.09)   3.24 (0.11) 3.77 (0.12)   p = 0.012 
Used >= 5 prescription medications last 30 
days, Nc (%d) 
196 (16.6) 307 (16.1)   332 (26.6) 534 (32.4)   p = 0.031 
Number of dietary supplements used last 30 
days, meanb (SE) 
1.97 (0.13) 1.80 (0.10)   2.07 (0.10) 2.11 (0.12)   p = 0.252 
Used >= 5 dietary supplements last 30 days, 
Nc (%d) 
128 (13.4) 168 (10.6)   144 (15.1) 175 (15.3)   p = 0.149 
Socio-demographic characteristics                       
Race, Nc (%d)                       
     Non-Hispanic White 645 (78.4) 793 (78.4)   741 (82.9) 846 (81.6)   p = 0.595 
     Non-Hispanic Black 231 (8.4) 439 (8.4)   216 (7.4) 343 (8.2)   p = 0.578 
     Hispanic 339 (8.5) 494 (7.1)   347 (6.6) 307 (5.9)   p = 0.724 
     Non-Hispanic others 50 (4.7) 144 (6.0)   32 (3.1) 88 (4.3)   p = 0.880 
Age (in years), meanb (SE) 59.01 (0.11) 59.12 (0.09)   69.18 (0.10) 69.04 (0.10)   N/A 
Female, Nc (%d) 671 (53.9) 942 (52.5)   663 (54.5) 801 (53.7)   p = 0.779 
Marital status, Nc (%d)                       
     Married 926 (75.6) 1254 (72.6)   903 (70.4) 975 (67.8)   p = 0.792 
     Widowed, divorced, separated 290 (20.5) 482 (21.2)   395 (27.6) 531 (29.1)   p = 0.810 
     Never married 49 (3.8) 134 (6.2)   38 (2.0) 78 (3.1)   p = 0.820 
Educational attainment, Nc (%d)                       
     Less than high school 413 (18.8) 445 (11.8)   530 (25.1) 507 (20.3)   p = 0.122 
     High school graduate 266 (23.5) 429 (23.9)   322 (30.3) 390 (24.7)   p = 0.049 
     Some college 297 (27.3) 502 (28.9)   272 (23.7) 374 (28.2)   p = 0.325 
     College graduate or above 289 (30.4) 494 (35.3)   212 (20.9) 313 (26.8)   p = 0.555 
Nativity and citizenship, Nc (%d)                       
     Citizen, born in the U.S. 982 (86.9) 1338 (87.2)   1089 (89.6) 1240 (89.6)   p = 0.873 







     Not a citizen 123 (4.1) 222 (5.0)   87 (2.8) 108 (2.9)   p = 0.482 
Insurance coverage                       
Has any health insurance, Nc (%d) 962 (84.8) 1328 (83.8)   1281 (98.6) 1506 (97.7)   p = 0.148 
Income                       
Household poverty thresholds, Nc (%d)                       
     < 100% 117 (4.9) 257 (6.2)   173 (7.0) 238 (7.5)   p = 0.465 
     100-199% 254 (12.7) 383 (11.7)   411 (26.6) 482 (23.8)   p = 0.839 
     200-299% 189 (13.9) 301 (16.0)   273 (22.5) 304 (19.3)   p = 0.103 
     300-399% 185 (16.1) 173 (11.0)   147 (13.7) 174 (12.9)   p = 0.130 
     400-499% 154 (15.4) 194 (13.6)   128 (11.6) 121 (11.1)   p = 0.709 
     500% or higher 366 (37.1) 562 (41.5)   204 (18.5) 265 (25.5)   p = 0.297 
Health                        
Number of chronic conditions, Nc (%d)                       
     None 345 (29.4) 557 (28.9)   215 (15.5) 203 (13.7)   p = 0.434 
     One or two 702 (53.5) 993 (53.8)   718 (53.0) 832 (52.2)   p = 0.801 
     Three or more 218 (17.1) 320 (17.2)   403 (31.5) 549 (34.1)   p = 0.466 
Whether overweight or obese, Nc (%d) 963 (73.4) 1441 (74.6)   1003 (74.2) 1196 (74.7)   p = 0.837 
Self-reported health status, Nc (%d)                       
     Excellent 219 (21.6) 239 (17.1)   177 (16.1) 167 (14.4)   p = 0.439 
     Very good 343 (32.9) 511 (34.3)   329 (28.8) 393 (31.1)   p = 0.726 
     Good 389 (28.7) 670 (33.2)   437 (32.1) 564 (34.5)   p = 0.454 
     Fair 252 (13.3) 366 (13.2)   303 (17.6) 365 (15.7)   p = 0.472 
     Poor 62 (3.5) 84 (2.3)   90 (5.4) 95 (4.2)   p = 0.626 
No. respondents 1,265 1,870   1,336 1,584     
a: p-value for the difference between eligible and ineligible groups before and after Part D was introduced, controlling for age. 












Table 2: Linear and Logit Regressions of The Impact of Medicare Part D on Medication Use and Polypharmacy Among U.S. 
Adults Aged 55-74 Without Public Insurancea. Data Source: NHANES 1999-2012. 
  Model 1:                                 
no covariates 
Model 2:                  
Model 1 + 
demographic 
covariates 
Model 3:                         
Model 2 + health 
insurance 
  Model 4:                         
Model 3 + income 
Model 5:                   
































OR        
(SE) 
  
Coeff.        
(SE) 
OR        
(SE) 
  
Coeff.        
(SE) 
OR        
(SE) 
  
Coeff.        
(SE) 
OR        
(SE) 
  
Coeff.        
(SE) 
OR        
(SE) 
Panel A: Difference-in-differences 
































































Panel B: Difference-in-differences with year fixed-effect 




















Ages 65-74 * years 1999-2000 (reference) 












































Ages 65-74 * years 2005-2006 (dropped) 








































































p-value for F-test of null hypothesis H0: Ages 65-74 * (years 2001-2002 + years 2003-2004) = Ages 65-74 * (years 2007-2008 + years 2009-2010 + 
years 2011-2012): 
  p < 0.01 p = 0.05   p < 0.01 p < 0.05   p < 0.01 p < 0.05   p < 0.01 p < 0.05   p < 0.01 p < 0.05 
Mean outcome 2.822 0.218   2.822 0.218   2.822 0.218   2.822 0.218   2.822 0.218 
No. respondents 6,055 6,055   6,055 6,055   6,055 6,055   6,055 6,055   6,055 6,055 
Notes: + p < 0.1, * p < 0.05, ** p < 0.01, *** p<0.001. All analyses excluded survey cycle in 2005-2006 that overlapped with the introduction of Part D. 
a: Public insurance includes insurance programs that likely provided their beneficiaries with prescription drug benefits before Medicare Part D took 
effect in 2006, including Medicaid, military insurance, Indian health service programs, Children's Health Insurance Program, and any other state-
sponsored or government health plans. 
Demographic covariates include age, age squared, race (non-Hispanic Whites, non-Hispanic Blacks, non-Hispanic others, and Hispanic), gender, marital 
status (married or cohabiting, widowed/divorced/separated, never married), education (less than high school graduate, high school graduate, some 
college, college graduate or above), and nativity/citizenship status (citizen born in the US, citizen born abroad, not a citizen). Health insurance indicates 
whether a person has any type of health insurance. Income covariates include household poverty level (less than 100%, 100-199%, 200-299%, 300-
399%, 400-499%, 500% or more). Health condition covariates include the number of chronic conditions (none, one or two, and three or more 





Figure 3: Marginal Effects (with 95% Confidence Intervals) of Medicare Part D on 
Polypharmacy by Race/Ethnicity Among U.S. Adults Aged 55-74 Without Public 
Insurancea. Data Source: NHANES 1999-2012. 
 
a: Public insurance includes insurance programs that likely provided their beneficiaries with prescription 
drug benefits before Medicare Part D took effect in 2006, including Medicaid, military insurance, Indian 
health service programs, Children's Health Insurance Program, and any other state-sponsored or 












Figure 4: Marginal Effects (with 95% Confidence Intervals) of Medicare Part D on 
Polypharmacy by Gender Among U.S. Adults Aged 55-74 Without Public 
Insurancea. Data Source: NHANES 1999-2012. 
 
a: Public insurance includes insurance programs that likely provided their beneficiaries with prescription 
drug benefits before Medicare Part D took effect in 2006, including Medicaid, military insurance, Indian 
health service programs, Children's Health Insurance Program, and any other state-sponsored or 












Figure 5: Marginal Effects (with 95% Confidence Intervals) of Medicare Part D on 
Polypharmacy by Marital Status Among U.S. Adults Aged 55-74 Without Public 
Insurancea. Data Source: NHANES 1999-2012. 
 
a: Public insurance includes insurance programs that likely provided their beneficiaries with prescription 
drug benefits before Medicare Part D took effect in 2006, including Medicaid, military insurance, Indian 
health service programs, Children's Health Insurance Program, and any other state-sponsored or 












Figure 6: Marginal Effects (with 95% Confidence Intervals) of Medicare Part D on 
Polypharmacy by Educational Attainment Among U.S. Adults Aged 55-74 Without 
Public Insurancea. Data Source: NHANES 1999-2012. 
 
a: Public insurance includes insurance programs that likely provided their beneficiaries with prescription 
drug benefits before Medicare Part D took effect in 2006, including Medicaid, military insurance, Indian 
health service programs, Children's Health Insurance Program, and any other state-sponsored or 












Figure 7: Marginal Effects (with 95% Confidence Intervals) of Medicare Part D on 
Polypharmacy by Nativity/Citizenship Status Among U.S. Adults Aged 55-74 
Without Public Insurancea. Data Source: NHANES 1999-2012. 
 
a: Public insurance includes insurance programs that likely provided their beneficiaries with prescription 
drug benefits before Medicare Part D took effect in 2006, including Medicaid, military insurance, Indian 
health service programs, Children's Health Insurance Program, and any other state-sponsored or 












Figure 8: Marginal Effects (with 95% Confidence Intervals) of Medicare Part D on 
Polypharmacy by Household Poverty Thresholds Among U.S. Adults Aged 55-74 
Without Public Insurancea. Data Source: NHANES 1999-2012. 
 
a: Public insurance includes insurance programs that likely provided their beneficiaries with prescription 
drug benefits before Medicare Part D took effect in 2006, including Medicaid, military insurance, Indian 
health service programs, Children's Health Insurance Program, and any other state-sponsored or 












Figure 9: Marginal Effects (with 95% Confidence Intervals) of Medicare Part D on 
Polypharmacy by Number of Chronic Conditions Among U.S. Adults Aged 55-74 
Without Public Insurancea. Data Source: NHANES 1999-2012. 
 
a: Public insurance includes insurance programs that likely provided their beneficiaries with prescription 
drug benefits before Medicare Part D took effect in 2006, including Medicaid, military insurance, Indian 
health service programs, Children's Health Insurance Program, and any other state-sponsored or 












Figure 10: Marginal Effects (with 95% Confidence Intervals) of Medicare Part D on 
Polypharmacy by Obesity Status Among U.S. Adults Aged 55-74 Without Public 
Insurancea. Data Source: NHANES 1999-2012. 
 
a: Public insurance includes insurance programs that likely provided their beneficiaries with prescription 
drug benefits before Medicare Part D took effect in 2006, including Medicaid, military insurance, Indian 
health service programs, Children's Health Insurance Program, and any other state-sponsored or 












Figure 11: Marginal Effects (with 95% Confidence Intervals) of Medicare Part D on 
Polypharmacy by Self-Reported Health Status Among U.S. Adults Aged 55-74 
Without Public Insurancea. Data Source: NHANES 1999-2012. 
 
a: Public insurance includes insurance programs that likely provided their beneficiaries with prescription 
drug benefits before Medicare Part D took effect in 2006, including Medicaid, military insurance, Indian 
health service programs, Children's Health Insurance Program, and any other state-sponsored or 













Table 3: Linear and Logit Regressions of The Impact of Medicare Part D on Dietary Supplement Use and Poly-
Supplementation Among U.S. Adults Aged 55-74 Without Public Insurancea. Data Source: NHANES 1999-2012. 
  Model 1:                                 
no covariates 
  Model 2:                  
Model 1 + 
demographic 
covariates 
  Model 3:                                  
Model 2 + health 
insurance 
 Model 4:                                       
Model 3 + 
income 
 Model 5:                   
Model 4 + health 
conditions 
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(SE) 




























































Mean outcome 1.955 0.131   1.955 0.131   1.955 0.131   1.955 0.131   1.955 0.131 
No. respondents 6,055 6,055   6,055 6,055   6,055 6,055   6,055 6,055   6,055 6,055 
Notes: + p < 0.1, * p < 0.05, ** p < 0.01, *** p<0.001. All analyses excluded survey cycle in 2005-2006 that overlapped with the introduction 
of Part D. 
a: Public insurance includes insurance programs that likely provided their beneficiaries with prescription drug benefits before Medicare Part D 
took effect in 2006, including Medicaid, military insurance, Indian health service programs, Children's Health Insurance Program, and any 
other state-sponsored or government health plans. 
Demographic covariates include age, age squared, race (non-Hispanic Whites, non-Hispanic Blacks, non-Hispanic others, and Hispanic), 
gender, marital status (married or cohabiting, widowed/divorced/separated, never married), education (less than high school graduate, high 
school graduate, some college, college graduate or above), and nativity/citizenship status (citizen born in the US, citizen born abroad, not a 
citizen). Health insurance indicates whether a person has any type of health insurance. Income covariates include household poverty level 
(less than 100%, 100-199%, 200-299%, 300-399%, 400-499%, 500% or more). Health condition covariates include the number of chronic 
conditions (none, one or two, and three or more conditions), whether a person is overweight or obese (BMI of at least 25), and self-reported 








Table 4: Linear and Logit Regressions of The Impact of Medicare Part D on Medication Use and Polypharmacy Among U.S. 
Adults Aged 55-74 With Public Insurancea. Data Source: NHANES 1999-2012. 
  Model 1:                                 
no covariates 
Model 2:                  
Model 1 + 
demographic 
covariates 
Model 3:                           
Model 2 + 
income 
Model 4:                   
Model 3 + health 
conditions 
Outcomes: Use of 
prescription 
medications 
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(SE) 
















































Mean outcome 4.087 0.398   4.087 0.398   4.087 0.398   4.087 0.398 
Number of respondents 1,190 1,190   1,190 1,190   1,190 1,190   1,190 1,190 
Notes: + p < 0.1, * p < 0.05, ** p < 0.01, *** p<0.001. All analyses excluded survey cycle in 2005-2006 that overlapped 
with the introduction of Part D. 
a: Public insurance includes insurance programs that likely provided their beneficiaries with prescription drug benefits 
before Medicare Part D took effect in 2006, including Medicaid, military insurance, Indian health service programs, 
Children's Health Insurance Program, and any other state-sponsored or government health plans. 
Demographic covariates include age, age squared, race (non-Hispanic Whites, non-Hispanic Blacks, non-Hispanic 
others, and Hispanic), gender, marital status (married or cohabiting, widowed/divorced/separated, never married), 
education (less than high school graduate, high school graduate, some college, college graduate or above), and 
nativity/citizenship status (citizen born in the US, citizen born abroad, not a citizen). Health condition covariates include 
the number of chronic conditions (none, one or two, and three or more conditions), whether a person is overweight or 









Table 5: Sensitivity Analyses for Linear and Logit Regressions of The Impact of Medicare Part D on Medication Use and 
Polypharmacy Among U.S. Adults Aged 55-74 Without Public Insurancea. Data Source: NHANES 1999-2016. 
  Model 1:                                 
no covariates 
Model 2:                              
Model 1 + 
demographic 
covariates 
Model 3:                      
Model 2 + health 
insurance 
Model 4:                     
Model 3 + income 
Model 5:                                   




















































OR        
(SE) 
Panel A: Difference-in-differences. Sample of individuals without public insurance coveragea in all years (1999-2016) 
































































Mean outcome 2.908 0.232   2.908 0.232   2.908 0.232   2.908 0.232   2.908 0.232 
No. respondents 8,158 8,158   8,158 8,158   8,158 8,158   8,158 8,158   8,158 8,158 
Panel B: Difference-in-differences. Sample of individuals without public insurance coveragea, excluding the Great Recession (1999-2004 and 
2011-2016) 
































































Mean outcome 2.895 0.232   2.895 0.232   2.895 0.232   2.895 0.232   2.895 0.232 
No. respondents 5,741 5,741   5,741 5,741   5,741 5,741   5,741 5,741   5,741 5,741 
Panel C: Difference-in-differences. Sample of individuals with health insurance, excluding those with public insurance coveragea in all years 
(1999-2016) 






































































Mean outcome 3.039 0.245   3.039 0.245   3.039 0.245   3.039 0.245   3.039 0.245 
No. respondents 6,836 6,836   6,836 6,836   6,836 6,836   6,836 6,836   6,836 6,836 
Notes: + p < 0.1, * p < 0.05, ** p < 0.01, *** p<0.001. All analyses excluded survey cycle in 2005-2006 that overlapped with the introduction of Part D. 
a: Public insurance includes insurance programs that likely provided their beneficiaries with prescription drug benefits before Medicare Part D took 
effect in 2006, including Medicaid, military insurance, Indian health service programs, Children's Health Insurance Program, and any other state-
sponsored or government health plans. 
Demographic covariates include age, age squared, race (non-Hispanic Whites, non-Hispanic Blacks, non-Hispanic others, and Hispanic), gender, marital 
status (married or cohabiting, widowed/divorced/separated, never married), education (less than high school graduate, high school graduate, some 
college, college graduate or above), and nativity/citizenship status (citizen born in the US, citizen born abroad, not a citizen). Health insurance indicates 
whether a person has any type of health insurance. Income covariates include household poverty level (less than 100%, 100-199%, 200-299%, 300-
399%, 400-499%, 500% or more). Health condition covariates include the number of chronic conditions (none, one or two, and three or more 


















Table 6: Linear and Logit Regressions of The Impact of Medicare Part D on Daily Use of Prescription Medications and 
Dietary Supplements Among U.S. Adults Aged 55-74 Without Public Insurancea. Data Source: NHANES 1999-2012. 
  Model 1:                                 
no covariates 
Model 2:                  
Model 1 + 
demographic 
covariates 
 Model 3:                         
Model 2 + health 
insurance 
 Model 4:                         
Model 3 + 
income 
 Model 5:                   
Model 4 + health 
conditions 
Outcomes: daily use of 
prescription medications 
or supplements last month 




































OR        
(SE) 
Panel A: Use of prescription medications 




























































Mean outcome 2.706 0.209   2.706 0.209   2.706 0.209   2.706 0.209   2.706 0.209 
No. respondents 6,055 6,055   6,055 6,055   6,055 6,055   6,055 6,055   6,055 6,055 
                              
Panel B: Use of dietary supplements 




























































Mean outcome 2.040 0.124   2.040 0.124   2.040 0.124   2.040 0.124   2.040 0.124 
No. respondents 6,055 6,055   6,055 6,055   6,055 6,055   6,055 6,055   6,055 6,055 
Notes: + p < 0.1, * p < 0.05, ** p < 0.01, *** p<0.001. All analyses excluded survey cycle in 2005-2006 that overlapped with the introduction of Part D. 
a: Public insurance includes insurance programs that likely provided their beneficiaries with prescription drug benefits before Medicare Part D took effect 
in 2006, including Medicaid, military insurance, Indian health service programs, Children's Health Insurance Program, and any other state-sponsored or 







Demographic covariates include age, age squared, race (non-Hispanic Whites, non-Hispanic Blacks, non-Hispanic others, and Hispanic), gender, marital 
status (married or cohabiting, widowed/divorced/separated, never married), education (less than high school graduate, high school graduate, some college, 
college graduate or above), and nativity/citizenship status (citizen born in the US, citizen born abroad, not a citizen). Health insurance indicates whether a 
person has any type of health insurance. Income covariates include household poverty level (less than 100%, 100-199%, 200-299%, 300-399%, 400-
499%, 500% or more). Health condition covariates include the number of chronic conditions (none, one or two, and three or more conditions), whether a 



















Table 7: Logit Regressions of The Impact of Medicare Part D on Polypharmacy and Poly-Supplementation Using Different 
Numerical Thresholds Among U.S. Adults Aged 55-74 Without Public Insurancea. Data Source: NHANES 1999-2012. 
  
Used          
1+ 
  
Used         
2+  
  
Used            
3+  
  
Used             
4+  
  
Used            
5+  
  
Used              
6+  
  
Used               
7+  
  
Used               
8+  
  
Used               
9+  
  
Used        
10+  
  
OR        
(SE) 
  
OR        
(SE) 
  
OR        
(SE) 
  
OR        
(SE) 
  
OR        
(SE) 
  
OR        
(SE) 
  
OR        
(SE) 
  
OR        
(SE) 
  
OR        
(SE) 
  
OR        
(SE) 





  0.905 
(0.173) 
  0.747 
(0.133) 
  0.822 
(0.157) 
  0.834 
(0.163) 
  0.986 
(0.259) 
  0.554+ 
(0.167) 
  0.582 
(0.194) 
  1.069 
(0.491) 
  1.222 
(0.615) 
Post 2006 1.163 
(0.278) 
  1.424+ 
(0.280) 
  1.266 
(0.230) 
  1.283 
(0.260) 
  1.399 
(0.308) 
  1.393 
(0.349) 
  1.321 
(0.388) 
  2.156* 
(0.803) 
  1.969 
(0.965) 
  2.344 
(1.463) 




  0.928 
(0.175) 
  1.217 
(0.193) 
  1.494* 
(0.253) 
  1.572** 
(0.250) 
  1.239 
(0.265) 
  1.766* 
(0.459) 
  1.924* 
(0.626) 
  2.487* 
(1.054) 
  2.641+ 
(1.388) 
Mean outcome 0.782   0.612   0.458   0.320   0.218   0.146   0.098   0.067   0.043   0.029 
No. 
respondents 
6,055   6,055   6,055   6,055   6,055   6,055   6,055   6,055   6,055   6,055 
                                        





  1.141 
(0.183) 
  1.022 
(0.197) 
  1.060 
(0.212) 
  0.936 
(0.219) 
  0.885 
(0.293) 
  0.811 
(0.322) 
  0.757 
(0.328) 
  1.044 
(0.605) 
  1.311 
(0.867) 
Post 2006 0.844 
(0.136) 
  0.786 
(0.139) 
  0.807 
(0.142) 
  0.736 
(0.141) 
  0.718 
(0.185) 
  0.688 
(0.208) 
  0.773 
(0.298) 
  0.947 
(0.425) 
  1.499 
(0.790) 
  3.075 
(2.470) 




  1.006 
(0.137) 
  1.022 
(0.147) 
  1.229 
(0.205) 
  1.338 
(0.278) 
  1.501 
(0.407) 
  1.686 
(0.625) 
  1.347 
(0.588) 
  1.017 
(0.540) 
  0.930 
(0.570) 
Mean outcome 0.714   0.485   0.315   0.202   0.131   0.083   0.051   0.036   0.025   0.019 
No. 
respondents 
6,055   6,055   6,055   6,055   6,055   6,055   6,055   6,055   6,055   6,055 
Notes: + p < 0.1, * p < 0.05, ** p < 0.01, *** p<0.001. All analyses excluded survey cycle in 2005-2006 that overlapped with the introduction of Part D. 
a: Public insurance includes insurance programs that provided their beneficiaries with prescription drug benefits before Medicare Part D took effect in 
2006, including Medicaid, military insurance, Indian health service programs, Children's Health Insurance Program, and any other state-sponsored or 







Each column is a separate regression model that controls for demographic, health insurance, income, and health covariates. Demographic covariates 
include age, age squared, race (non-Hispanic Whites, non-Hispanic Blacks, non-Hispanic others, and Hispanic), gender, marital status (married or 
cohabiting, widowed/divorced/separated, never married), education (less than high school graduate, high school graduate, some college, college 
graduate or above), and nativity/citizenship status (citizen born in the US, citizen born abroad, not a citizen). Health insurance indicates whether a 
person has any type of health insurance. Income covariates include household poverty level (less than 100%, 100-199%, 200-299%, 300-399%, 400-
499%, 500% or more). Health condition covariates include the number of chronic conditions (none, one or two, and three or more conditions), whether a 






Utilization of Medications with Cognitive Impairment Side Effects and The 
Implications for Older Adults’ Cognitive Function 
 
Objective: Many medications have cognitive impairment, memory loss, amnesia, or 
dementia as side effects (“cognitive side effects” hereafter), but little is known about 
trends in the prevalence of these medications or their implications for population-level 
cognitive impairment. 
Data source: I use data from the National Health and Nutrition Examination Survey 
(1999-2016) to describe trends in the use of medications with cognitive side effects 
among adults aged 60+ (N=16,937) and their implications for cognitive functioning 
(measured using word learning and recall, animal fluency, and digit symbol substitution 
assessments). 
Principle findings: Between 1999-2000 and 2015-2016, the prevalence of older adults 
taking one, two, and at least three medications with cognitive side effects increased by 
10.2%, 57.3%, and 298.7%, respectively. Compared to non-users, respondents who 
simultaneously used three or more medications with cognitive side effects scored 0.22 to 
0.27 standard deviations lower in word learning and recall (p = 0.02), digit symbol 
substitution (p < 0.01), and the average standardized score of the three assessments (p < 
0.001).  
Conclusion: Concurrent use of medications with cognitive side effects among older 
adults has increased dramatically over the past two decades. The use of such medications 
is associated with cognitive impairment and may explain for disparities in cognitive 




among patients who consume medications with cognitive side effects. They also highlight 



























Adults aged 65 and older represent the fastest-growing population in the United States 
and their numbers are expected to nearly double by 2060, creating urgency around the 
prevention and treatment of aging-related health conditions (Federal Interagency Forum 
on Aging-Related Statistics, 2016). Cognitive impairment has emerged as a significant 
public health concern for older adults as it leads to a loss of independence, worsened 
quality of life, and increased disability, which in turn have important implications for 
individuals, families, and government programs (Hurd et al., 2013; Langa et al., 2008; 
Seeher et al., 2013). In 2002, more than ten million U.S. adults aged 70 and older lived 
with dementia or milder cognitive impairments without dementia, with an expected 
doubling by 2050 (Brenda L Plassman et al., 2007; Brenda L Plassman et al., 2008). 
Although the prevalence of cognitive impairment has declined gradually in the past 
decades due to better control of some key risk factors (Langa et al., 2017; Sheffield & 
Peek, 2011), substantial growth in the absolute number of older adults living with 
cognitive impairment continues to expand the scope of this public health concern. 
 
Risk factors for cognitive impairment have been well-documented in the literature, 
including age, socio-demographic status, chronic conditions, and health behaviors 
(Livingston et al., 2017). Despite efforts to document a wide assortment of risk factors, 
little is known about the consequences of using medications with cognitive side effects 
on cognitive function among community-dwelling older adults. This is a potentially 
significant omission. Medications have become increasingly common among older 
adults. In 2011-2012, 40% of older adults reported using five or more medications in the 




critical for disease management and prevention, recent research has emphasized the 
adverse effects of commonly used medications on health, especially under conditions of 
polypharmacy (Qato et al., 2018). Particularly, older adults taking multiple medications 
simultaneously are two times more likely to experience adverse drug events and four 
times more likely to be hospitalized due to adverse drug events, compared to those taking 
fewer or no medications (Bourgeois et al., 2010; Marcum et al., 2012; Nguyen et al., 
2006).  
 
Prior studies on medications with cognitive side effects have produced contradictory 
results with respect to outcomes and statistical significance, potentially dampening the 
relevance of cognitive side effects in particular. Studies have found that benzodiazepines, 
lorazepam, and oxybutynin significantly increase the incidence of amnestic and non-
amnestic cognitive impairments, while H(1)-antihistamine agents and tricyclic 
antidepressants only induce non-amnestic deficits in attention and information processing 
(Tannenbaum et al., 2012). Other studies have found that benzodiazepines, tricyclic 
antidepressants, first-generation antihistamines, and bladder antimuscarinics are 
associated with an increased risk of Alzheimer’s disease, raising concerns that the 
cognitive side effects of medications are irreversible and long-lasting (de Gage et al., 
2014; Gray et al., 2015). Yet, a handful of studies have reported a trivial and potentially 
non-causal increase in cognitive deficits as a result of using benzodiazepine (Gray et al., 
2016; Imfeld et al., 2015). 
 
Further investigation of this topic is warranted, especially in the context of community 




pronounced in naturalistic and population settings. Many prior studies have been clinical 
in nature, exploring the effects of a single medication or a class of medication, or using 
relatively small and non-representative samples. For this reason, little is known about 
how frequently such medications are used in the adult population or about how the use of 
such medications has changed over time. Moreover, little is known about how many 
adults simultaneously consume multiple such medications and the consequences of such 
combinations for cognitive health. Even if much of the evidence suggests that the risks 
associated with a single medication are small or inconsistent, the total impact of 
medications with cognitive side effects on population-level cognitive health could be 
much larger, especially in a context of polypharmacy.  
 
I follow the theoretical framework developed by Inouye & Charpentier (1996) to 
conceptualize the adverse effects of medications with cognitive side effects on the 
cognitive health of older adults. This model was originally developed to examine factors 
that predicted the onset of delirium – an acute disorder of attention and cognition – 
among hospitalized older adults, though the model can be extended and generalized for 
the purpose of this study. Risk factors for delirium are multifactorial, but they can be 
categorized into two interdependent groups factors: predisposing (baseline vulnerability) 
and precipitating (acute insult) risk factors. Predisposing risk factors documented in prior 
studies include demographic characteristics and pre-existing conditions (Francis, 1992; 
Inouye, 1994), while precipitating factors include medication administration, intercurrent 
illnesses, infections, malnutrition, and environment and psychosocial factors (Inouye & 
Charpentier, 1996). These factors do not operate individually, but rather 




regardless of any precipitating factors. In contrast, patients with low-risk baseline 
characteristics may require a high level of acute insult to develop delirium. Following this 
theoretical framework, I hypothesize that precipitating factors such as the use of 
medications with cognitive side effects is associated with an increased risk of cognitive 
impairment after controlling for predisposing factors such as socio-demographic 
characteristics and comorbidity. 
 
This study improves the previous literature by using a nationally representative survey 
and a comprehensive database of medications that have been previously linked to 
cognitive impairment. This study has two aims: 
1. What are the trends in the utilization of medications with cognitive side effects 
from 1999 to 2016 among adults aged 60 and older? 
2. What is the relationship between cognitive function and concurrent use of 
medications with cognitive side effects for older adults? 
 
Methods 
I used the National Health and Nutrition Examination Survey (NHANES), a nationally 
representative survey of the civilian noninstitutionalized U.S. population. NHANES was 
obtained using a multistage probability sampling design to represent the general 
population but with an oversampling of Black, Hispanic, and adults aged 60 and older. 
The average non-response rate was 22%. All analyses used survey weight to produce 
nationally representative estimates and to avoid non-response bias. This study first relied 
on data from all nine most recent two-year cycles (1999-2000 to 2015-2016) to assess 




(n=16,937). I then used data in 2011-2012 and 2013-2014 to investigate the association 
between cognitive function and the use of medications with cognitive side effects 
(n=2,908), after excluding 697 respondents who were not administered or did not 
complete all cognitive assessments and 27 respondents who were currently taking anti-
dementia or anti-Parkinson’s medications. Information on cognitive function was only 
available in these years.  
 
Cognitive function was measured using a series of objective assessments that remained 
unchanged in both survey cycles, including word learning and recall, animal fluency, and 
digit symbol substitution. Respondents who needed a proxy informant or who did not 
understand any of languages offered by NHANES were not administered these 
assessments. Non-response among those administered the assessments ranged from 2% to 
3%. The word leaning and recall assessment has been successfully implemented in major 
epidemiological studies in various ethnic and cultural contexts to investigate learning 
ability for new verbal information (Fillenbaum et al., 2008; Prince et al., 2003). The 
assessment was comprised of three trials and one delayed recall challenge. In each trial, 
respondents were asked to read out loud ten unrelated words, one at a time, as they were 
presented on a computer. Following the presentation, respondents were asked to recall as 
many words as possible. The delayed word recall challenge took place after the animal 
fluency and digit symbol substitution tests were completed (approximately 8-10 minutes 
following the start of the trials). Each correct word was worth one point, and the 





The animal fluency assessment examined verbal fluency independent of educational 
attainment (Prince et al., 2003). The test has been proven to differentiate persons with 
normal cognition from those with mild and more-severe cognitive impairment (Henry et 
al., 2004). Respondents were instructed to name as many animals as they can in one 
minute. Each distinct animal was worth one point. The total observed score ranged from 
3 to 40. 
 
Finally, the digit symbol substitution assessment was adopted from the Wechsler Adult 
Intelligence Scale and was used to assess processing speed, sustained attention, and 
working memory (Dumont & Willis, 2008). The test was conducted on a sheet of paper 
that contained a key at the top with nine numbers, each paired with a symbol. 
Respondents had two minutes to copy the corresponding symbols to 133 boxes 
underneath adjoining numbers. Each correct symbol was worth one point, and the total 
observed score ranged from 0 to 105.  
 
Using the total scores, I constructed two sets of outcome variables for each assessment. 
The first set of variables were the standardized scores for each assessment. The second 
set of variables were indicators for whether a respondent’s score was more than one 
standard deviation below the mean. Finally, I constructed two composite variables to 
represent global cognitive function, an average standardized score of the three 
assessments and a binary indicator of whether a person’s standardized scores were more 
than one standard deviation below the mean for at least two assessments. Although these 




meaningful information to study the association between cognitive impairment and 
medications with cognitive side effects. 
 
Medications were recorded during the prescription medication interviews. Respondents 
were asked to show interviewers the containers of all medications they had taken last 
month. Respondents who could not show a container were asked to verbally report the 
medication’s name. When interviewers entered medication names into a computer, more 
than 95% of entries resulted in exact or similar matches with an existing drug. The drug 
database used for the match was obtained from Lexicon Plus, a proprietary database of 
Cerner Multum that provided, on an annual basis a comprehensive list of all prescription 
and some non-prescription medications available in the U.S. market.  
 
Medications with cognitive side effects were identified using Micromedex. Prior studies 
have independently established the accuracy and reliability of the adverse effects listed in 
Micromedex (Cheng et al., 2010). The database is based on several sources: the U.S. 
Food and Drug Administration’s black box warnings, MedWatch, post-marketing 
surveillance, and comprehensive literature reviews. I identified 94 medications with 
cognitive side effects using a keyword search including the following words: cognitive 
impairment, cognitive decline, memory loss, amnesia, and dementia. This number of 
medications does not represent all medications with such side effects in the U.S market, 
but rather the number of medications with cognitive side effects that were consumed by 
respondents aged 60 and older in this study (see Table 1). I included all 94 medications 
with cognitive side effects, irrespective of any reported frequency of those side effects as 




cognitive function and the use of medications with cognitive side effects, though it is 
possible that small clinical trials underestimated the prevalence of side-effects among 
those who took the drug. Using the reported number of medications with cognitive side 
effects, I constructed a variable that indicated whether in the past 30 days a respondent 
took no medications with cognitive side effects (the reference category in the analysis 
model), one medication, two medications, or three or more medications with cognitive 
side effects. I created a similar variable for the use of medications without known 
cognitive side effects. 
 
-Insert Table 1 About Here- 
 
Length of time a respondent had been taking each medication was recorded during the 
prescription medication interviews. All responses were converted to days. Respondents 
who consumed multiple medications with cognitive side effects were assigned to a length 
of time that corresponded with the length of time for the medication they had been taking 
the longest. In secondary analyses, the use of medications with and without cognitive side 
effects was further classified into categories of duration of use (at most one year and 
more than one year). 
 
Comorbidities that were potentially associated with cognitive health and/or the use of 
medications such as depression, obesity, and other health conditions were ascertained 
based on self-reports (Beydoun et al., 2008; Cherbuin et al., 2015; Livingston et al., 2017; 
Luppino et al., 2010). Depression was measured using a nine-item depression-screening 
instrument from the Patient Health Questionnaire (PHQ-9), which scored each of the nine 




experienced in the past two weeks from “0” (not at all) to “3” (nearly every day). 
Respondents were classified as likely having depression if their total score was 10 or 
higher (Kroenke et al., 2001). Obesity was defined as having a body mass index of at 
least 30. Other health conditions were measured using a series of self-reported diagnoses 
of asthma, arthritis, cancer, congestive health failure, coronary heart disease, heart attack, 
angina, emphysema, bronchitis, stroke, hypertension, diabetes, and sleep disorder. Each 
of these health conditions was introduced in the models as a binary variable. 
 
Other covariates in this paper included socio-demographic characteristics, health 
behaviors, and access to medical services such as age, gender, marital status (married or 
living with a partner: reference category, widowed/divorced/separated, never married), 
educational attainment (less than high school: reference category, high school graduate, 
some college or two-year degree, college graduate or higher), poverty (less than 100% of 
federal poverty guideline: reference category, 100-199%, 200-299%, 300-399%, 400-
499%, 500% or higher), citizenship, whether a person had any health insurance, whether 
a person had a routine place for medical care, and smoking (never smoked: reference 
category, smoked at least 100 cigarettes in the past but not a current smoker (former 
smoker), smoked at least 100 cigarettes in the past and currently smoke (current 
smoker)). I included a dummy variable for year to account for any trend in the outcome. 
To adjust for complex sampling, weighted prevalence estimates of medications with 
cognitive side effects in each year were calculated using Taylor linearization methods. 
The statistical significance of trends of medications with cognitive side effects was 
assessed using logistic regression. Weighted multivariate linear least-squared and logistic 




and the use of medications with cognitive side effects, controlling for potential 
confounders. I imputed missing data for all control variables using multiple imputation 
with chained equations. I generated ten imputed datasets and used them in all analyses. 
Most control variables had a small number of missing cases (<1%), except for depression 
and poverty status, which had up to 10% missing cases. Following conventions, I 
considered a p-value of less than 0.05 as statistically significant and I did not correct for 
multiple testing due to the exploratory nature of this study.  
 
Results 
Figure 1 presents the unadjusted (Panel A) and age/gender adjusted (Panel B) trends in 
utilization of medications with cognitive side effects from 1999 to 2016 for adults aged 
60 and older. In Panel A, about 55.3% (95% CI, 51.3%-59.3%) of older adults did not 
consume any medications with cognitive side effects in 1999-2000. In 2015-2016, this 
estimate declined to 37.7% (95% CI, 34.3%-41.2%). The prevalence of older adults 
taking one medication with such side effects increased modestly by 3.2 percentage points 
(95% CI, -1.8%-8.3%) over the same period of time. The largest increase was 
concentrated among those who consumed two or more such medications. Relative to 
1999-2000, the prevalence of older adults concurrently taking two or three or more 
medications with cognitive side effects in 2015-2016 went up by 5.8 percentage points 
(95% CI, 3.2%-8.4%) and 8.5 percentage points (95% CI, 6.5%-10.5%) respectively. 
Adjusting for age and gender (Panel B) did not significantly change the interpretation of 
the results. Table 2 lists 25 medications with the largest change over time in absolute 
prevalence. A large proportion of the total increase in the prevalence of medications with 




treated hypercholesterolemia, cardiovascular disease, gastrointestinal disease, and the 
central nervous system. 
 
-Insert Figure 1 About Here- 
-Insert Table 2 About Here- 
 
Table 3 presents descriptive statistics for the use of medications with cognitive side 
effects, as well as cognitive function measurements and other covariates by the number of 
medications with cognitive side effects. Overall, 38.6% of respondents did not consume 
any medications with cognitive side effects, while 9.4% had been taking such 
medications for at most one year and 52% had been taking those medications for more 
than one year. Almost 8% of respondents used at least one prescription opioid5 in the last 
30 days, and such use of opioids increased as respondents consumed more medications 
with cognitive side effects.6 Consistently across all cognitive measurements, those who 
took more medications with cognitive side effects scored lower on cognitive assessments. 
Compared to older adults who did not use any medications with cognitive side effects, 
those who consumed at least three such medications scored 0.29 standard deviations (SD) 
(95% CI, -0.43 to -0.14) lower in the average standardized score of the three tests, and 
 
5 Prescription opioids include all narcotic analgesics and narcotic analgesic combinations, excluding 
opioids that are often used in treatment for opioid dependence such as buprenorphine and naloxone. 
6 Several studies found that the use of opioids was harmful to cognitive health (Kamboj et al., 2005; 
Sjøgren et al., 2005). However, Micromedex did not classify any opioids as having cognitive side effects. 
This may be due to conflicting evidence regarding whether the use of opioid is associated with cognitive 
impairment (S. L. Chapman et al., 2002; Dublin et al., 2015). For information purposes, I included the 




were 8.5 percentage points (95% CI, 3.0% to 14.0%) more likely to score more than one 
standard deviation below the mean for at least two of the tests. 
 
-Insert Table 3 About Here- 
 
Socio-demographic characteristics, health services utilization, health behaviors, and 
comorbidities also varied by the number of medications with cognitive side effects 
consumed. Compared to respondents who did not consume medications with cognitive 
side effects, those who consumed at least three medications with such side effects were 
more likely to also consume at least three medications without cognitive side effects, to 
be female, older, insured, U.S. citizens, former smokers, to have a routine place for 
medical care, to be obese, to report other health conditions, and were less likely to have a 
college degree or higher. 
 
Table 4 presents results from the adjusted multivariate analyses. I found that respondents 
who consumed at least three medications with cognitive side effects scored 0.22 SD (95% 
CI, -0.34 to -0.10) lower in the average standardized score of the three assessments, and 
that this relationship was in part driven by the association between medications with such 
side effects and the word learning and recall assessment (coefficient, -0.24; 95% CI, -
0.43 to -0.04) and the digit symbol substitution assessment (coefficient, -0.27; 95% CI, -
0.42 to -0.12). There is no relationship between the use of medications with cognitive 
side effects and the animal fluency assessment (coefficient, -0.15; 95% CI, -0.33 to 0.03). 
I also found that taking numerous such medications was critical: the association between 
medications with cognitive side effects and cognitive function was small and not 




observed a dose-response relationship such that the association between medications with 
cognitive side effects and cognitive function generally increased over each category of 
additional medication. 
 
-Insert Table 4 About Here- 
 
In Table 5, I found similar patterns between medications with cognitive side effects and 
whether a respondent scored more than one standard deviation below the mean for each 
assessment. Particularly, compared to the reference group, individuals consuming at least 
three medications with cognitive side effects were about two times (OR, 2.10; 95% CI, 
1.25 to 3.53) more likely to score more than one standard deviation below the mean for at 
least two tests, and this result was also driven by the relationship between medications 
with cognitive side effects and respondents’ performance on the word learning and recall 
and the digit symbol substitution assessments.  
 
-Insert Table 5 About Here- 
 
 
In both Tables 4 and 5, I followed a previous study and introduced a categorical variable 
for the number of medications without cognitive side effects into the models (Qato et al., 
2018). If the relationship between medications with cognitive side effects and cognitive 
function was driven by unobserved heterogeneity in health, the relationship between 
medications without cognitive side effects and cognitive function should be equally 
significant as that between medications with cognitive side effects and cognitive function. 
I found no significant relationship between medications without cognitive side effects and 




in Table 4, and in this case the coefficients were smaller than the coefficients for three or 
more medications with side effects. 
 
In Table 6, I further classified the use of medications with and without cognitive side 
effects into categories of duration of use (at most one year and more than one year). 
Consistent with previous results in Tables 4 and 5, only the use of at least three 
medications with cognitive side effects was associated with cognitive deficits, and this 
association was unlikely to have been driven by the duration of use. I also found that 
more recent use (at most one year) of three or more medications with such side effects 
was more deleterious to cognitive health compared to having used three of more such 
medications for more than a year. Although the estimates were not significantly different 
from one another, these results potentially suggest that the negative consequences of 
medications with cognitive side effects might be short-term or reversible.  
 
-Insert Table 6 About Here- 
 
Finally, in Figures 2 to 6, I assessed the heterogeneous association between medications 
with cognitive side effects and the global cognitive score (average standardized score of 
the three assessments) by socio-demographic subgroups according to age, gender, 
educational attainment, race/ethnicity, and marital status. Overall, I observed the negative 
consequences of medications with cognitive side effects among all subgroups: among 
younger respondents (under 75 years of age), both men and women, all education 
subgroups (high school graduate or lower and college or higher), non-Hispanic whites, 




married or cohabiting). The heterogeneity that exists across subgroups may be explained 
by the more frequent use of medications among certain subgroups.  
 
-Insert Figures 2 to 6 About Here- 
 
Discussion  
To my knowledge, this study was the first to assess trends in the utilization of 
medications with cognitive side effects among U.S. community-dwelling older adults. I 
found that between 1999-2000 and 2015-2016, the prevalence of older adults taking one, 
two, or at least three medications with cognitive side effects increased by 10.2%, 57.3%, 
and 298.7%, respectively. Much of the increase in utilization of medications with 
cognitive side effects was attributed to an increase in consumption of medications that 
treated hypercholesterolemia, the central nervous system, or cardiovascular disease. 
Concurrent use of three or more such medications was associated with reductions in the 
global cognitive score, performance on the word learning and recall assessment, and 
performance on the digit symbol substitution assessments. These relationships persisted 
even after excluding individuals who were currently taking medications for dementia or 
Parkinson’s disease, and after controlling for socio-demographic characteristics, access to 
health services, health behaviors, and health conditions. Medications without known 
cognitive side effects were not associated with declines in the cognitive tests scores. 
 
The summary measures of the use of medications with cognitive side effects produced 
coefficients that were either similar to or smaller than those produced in studies of 
specific medications or types of medication. Using a longitudinal survey that was 




(2011) reported that exposure to at least one anticholinergic medication7 at the baseline 
was associated with a reduction of 1.27% in the Mini-Mental State Examination score, 
compared to respondents who did not take any anticholinergics. Using a longitudinal 
survey in France, Ancelin et al. (2006) found that consistent users of anticholinergics 
scored 0.6 to 0.8 standard deviations lower in various cognitive tests. My estimates for 
the use of a single medication with cognitive side effects were much smaller than those in 
Ancelin et al. (2006), in part because I included in this study many medications other 
than anticholinergics that had smaller incidence rates of cognitive impairment. 
Nonetheless, this study contributed to the existing literature by demonstrating the 
increasing trend in prevalence of concurrent use of medications with cognitive side 
effects among community-dwelling older adults, and the association between the use of 
such medications and cognitive health under conditions of polypharmacy. I find that the 
use of three or more medications with side effects is much more consequential than the 
sum of three individual medications with side effects.  
 
The role of medications in the cognitive performance of older adults has likely been 
underappreciated, especially when a decline in performance might reasonably be 
attributed to a normal aging process. Although there are numerous guidelines for the 
diagnosis and treatment of chronic physical diseases (Bingley et al., 2001; Chobanian et 
al., 2003; Criner et al., 2015; Wender et al., 2013), there are currently no guidelines for 
 
7 Examples include antiemetics, antispasmodics, bronchodilators, antiarrhythmic drugs, antihistamines, 
analgesics, antihypertensives, antiparkinsonian agents, corticosteroids, skeletal muscle relaxants, ulcer 




the screening of cognitive impairment. Part of this may reflect the limited clinical 
benefits of such screenings. Following a review of the literature, the U.S. Preventive 
Services Task Force (2015) concluded that there was insufficient evidence on the benefits 
of screening for cognitive impairment. Yet a large number of older adults report 
worrisome cognitive impairments (Aigbogun et al., 2017), and, given the trends 
documented here, medication use may play an increasingly important role in their 
experience. In tandem with a lack of clinical guidelines for screening cognitive 
impairment, the growing intensity of diagnosis and treatment for chronic and physical 
diseases may contribute significantly to cognitive impairment among older adults. 
Physicians could limit the risk of cognitive impairment from side effects by collecting 
information on their patients’ cognitive function prior to and during drug administration 
and adjust prescriptions and doses accordingly.  
 
The results also highlight the impact of polypharmacy. The most significant side effects 
documented in this study were limited to those taking three of more medications. 
Although most people who take medications with such side effects take only one or two, 
polypharmacy is increasingly common. In this study, about 9% of older adults took three 
or more medications with cognitive side effects in the past 30 days. Although the 
prevalence of older adults taking at least five medications increased by 81.8% from 1999-
2000 to 2011-2012 (Kantor et al., 2015), the present study found that the prevalence of 
older adults taking at least three medications with cognitive side effects has increased 
considerably more over this baseline increase in polypharmacy, by almost 300% between 
1999-2000 and 2015-2016. Polypharmacy may present unique risks for side effects, 




increases the risk of drug-drug interactions that may lead to negative cognitive outcomes. 
Prior research has shown that taking multiple medications is a risk factor for dementia 
and delirium, as well as other adverse events (Jyrkkä et al., 2011; Martin et al., 2000). 
Research on the reasons for an increase in polypharmacy is limited, though prior studies 
points to the growing presence of comorbidity (Slabaugh et al., 2010), the failure to 
consider comorbidity in clinical practice guidelines (Tinetti et al., 2004), visiting multiple 
providers (Col et al., 1990), and marked variation in patterns of medical practice of 
individual providers (Hovstadius & Petersson, 2012). Since exposure to adverse side 
effects is positively correlated with the number of medications taken (Marcum et al., 
2012), efforts to reduce polypharmacy might also lessen exposure to multiple drugs with 
similar side effects. As the pharmaceutical treatment of chronic disease is increasingly 
common, future research should further investigate its spillover effects to other illnesses 
and symptoms. 
 
To help guide clinical decisions, Table 7 provides the most common combinations of 
medications with cognitive side effects among respondents who consumed at least three 
such medications. Such combinations of medications in part reflect the common chronic 
conditions triad for U.S. older adults (Ward & Schiller, 2013). All combinations, for 
instance, include either antihyperlipidemic agents or proton pump inhibitors. While prior 
studies found no association between cognitive function and the use of 
antihyperlipidemic agents (Bitzur, 2016) or conflicting evidence in the case of proton 
pump inhibitors (Gomm et al., 2016; Kuller, 2016), most studies have only examined 
these medications individually. It is possible that the association between these 




especially when antihyperlipidemic agents or proton pump inhibitors are combined with 
other medications that have cognitive side effects. Although the clinical benefits of 
antihyperlipidemic agents and proton pump inhibitors might outweigh the risks of 
cognitive side effects, clinicians might want to be cautious when prescribing these 
medications in combination with others that also have cognitive side effects.  
 
-Insert Table 7 About Here- 
 
Some medications in Appendix Table 1 are available over the counter (OTC). An 
increase in the consumption of medications with cognitive side effect may be in part due 
to the rapidly growing availability of OTC medications (S.-A. Francis et al., 2005). Many 
Americans are either unaware of the side effects of OTC medications or incorrectly 
believe that such medications do not have significant side effects (Wilcox et al., 2005). 
Almost 60% of patients used OTC medications in the past month, but only 58% of those 
who used such medications informed their physician about it and, for their part, 
physicians only asked about OTC medications during 37% of visits (Sleath et al., 2001). 
The lack of communication between physicians and patients and the growing availability 
of OTC medications may result in duplicate prescribing of medications with cognitive 
side effects. Carefully monitoring patients’ use of OTC medications can prevent the risk 
of combining OTC and prescription medications that both have cognitive side effects. 
 
Finally, I found that medications with cognitive side effects were more debilitating to 
cognitive health among younger adults than among older adults (Figure 2). This finding 
suggests that the association between medications with cognitive side effect and 




implies that the selection into consuming these medications at young ages due to the early 
onset of chronic conditions and comorbidity can be more debilitating to cognitive health 
than those that occur at older ages (Huang et al., 2010). In addition, young adults 
generally have more cognitive abilities than older adults, as many cognitive abilities – 
such as conceptual reasoning, memory, and processing speed – gradually diminish over 
time (Harada et al., 2013). The low stock of cognitive abilities among older adults may in 
part explain why medications with cognitive side effects play a less important role in 
their cognitive health compared to that of younger adults. 
 
While this study improved the previous literature by using nationally representative data 
and including a comprehensive list of all medications with cognitive side effects, it faced 
several limitations. First, I was not able to establish a causal relationship between 
cognitive function and medications with cognitive side effects. Due to the cross-sectional 
nature of the NHANES, it was challenging to determine whether medications with 
cognitive side effects caused cognitive impairment or if cognitive impairment led to the 
onset of other health conditions that required pharmaceutical treatment involving 
additional cognitive side effects. Second, the medications in this study not only involved 
cognitive side effects but also other side effects that might indirectly influence cognitive 
function. I addressed both issues by controlling for a comprehensive list of health 
conditions, including conditions that might influence a respondent’s cognitive function, 
but there were likely other unobserved conditions that are influential. Third, although 
Micromedex is a reliable source of information on adverse side effects, it is possible that 
there were medications with cognitive side effects that were not included in the database. 




medications, I lacked information on medications administered to inpatients at hospitals. 
To address some forms of unobserved heterogeneity, I followed another similar study and 
included in all analysis models the number of medications without any known cognitive 
side effects (Qato et al., 2018). I found that there was almost no association between 
medications without such side effects and cognitive function. This suggests both that 
unobserved heterogeneity with respect to health is unlikely to explain the results and that 
there were few medications with cognitive side effects that have not been correctly 
identified by Micromedex. Finally, the data lacked information on dosage of medications 
associated with cognitive side effects. This is an important omission because the 
association between medications with cognitive side effects and cognitive health may 
depend on the treatment intensity. I did, however, attempt to test the effects of treatment 
intensity in other ways. In a secondary analysis presented in Table 4, I further classified 
the use of medications with and without cognitive side effects into categories of duration 
of use (at most one year and more than one year). I found that the association between 
medications with cognitive side effects and cognitive function was unlikely to have been 
driven by differences in the duration of use. I also found that more recent use (at most 
one year) of three or more medications with such side effects was more deleterious to 
cognitive health compared to having used three or more medications for more than a 
year, a result consistent with the fact that side-effects occur as a consequence of the 
recent use of medication. While the duration of medications cannot perfectly substitute 
for information on dosage, duration of use does reflect the long-run amount of medication 






This study demonstrated a strong relationship between taking multiple medications with 
cognitive side effects and cognitive functioning. Almost 9% of older adults take three or 
more such medications, and this percentage is likely to increase more in the future. The 
investigation of cognitive side effects is an important frontier for future research and 
could help to explain important trends and disparities. Research on the population-level 
implications of medication use could help to explain, among other things, the decline in 
intelligence test scores beginning in the 21st century (Flynn & Shayer, 2018), as well as 
some of the apparent sociodemographic variation in cognitive function among older 
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Table 1. Medications with Cognitive Side Effects Consumed by U.S. Adults Aged 60+ in NHANES from 1999-2000 to 2015-
2016 
Acamprosate Fluorouracil Pantoprazole 
Alprazolam Fluoxetine Phenobarbital 
Amitriptyline Fluvastatin Phenytoin 
Amitriptyline Hydrochloride/Perphenazine Heparin Pitavastatin 
Atorvastatin Hydrochlorothiazide/Propranolol Pravastatin 
Baclofen Ibuprofen Prednisolone 
Bendroflumethiazide/Nadolol Interferon Alfa-2A Pregabalin 
Benztropine Isoniazid Progesterone 
Ciprofloxacin Ketoprofen Promethazine 
Clomipramine Lamotrigine Propafenone 
Clonazepam Leuprolide Propranolol 
Conjugated Estrogens Levetiracetam Pyridoxine 
Cyclopentolate Levofloxacin Quinidine 
Cyclophosphamide Lorazepam Rabeprazole 
Cyclosporine Lovastatin Ramelteon 
Cyproheptadine Meclizine Ribavirin 
Dexlansoprazole Mefloquine Rosuvastatin 
Diazepam Methocarbamol Scopolamine 
Diltiazem Methotrexate Simvastatin 
Dorzolamide Methyldopa Tamsulosin 
Dronabinol Montelukast Temazepam 
Enzalutamide Moxifloxacin Testosterone 
Esomeprazole Naproxen Tolterodine 
Estazolam Niacin/Simvastatin Topiramate 







Estradiol Nortriptyline Tretinoin 
Estradiol/Norethindrone Ofloxacin Triazolam 




Bicarbonate  Zaleplon 
Estrogens/Methyltestosterone Oxcarbazepine Zolmitriptan 
Estropipate Oxybutynin Zolpidem 




















Figure 1. Unadjusted and Adjusted Weighted Prevalence of U.S. Adults Aged 60+ Taking Medications with Cognitive Side 








Table 2. Top 25 Medications with the Largest Change in Utilization Among U.S. Adults Aged 60+ from 1999-2000 to 2015-
2016. Data Source: NHANES 1999-2000 to 2015-2016. 
Medications   Weighted Prevalence of Utilization Among U.S. Adults Aged 60+ (%)   
Difference Between 2015-
2016 and 1999-2000 (%) 
P-value for 
Trend a 



















      
Simvastatin   5.81 7.20 8.09 10.74 13.45 18.94 18.68 14.97 14.35   8.54 <0.001 
Atorvastatin   7.36 10.67 13.38 16.06 14.44 9.40 9.63 15.05 14.99   7.63 <0.001 
Conjugated estrogens 7.08 10.35 3.18 1.60 2.12 1.33 1.07 0.83 0.60   -6.48 <0.001 
Omeprazole   4.48 4.48 2.44 4.34 7.23 9.29 9.95 12.44 10.43   5.94 <0.001 
Pravastatin   2.45 2.56 3.46 1.60 2.46 2.74 4.82 5.60 7.12   4.67 <0.001 
Rosuvastatin   0.00 0.00 0.51 0.87 2.47 3.24 3.37 6.77 4.54   4.54 <0.001 
Gabapentin   0.55 1.98 2.18 1.84 2.79 3.12 3.60 4.67 4.34   3.79 <0.001 
Tamsulosin   0.76 1.24 2.54 2.61 2.56 3.03 3.53 4.34 4.43   3.67 <0.001 
Esomeprazole   0.00 0.00 3.56 4.53 4.75 3.96 2.81 2.94 3.28   3.28 0.11 
Nifedipine   3.38 2.52 2.22 1.90 1.27 1.86 1.18 0.85 0.83   -2.55 <0.001 
Pantoprazole   0.05 1.32 2.96 2.25 2.04 2.02 1.60 3.69 2.58   2.53 <0.001 
Montelukast   0.44 0.94 1.57 1.50 1.90 2.43 1.27 1.91 2.97   2.53 0.001 
Lovastatin   0.98 1.60 1.73 3.60 3.16 4.04 3.25 3.15 2.90   1.92 <0.001 
Propranolol   2.30 1.17 1.57 2.19 1.45 0.62 1.03 0.78 0.43   -1.86 0.001 
Diltiazem   3.89 4.78 4.23 3.92 2.86 2.13 1.77 1.95 2.07   -1.82 <0.001 
Pregabalin   0.00 0.00 0.00 0.16 0.27 1.11 0.34 0.99 1.70   1.70 <0.001 
Zolpidem   1.01 0.75 1.65 1.84 1.65 1.88 1.39 3.02 2.47   1.47 0.003 
Fluoxetine   0.86 1.31 1.20 1.34 2.01 1.69 0.81 2.70 2.29   1.44 0.01 
Meclizine   1.87 1.34 1.28 0.53 1.11 0.76 0.88 0.63 0.44   -1.43 0.05 
Fluvastatin   1.33 1.04 1.04 0.96 0.41 0.02 0.00 0.00 0.00   -1.33 0.01 
Alprazolam   1.63 1.34 2.36 2.08 2.63 1.02 1.88 3.30 2.89   1.26 0.02 
Cyclosporine   0.00 0.25 0.05 0.36 0.21 0.44 0.28 0.72 1.23   1.23 0.02 
Clonazepam   0.30 0.57 0.63 0.42 0.81 1.06 1.78 0.77 1.44   1.14 0.001 
Naproxen   1.96 1.47 1.54 1.55 1.70 1.15 1.68 1.41 0.92   -1.04 0.83 
Baclofen   0.02 0.00 0.10 0.12 0.10 0.48 0.24 0.35 0.90   0.87 0.003 
                            
No. observations   1834 1872 1901 1570 2154 2073 1791 1841 1901       







 Table 3. Descriptive Statistics of Cognitive Function Measurements and Covariates Among U.S. Adults Aged 60+. Data 
Source: NHANES 2011-2012 and 2013-2014.  
  All 
respondents 
  Number of medications with cognitive side effects taken 
by respondents 
  P-value 
a 
        






    
  N=2,908   N=1,180 N=941 N=526 N=261     
Cognitive assessment score, meanc (SD)c                         
     Word learning and recall 6.3 (2.3)   6.4 (2.3) 6.2 (2.2) 6.1 (2.4) 6.0 (2.3)   0.04 
     Animal fluency 18.2 (5.7)   18.7 (6.0) 18.0 (5.1) 17.9 (5.8) 17.3 (6.0)   0.03 
     Digit symbol substitution 52.3 (16.8)   54.3 (17.0) 52.2 (16.0) 50.3 (17.0) 47.5 (16.7)   < 0.001 
Whether score was more than 1 standard deviation (SD) below the mean, Nb (%)c               
     Word learning and recall 432 (11.4)   148 (9.3) 142 (12.1) 97 (14.0) 45 (12.9)   0.08 
     Animal fluency 691 (15.9)   266 (14.8) 210 (14.1) 138 (17.3) 77 (24.8)   0.02 
     Digit symbol substitution 846 (16.9)   323 (14.0) 250 (16.0) 179 (20.0) 94 (26.9)   < 0.001 
Composite global cognitive function                           
     Average standardized score  
-0.0 (1.00) 
  
0.1 (1.03) -0.0 (0.93) -0.1 (1.02) -0.2 (1.00) 
  
< 0.001 
     of 3 tests, meanc (SD)c     
     Whether 2+ test scores were more than 
543 (11.4) 
  
200 (9.7) 155 (9.6) 128 (15.3) 60 (18.2) 
  
< 0.001 
      one SD below the mean, Nb (%)c     
Whether used medications WITH cognitive side effects last 30 days, Nb (%)c             
     None 1180 (38.6)                       
     1 medication 941 (34.7)                       
     2 medications 526 (17.7)                       
     3+ medications 261 (9.0)                       
Whether used medications WITHOUT cognitive side effects last 30 days, Nb (%)c           
     None 557 (18.5)   430 (34.2) 95 (11.8) 23 (5.2) 9 (3.1)   < 0.001 
     1 medication 490 (17.8)   275 (25.8) 136 (15.4) 65 (11.5) 14 (5.3)   < 0.001 
     2 medications 470 (17.6)   179 (16.5) 175 (19.9) 96 (21.0) 20 (6.4)   < 0.001 
     3+ medications 1391 (46.1)   296 (23.5) 535 (52.9) 342 (62.4) 218 (85.2)   < 0.001 
Whether used medications WITH cognitive side effects last 30 days and duration of use, Nb (%)c       
     None 1180 (38.6)   N/A N/A N/A N/A     
     Used 1+ medication, at most 1 year 298 (9.4)   N/A 218 (21.4) 63 (8.8) 17 (4.5)   < 0.001 







Whether used medications WITHOUT cognitive side effects last 30 days and duration of use, Nb (%)c     
     None 557 (18.5)   430 (34.2) 95 (11.8) 23 (5.2) 9 (3.1)   < 0.001 
     Used 1+ medication, at most 1 year 261 (8.2)   128 (11.6) 79 (7.3) 35 (4.1) 19 (5.2)   < 0.001 
     Used 1+ medication, > 1 year 2090 (73.3)   622 (54.2) 767 (80.9) 468 (90.7) 233 (91.8)   < 0.001 
Whether used any prescription opioid last 30 days, Nb (%)c                 
  254 (7.9)   39 (3.3) 78 (6.2) 63 (11.3) 74 (27.9)   < 0.001 
Race & ethnicity, Nb (%)c                           
     Non-Hispanic White 1380 (79.5)   494 (77.0) 468 (80.7) 271 (80.3) 147 (83.7)   0.09 
     Hispanic 550 (7.0)   266 (8.7) 150 (5.6) 91 (6.7) 43 (5.8)   0.03 
     Non-Hispanic Black 697 (8.4)   288 (8.7) 230 (8.6) 123 (8.2) 56 (7.3)   0.76 
     Non-Hispanic others 281 (5.0)   132 (5.6) 93 (5.1) 41 (4.8) 15 (3.1)   0.22 
Gender, Nb (%)c                         0.03 
     Women 1493 (54.1)   597 (53.7) 471 (50.6) 275 (56.8) 150 (64.1)     
     Men 1415 (45.9)   583 (46.3) 470 (49.4) 251 (43.2) 111 (35.9)     
Age groups, Nb (%)c                           
     60-69 1581 (56.8)   736 (62.0) 463 (53.4) 243 (50.6) 139 (59.7)   0.004 
     70-79 855 (29.3)   293 (26.6) 317 (32.1) 175 (32.2) 70 (24.7)   0.03 
     80+ 472 (13.9)   151 (11.4) 161 (14.5) 108 (17.2) 52 (15.6)   0.04 
Marital status, Nb (%)c                           
     Married or partnered 1676 (65.1)   669 (62.7) 553 (67.3) 306 (65.7) 148 (66.2)   0.22 
     Widowed/divorced/separated 1063 (30.5)   426 (31.6) 337 (28.8) 198 (31.6) 102 (30.5)   0.71 
     Never married 165 (4.3)   83 (5.7) 49 (3.9) 22 (2.7) 11 (3.4)   0.12 
Education, Nb (%)c                           
     Less than high school 741 (15.7)   290 (13.0) 223 (15.5) 156 (20.1) 72 (19.4)   0.05 
     High school graduate 680 (22.1)   268 (20.5) 228 (23.9) 124 (22.5) 60 (20.9)   0.41 
     Some college  816 (31.6)   323 (31.9) 275 (31.5) 133 (29.5) 85 (34.6)   0.71 
     College graduate or above 668 (30.6)   297 (34.6) 215 (29.1) 112 (28.0) 44 (25.1)   0.03 
Poverty, Nb (%)c                           
     <100% poverty threshold 455 (9.4)   182 (9.4) 136 (8.7) 81 (9.3) 56 (12.0)   0.18 
     100-199% 794 (23.6)   319 (24.0) 247 (22.7) 159 (25.6) 69 (21.7)   0.55 
     200-299% 376 (15.3)   155 (14.2) 121 (14.5) 63 (17.2) 37 (19.7)   0.41 
     300-399% 323 (13.4)   115 (12.2) 121 (14.1) 58 (14.1) 29 (14.7)   0.63 
     400-499% 207 (10.5)   80 (10.1) 72 (10.9) 40 (10.3) 15 (10.5)   0.98 
     500%+ 505 (27.8)   217 (30.1) 173 (29.0) 83 (23.5) 32 (21.4)   0.13 
U.S. citizenship, Nb (%)c                         < 0.001 
     Not U.S. citizen 198 (2.6)   134 (4.7) 41 (1.6) 15 (1.0) 8 (1.0)     







Had any health insurance, Nb (%)c                         < 0.001 
     Yes 2666 (94.5)   1005 (90.5) 903 (97.0) 505 (97.7) 253 (96.0)     
     No 238 (5.5)   173 (9.5) 37 (3.0) 20 (2.3) 8 (4.0)     
Had routine place for medical care, Nb (%)c                       < 0.001 
     Yes 2739 (95.7)   1032 (91.0) 925 (98.3) 523 (99.6) 259 (98.7)     
     No 169 (4.3)   148 (9.0) 16 (1.7) 3 (0.4) 2 (1.3)     
Smoking status, Nb (%)c                           
     Never smoked 1432 (49.6)   633 (53.9) 454 (49.3) 242 (47.1) 103 (37.8)   0.004 
     Former smoker 1106 (39.3)   376 (34.4) 385 (40.9) 221 (40.8) 124 (51.8)   0.002 
     Current smoker 368 (11.0)   170 (11.8) 101 (9.9) 63 (12.1) 34 (10.4)   0.79 
Health conditions, Nb (%)c                           
     Asthma 401 (13.9)   124 (11.7) 122 (11.0) 80 (15.4) 75 (31.7)   < 0.001 
     Arthritis 1417 (49.9)   428 (37.9) 468 (48.1) 326 (65.2) 195 (78.1)   < 0.001 
     Cancer 589 (24.0)   203 (22.5) 209 (25.2) 116 (23.5) 61 (27.4)   0.51 
     Congestive heart failure 202 (6.7)   41 (3.5) 67 (6.5) 60 (12.4) 34 (10.0)   < 0.001 
     Coronary heart disease 261 (9.4)   35 (2.6) 100 (11.4) 84 (17.4) 42 (15.4)   < 0.001 
     Heart attack 244 (8.5)   45 (3.1) 88 (9.7) 83 (16.3) 28 (11.5)   < 0.001 
     Angina 157 (5.8)   26 (1.6) 57 (5.9) 45 (11.2) 29 (13.0)   < 0.001 
     Emphysema 106 (4.6)   23 (2.7) 34 (3.8) 26 (7.3) 23 (10.8)   < 0.001 
     Bronchitis 207 (7.7)   71 (6.7) 61 (6.6) 44 (11.0) 31 (9.4)   0.15 
     Stroke 200 (6.3)   53 (4.6) 69 (6.4) 50 (8.2) 28 (9.7)   0.07 
     Hypertension 1257 (39.4)   507 (39.6) 398 (39.7) 237 (37.7) 115 (40.5)   0.90 
     Diabetes 678 (20.4)   155 (10.2) 272 (25.5) 159 (28.1) 92 (28.7)   < 0.001 
     Sleep disorder 946 (34.5)   261 (23.1) 301 (33.3) 226 (44.8) 158 (67.9)   < 0.001 
Depression (PHQ-9), Nb (%)c                         < 0.001 
     Yes (score >= 10) 258 (7.2)   73 (4.5) 68 (5.9) 67 (10.4) 50 (17.7)     
     No (score < 10) 2602 (92.8)   1085 (95.5) 857 (94.1) 452 (89.6) 208 (82.3)     
Obese, Nb (%)c                         0.003 
     Yes (BMI >= 30) 1081 (37.7)   380 (32.9) 371 (37.1) 207 (42.4) 123 (51.8)     
     No (BMI < 30) 1778 (62.3)   779 (67.1) 560 (62.9) 307 (57.6) 132 (48.2)     
a: P-value indicates if means are significantly different across respondents who took none, one, two, or at least three medications with 
cognitive side effects, based on logistics regression, survey weights, and 10 imputed datasets. 
b: Unweighted and non-imputed raw frequency. The numbers may not add up to the total due to missing data. 








Table 4. Adjusted Linear Least-Squared Regressions of Standardized Cognitive Test Scores on Utilization of Medications with 
Cognitive Side Effects for Adults Aged 60+. Data Source: NHANES 2011-2012 and 2013-2014. 
  















of three tests 
  Coef. (SE)   Coef. (SE)   Coef. (SE)   Coef. (SE) 
Whether taking medications WITH cognitive side effects 
     None (reference) 
     1 medication -0.02 (0.06)   -0.04 (0.06)   0.00 (0.06)   -0.02 (0.05) 
     2 medications -0.10 (0.06)   0.01 (0.08)   -0.03 (0.07)   -0.04 (0.05) 
     3+ medications -0.24* (0.09)   -0.15 (0.09)   -0.27** (0.07)   -0.22*** (0.06) 
Whether taking medications WITHOUT cognitive side effects 
     None (reference) 
     1 medication 0.00 (0.07)   -0.10 (0.08)   -0.11 (0.08)   -0.07 (0.05) 
     2 medications -0.10 (0.06)   -0.05 (0.08)   -0.07 (0.07)   -0.07 (0.05) 
     3+ medications -0.07 (0.05)   -0.07 (0.08)   -0.17* (0.06)   -0.10* (0.05) 
Race & ethnicity 
     Non-Hispanic White (reference) 
     Hispanic -0.20** (0.06)   -0.23*** (0.06)   -0.58*** (0.05)   -0.34*** (0.05) 
     Non-Hispanic Black -0.15* (0.06)   -0.49*** (0.05)   -0.65*** (0.05)   -0.43*** (0.04) 
     Non-Hispanic others 0.11 (0.08)   -0.46*** (0.10)   -0.09 (0.07)   -0.15* (0.05) 
Female 0.36*** (0.04)   0.00 (0.05)   0.34*** (0.03)   0.23*** (0.03) 
Age (in years) -0.05*** (0.00)   -0.04*** (0.00)   -0.05*** (0.00)   -0.05*** (0.00) 
Marital status               
     Married or living with partner (reference) 
     Widowed, divorced, separated -0.05 (0.04)   0.02 (0.05)   -0.02 (0.04)   -0.02 (0.03) 
     Never married -0.02 (0.11)   -0.04 (0.13)   -0.02 (0.10)   -0.03 (0.09) 
Educational attainment                
     Less than high school (reference)               
     High school graduate 0.05 (0.07)   0.13* (0.05)   0.39*** (0.04)   0.19*** (0.04) 
     Some college or AA degree 0.23*** (0.06)   0.42*** (0.05)   0.61*** (0.04)   0.42*** (0.03) 
     College graduate or above 0.26* (0.10)   0.72*** (0.08)   0.77*** (0.05)   0.59*** (0.06) 







     <100% federal guideline (reference)               
     100-199% -0.01 (0.06)   0.05 (0.06)   0.10 (0.06)   0.05 (0.05) 
     200-299% 0.14 (0.08)   0.05 (0.09)   0.24** (0.06)   0.14* (0.05) 
     300-399% 0.18* (0.08)   0.08 (0.09)   0.41*** (0.07)   0.22*** (0.05) 
     400-499% 0.05 (0.09)   0.13 (0.08)   0.44*** (0.08)   0.21** (0.06) 
     500%+ 0.17 (0.09)   0.13 (0.08)   0.38*** (0.08)   0.23** (0.07) 
Not U.S. citizen -0.21** (0.07)   -0.26* (0.11)   -0.46*** (0.07)   -0.31*** (0.07) 
Has any health insurance 0.09 (0.07)   0.10 (0.12)   0.14 (0.08)   0.11 (0.06) 
Has routine place for medical care 0.17* (0.07)   -0.01 (0.12)   0.07 (0.08)   0.08 (0.07) 
Smoking               
     Never smoked (reference)               
     Smoked 100+ cigarettes, not current smoker 0.05 (0.06)   0.02 (0.05)   0.02 (0.05)   0.03 (0.04) 
     Smoked 100+ cigarettes, current smoker -0.00 (0.07)   0.01 (0.09)   -0.15* (0.06)   -0.04 (0.05) 
Depression (PHQ-9 >= 10) -0.10 (0.07)   -0.25** (0.07)   -0.17 (0.09)   -0.17** (0.05) 
Obese (BMI >= 30) 0.09 (0.05)   0.07 (0.05)   0.06 (0.04)   0.07 (0.04) 
Year fixed effect (2013-2014 vs. 2011-2012) 0.33*** (0.06)   -0.03 (0.05)   -0.04 (0.04)   0.09* (0.03) 
Health conditions a Yes   Yes   Yes   Yes 
No. observations  2,908   2,908   2,908   2,908 
Notes: a Health conditions include a set of binary indicators for whether a person has ever been told by a health professional 
that they have asthma, arthritis, cancer, congestive health failure, coronary heart disease, heart attack, angina, emphysema, 
bronchitis, stroke, diabetes, hypertension, and sleep disorder. 














Table 5. Adjusted Logistic Regressions of Whether Cognitive Assessment Scores Are More Than One Standard Deviation 
Below the Mean on Utilization of Medications with Cognitive Side Effects for Adults Aged 60+. Data Source: NHANES 2011-
2012 and 2013-2014.  
  
Whether scores are one standard deviation below the mean   Composite 
measure 
Outcome: Word learning 
and recalls 




  Whether 2+ test 
scores are more 
than one standard 
deviation below 
the mean 
  OR (SE)   OR (SE)   OR (SE)   OR (SE) 
Whether taking medications WITH cognitive side effects 
     None (reference) 
     1 medication 1.38* (0.22)   0.77 (0.12)   1.20 (0.18)   0.88 (0.15) 
     2 medications 1.55* (0.28)   0.85 (0.13)   1.34 (0.29)   1.38 (0.23) 
     3+ medications 2.04* (0.64)   1.59 (0.39)   2.82*** (0.67)   2.10** (0.54) 
Whether taking medications WITHOUT cognitive side effects 
     None (reference) 
     1 medication 0.68 (0.15)   1.10 (0.27)   0.98 (0.24)   0.92 (0.23) 
     2 medications 1.08 (0.25)   0.98 (0.25)   0.61* (0.14)   0.82 (0.21) 
     3+ medications 0.83 (0.18)   1.41 (0.33)   1.22 (0.28)   1.28 (0.27) 
Race & ethnicity 
     Non-Hispanic White (reference) 
     Hispanic 1.60* (0.35)   1.62* (0.34)   4.54*** (0.77)   2.28** (0.56) 
     Non-Hispanic Black 1.39 (0.30)   3.23*** (0.55)   5.18*** (0.83)   3.25*** (0.82) 
     Non-Hispanic others 0.69 (0.18)   2.46*** (0.53)   0.99 (0.19)   1.18 (0.32) 
Female 0.60* (0.11)   0.88 (0.15)   0.51*** (0.09)   0.70* (0.12) 
Age (in years) 1.13*** (0.02)   1.09*** (0.01)   1.15*** (0.01)   1.14*** (0.02) 
Marital status               
     Married or living with partner (reference) 
     Widowed, divorced, separated 0.93 (0.17)   1.12 (0.18)   1.21 (0.22)   1.14 (0.14) 
     Never married 1.20 (0.45)   1.18 (0.34)   1.61 (0.51)   1.66 (0.60) 
Educational attainment                







     High school graduate 1.06 (0.21)   0.75 (0.12)   0.37*** (0.05)   0.61* (0.12) 
     Some college or AA degree 0.74 (0.13)   0.41*** (0.07)   0.20*** (0.03)   0.29*** (0.06) 
     College graduate or above  0.51** (0.12)   0.34*** (0.07)   0.15*** (0.03)   0.21*** (0.04) 
Poverty               
     <100% federal guideline (reference)               
     100-199% 0.88 (0.17)   0.93 (0.17)   0.91 (0.17)   1.01 (0.21) 
     200-299% 0.73 (0.21)   0.91 (0.23)   0.58** (0.11)   0.64 (0.18) 
     300-399% 0.51* (0.14)   0.67 (0.14)   0.25*** (0.06)   0.44* (0.13) 
     400-499% 0.58 (0.19)   0.65 (0.23)   0.30*** (0.09)   0.47* (0.17) 
     500%+ 0.65 (0.23)   0.60 (0.18)   0.39** (0.12)   0.51 (0.23) 
Not U.S. citizen 1.37 (0.37)   1.82 (0.76)   3.75*** (0.89)   2.07* (0.55) 
Has any health insurance 0.90 (0.25)   1.07 (0.27)   0.76 (0.19)   0.79 (0.20) 
Has routine place for medical care 0.55 (0.23)   0.70 (0.22)   0.43* (0.13)   0.42* (0.14) 
Smoking               
     Never smoked (reference)               
     Smoked 100+ cigarettes, not current smoker 0.61* (0.11)   1.00 (0.14)   0.85 (0.12)   0.72* (0.11) 
     Smoked 100+ cigarettes, current smoker 0.85 (0.22)   1.11 (0.22)   1.42 (0.38)   1.19 (0.25) 
Depression (PHQ-9 >= 10) 1.48 (0.34)   1.87*** (0.29)   1.69* (0.42)   2.18*** (0.40) 
Obese (BMI >= 30) 0.79 (0.13)   0.80 (0.12)   0.74 (0.14)   0.72 (0.12) 
Year fixed effect (2013-2014 vs. 2011-2012) 0.55*** (0.09)   0.89 (0.09)   1.00 (0.14)   0.81 (0.13) 
Health conditions a Yes   Yes   Yes   Yes 
Number of observations  2,908   2,908   2,908   2,908 
Notes: a Health conditions include a set of binary indicators for whether a person has ever been told by a health professional 
that they have asthma, arthritis, cancer, congestive health failure, coronary heart disease, heart attack, angina, emphysema, 
bronchitis, stroke, diabetes, hypertension, and sleep disorder. 












Table 6. Adjusted Linear and Logistic Regressions of Composite Cognitive Measures on Utilization of Medications with 
Cognitive Side Effects and Duration of Using These Medications for Adults Aged 60+. Data Source: NHANES 2011-2012 and 
2013-2014. 
  Global cognitive measures 
Outcome: Average standardized 
score of the 3 tests 
  Whether 2+ test 
scores are more than 
one standard 
deviation below the 
mean 
  Coef. (SE)   OR (SE) 
Whether taking medications WITH cognitive side effects and duration of using such medications 
     None (reference) 
     1 medication       
          At most one year 
-0.00 (0.07)   0.81 (0.21) 
          More than one year 
-0.01 (0.05)   0.87 (0.14) 
     2 medications       
          At most one year 
-0.08 (0.09)   1.02 (0.38) 
          More than one year 
-0.02 (0.05)   1.35 (0.22) 
     3+ medications       
          At most one year 
-0.69** (0.25)   14.80** (11.38) 
          More than one year 
-0.19** (0.06)   1.79* (0.48) 
Whether taking medications WITHOUT cognitive side effects and duration of using such medications 
     None (reference) 
     1 medication       
          At most one year 
-0.07 (0.06)   0.98 (0.42) 
          More than one year 
-0.04 (0.06)   0.76 (0.20) 







          At most one year 
0.01 (0.08)   0.48 (0.25) 
          More than one year 
-0.06 (0.06)   0.79 (0.22) 
     3+ medications       
          At most one year 
0.04 (0.15)   1.37 (0.59) 
          More than one year 
-0.09 (0.04)   1.12 (0.24) 
Number of observations  2,908   2,908 
Notes: All analyses controlled for race, age, gender, marital status, educational attainment, poverty, 
citizenship, health insurance coverage, whether the person has a routine place for medical care, smoking 
status, binary indicator for each self-reported health condition (asthma, arthritis, cancer, congestive health 
failure, coronary heart disease, heart attack, angina, emphysema, bronchitis, stroke, diabetes, hypertension, 
and sleep disorder), depression (PHQ-9 scale), obesity (BMI of at least 30), and time trends. 













Figure 2: Marginal Effects (with 95% Confidence Intervals) of Medications 
With/Without Cognitive Side Effects on Global Cognitive Score by Age Among 
Adults Aged 60+. Data Source: NHANES 2011-2012 and 2013-2014. 
 
Notes: The marginal effects were calculated from the linear regression of the global cognitive score 
(average of the three standardized cognitive assessment scores) on the interactions between medications 
with/without cognitive side effects and age groups (60-64, 65-74, and 75+), while controlling for other 
covariates such as race, gender, marital status, educational attainment, poverty, citizenship, health 
insurance coverage, whether the person has a routine place for medical care, smoking status, binary 
indicator for each self-reported health condition (asthma, arthritis, cancer, congestive health failure, 
coronary heart disease, heart attack, angina, emphysema, bronchitis, stroke, diabetes, hypertension, and 








Figure 3: Marginal Effects (with 95% Confidence Intervals) of Medications 
With/Without Cognitive Side Effects on Global Cognitive Score by Gender Among 
Adults Aged 60+. Data Source: NHANES 2011-2012 and 2013-2014. 
 
Notes: The marginal effects were calculated from the linear regression of the global cognitive score 
(average of the three standardized cognitive assessment scores) on the interactions between medications 
with/without cognitive side effects and gender, while controlling for other covariates such as race, age, 
marital status, educational attainment, poverty, citizenship, health insurance coverage, whether the person 
has a routine place for medical care, smoking status, binary indicator for each self-reported health condition 
(asthma, arthritis, cancer, congestive health failure, coronary heart disease, heart attack, angina, 
emphysema, bronchitis, stroke, diabetes, hypertension, and sleep disorder), depression (PHQ-9 scale), 








Figure 4: Marginal Effects (with 95% Confidence Intervals) of Medications 
With/Without Cognitive Side Effects on Global Cognitive Score by Educational 
Attainment Among Adults Aged 60+. Data Source: NHANES 2011-2012 and 2013-
2014. 
 
Notes: The marginal effects were calculated from the linear regression of the global cognitive score 
(average of the three standardized cognitive assessment scores) on the interactions between medications 
with/without cognitive side effects and educational attainment (high school graduate or lower and college 
or higher), while controlling for other covariates such as race, gender, age, marital status, poverty, 
citizenship, health insurance coverage, whether the person has a routine place for medical care, smoking 
status, binary indicator for each self-reported health condition (asthma, arthritis, cancer, congestive health 
failure, coronary heart disease, heart attack, angina, emphysema, bronchitis, stroke, diabetes, hypertension, 








Figure 5: Marginal Effects (with 95% Confidence Intervals) of Medications 
With/Without Cognitive Side Effects on Global Cognitive Score by Race/Ethnicity 
Among Adults Aged 60+. Data Source: NHANES 2011-2012 and 2013-2014. 
 
Notes: The marginal effects were calculated from the linear regression of the global cognitive score 
(average of the three standardized cognitive assessment scores) on the interactions between medications 
with/without cognitive side effects and race/ethnicity (non-Hispanic whites, Hispanic, non-Hispanic blacks, 
and non-Hispanic others), while controlling for other covariates such as age, gender, marital status, 
educational attainment, poverty, citizenship, health insurance coverage, whether the person has a routine 
place for medical care, smoking status, binary indicator for each self-reported health condition (asthma, 
arthritis, cancer, congestive health failure, coronary heart disease, heart attack, angina, emphysema, 
bronchitis, stroke, diabetes, hypertension, and sleep disorder), depression (PHQ-9 scale), obesity (BMI of at 









Figure 6: Marginal Effects (with 95% Confidence Intervals) of Medications 
With/Without Cognitive Side Effects on Global Cognitive Score by Marital Status 
Among Adults Aged 60+. Data Source: NHANES 2011-2012 and 2013-2014. 
 
Notes: The marginal effects were calculated from the linear regression of the global cognitive score 
(average of the three standardized cognitive assessment scores) on the interactions between medications 
with/without cognitive side effects and marital status (married or cohabiting and not married or cohabiting), 
while controlling for other covariates such as race, age, gender, educational attainment, poverty, 
citizenship, health insurance coverage, whether the person has a routine place for medical care, smoking 
status, binary indicator for each self-reported health condition (asthma, arthritis, cancer, congestive health 
failure, coronary heart disease, heart attack, angina, emphysema, bronchitis, stroke, diabetes, hypertension, 










Table 7. Most Common Combinations of Medications with Cognitive Side Effects Among Adults Aged 60+ Who Consumed At 
Least Three Medications with Cognitive Side Effects. Data Source: NHANES 1999-2000 to 2015-2016. 
Combinations of medications with cognitive side effects   N   % 
Anticonvulsants - antihyperlipidemic agents - proton pump inhibitors   66   5.31 
     Omeprazole-gabapentin-simvastatin         
     Omeprazole-atorvastatin-gabapentin         
     Omeprazole-gabapentin-pravastatin         
     Pantoprazole-gabapentin-simvastatin         
     Pantoprazole-atorvastatin-gabapentin         
     Omeprazole-pregabalin-atorvastatin         
     Esomeprazole-gabapentin-simvastatin         
     Rabeprazole-atorvastatin-gabapentin         
Antiadrenergic agents - antihyperlipidemic agents - proton pump inhibitors   37   3.2 
     Omeprazole-tamsulosin-simvastatin         
     Omeprazole-tamsulosin-atorvastatin         
     Pantoprazole-tamsulosin-simvastatin         
     Pantoprazole-tamsulosin-atorvastatin         
     Omeprazole-tamsulosin-pravastatin         
     Esomeprazole-tamsulosin-simvastatin         
     Esomeprazole-tamsulosin-rosuvastatin         
Sex hormones - antihyperlipidemic agents - proton pump inhibitors   23   3.02 
     Conjugated estrogens-omeprazole-atorvastatin         
     Omeprazole-simvastatin-testosterone         
     Esomeprazole-estrogens methyltestosterone-atorvastatin         
     Conjugated estrogens-omeprazole-simvastatin         
     Conjugated estrogens-esomeprazole-atorvastatin         
Anxiolytics, sedatives, and hypnotics - antihyperlipidemic agents - proton pump inhibitors   33   2.91 
     Alprazolam-omeprazole-simvastatin         
     Alprazolam-esomeprazole-atorvastatin         
     Esomeprazole-atorvastatin-zolpidem         
     Alprazolam-omeprazole-lovastatin         
     Alprazolam-omeprazole-atorvastatin         
Antidepressants - antihyperlipidemic agents - proton pump inhibitors   26   2.86 
     Omeprazole-trazodone-simvastatin         
     Omeprazole-fluoxetine-simvastatin         







     Pantoprazole-amitriptyline-simvastatin         
     Pantoprazole-amitriptyline-fluoxetine-lovastatin         
Anticonvulsants - antidepressants - antihyperlipidemic agents   26   2.02 
     Amitriptyline-diazepam-simvastatin         
     Amitriptyline-atorvastatin-gabapentin         
     Trazodone-gabapentin-simvastatin         
     Trazodone-diazepam-simvastatin         
     Clonazepam-fluoxetine-simvastatin         
Antiarrhythmic agents - antihyperlipidemic agents - proton pump inhibitors   27   1.87 
     Diltiazem-omeprazole-simvastatin         
     Diltiazem-omeprazole-atorvastatin         
     Diltiazem-esomeprazole-simvastatin         
     Omeprazole-propranolol-simvastatin         
     Omeprazole-phenytoin-simvastatin         
Leukotriene modifiers - antihyperlipidemic agents - proton pump inhibitors   16   1.59 
     Montelukast-omeprazole-atorvastatin         
     Montelukast-pantoprazole-simvastatin         
     Montelukast-omeprazole-simvastatin         
     Montelukast-omeprazole-rosuvastatin         
     Montelukast-rabeprazole-simvastatin         
Antidepressants - antihyperlipidemic agents - anxiolytics, sedatives, and hypnotics   12   1.5 
     Alprazolam-amitriptyline-atorvastatin         
     Fluoxetine-rosuvastatin-zolpidem         
     Atorvastatin-fluoxetine-zolpidem         
     Amitriptyline-simvastatin-zaleplon         
     Amitriptyline-rosuvastatin-zolpidem         
Analgesics - antihyperlipidemic agents - proton pump inhibitors   19   1.27 
     Omeprazole-ibuprofen-simvastatin         
     Esomeprazole-naproxen-atorvastatin         
     Pantoprazole-ibuprofen-simvastatin         
     Omeprazole-ibuprofen-pravastatin         
     Naproxen-omeprazole-rosuvastatin         
Notes: Estimates were based on 1,153 adults aged 60+ who consumed at least three medications with cognitive side effects in the past 30 days using the 





The Consequences of Medications with Insomnia, Depression, Anxiety, and Suicidal 
Side Effects on U.S. Adults’ Mental Health and Use/Cost of Mental Health Services. 
 
Objective: To document the trends in using medications with insomnia, depression, 
anxiety, and suicidal side effects (“mental health side effect” hereafter) among U.S. 
adults from 1996 to 2016, and to investigate the association between the use of these 
medications and psychiatric distress and the use of mental health services. 
Data source: Nationally representative sample of adults aged 25-84 from the Medical 
Expenditure Panel Survey (MEPS) in 1996-2016 (N = 211,551). Psychological distress is 
measured using the Kessler-6 scale. 
Principal findings: In 2016, 50% U.S. adults used medications with mental health side 
effects, an increase from 45% in 1996. Much of the growth was driven by increasing use 
of medications with insomnia (relative increase of 66.8% between 1996 and 2016), 
anxiety (relative increase of 80.7%), and suicidal (relative increase of 77.3%) side effects. 
Compared to respondents who did not consume medications with mental health side 
effects at the baseline, individuals who used three or more of these medications 
simultaneously had higher odds of reporting psychological distress (OR = 1.859, p < 
0.001), new mental disorders at follow-up (OR = 1.986, p < 0.001), having more visits 
for mental disorders at follow-up (coefficient = 0.153, p < 0.001), having higher total 
charges for mental disorders at follow-up (coefficient = 103.2, p < 0.001), and using 
more psychotropic medications for treatments of mental disorders at follow-up (OR = 




effects was not associated with psychological distress or the use of mental health 
services. 
Conclusion: Concurrent use of medications with mental health side effects has increased 
significantly since 1996. The use of these medications was associated with an increase in 
psychological distress and the use/costs of mental health services. Since many 
medications with mental health side effects are intended for treatments of physical 
disease, these findings suggest that physicians may have neglected the role of mental 
health when proving care to patients, and that any mental health side effects may be 
subsequently treated by prescribing psychotropic medications. These findings also 



















Mental disorders refers to a wide range of conditions that influence one’s mood, thinking, 
and behaviors (Mental Health: A Report of the Surgeon General, 1999). It has been 
estimated that more than one-fourth of American adults currently have at least one mental 
disorder, and half will develop a mental disorder in their lifetime (Kessler, Berglund, et 
al., 2005; Kessler, Chiu, et al., 2005). The most common mental disorders are anxiety 
disorders (lifetime prevalence of 31.5%), mood disorders (28%), and impulse-control 
disorders (25.4%) (Kessler, Berglund, et al., 2005). Although many U.S. adults have at 
least one mental disorder, only 15.5% of them receive treatment (Thorpe et al., 2017). 
While mental illness is a significant public health concern itself, its association with other 
chronic and physical conditions has important implications for morbidity and mortality 
(Chapman et al., 2005; Evans et al., 2005). In 2010, mental and substance disorders 
accounted for 183.9 million disability-adjusted life years worldwide, 8.6 million years of 
life lost, and 175.3 million years lost due to disability, and these burdens have increase by 
37.6% since 1990 (Whiteford et al., 2013). Having a mental disorder is also associated 
with increased health care utilization and costs. In 2013, mental disorders collectively 
represented the costliest conditions in the United States, which totaled $201 billion in 
health care expenditures (Roehrig, 2016). The total cost would be even higher when 
adding lost earnings wages and disability benefits, which were estimated to be $193 
billion and $24 billion in 2002, respectively (Insel, 2008).  
 
Not only is the prevalence of mental disorders high and their consequences on morbidity 




are also of important concerns to policy makers. While the age of onset varies 
significantly, many disorders first occur in young ages, from 11 years old for anxiety and 
impulse-control disorders to 30 years old for mood disorders (Kessler, Berglund, et al., 
2005). In addition, adolescents and young adults are much more likely to experience 
mood and anxiety disorders than older adults (Kessler et al., 2012). Since the early onset 
of mental disorders is a significant predictor for late-life mental and cognitive illnesses 
(Kraaij et al., 2002; Schoevers et al., 2005), a large number of young adults reporting 
worrisome mental illness today implies that the future aging population may be mentally 
sicker and require more health care resources than the current one. 
 
Given the adverse health consequences and financial burdens of mental disorders on 
individuals, families, and society, prior studies have investigated risk factors of mental 
disorders to provide recommendations for public health interventions. Well-documented 
risk factors include dietary factors, drugs and substance abuse, family background, 
socioeconomic status, lifestyle, medical history and comorbidity, and trauma (Köhler et 
al., 2018). However, little is known about the role of medications in mental health, 
despite the growing popularity of medication use. In 2011-2012, almost 60% of 
American adults used at least one prescription medication and 15% used at least five, an 
increase from 51% and 8.2% in 1999-2000 respectively (Kantor et al., 2015). While 
medication use is important and critical for disease management, a growing literature 
suggests that many commonly used medications have adverse effects on mental disorders 
(Gorton et al., 2016; Lavigne, 2016; Qato et al., 2018). For example, Qato et al. (2018) 




Nutrition Examination Survey (NHANES) and found that the prevalence of using at least 
one medication with depression as a potential side effect increased from 35% in 2005-
2006 to 38.4% in 2013-2014. The prevalence of using at least three of such medications 
increased even more: from 6.9% to 9.5% during the same period, or a relative increase of 
almost 38%. The authors also found that respondents who consumed at least three 
medications with depression side effects were 10.7 percentage points more likely to 
report depressive symptoms, compared to nonusers.  
 
Despite previous evidence on the adverse consequences of medications on mental health, 
more research on this topic is warranted. Many prior studies only focused on a single 
medication or a class of medication, and/or used a non-representative sample (Gorton et 
al., 2016). As such, little is known about the adverse consequences of medications on 
mental health at the population level and how the use of these medications has changed 
over time. Qato et al. (2018) was the first to investigate trends in the prevalence of 
medications with depression as a potential side effect at the population level and how the 
use of these medications influenced depression among community-dwelling adults. While 
the authors improved the existing literature by using a nationally representative sample of 
U.S. adults and examining more than 200 medications that had depression as a potential 
side effect, their study faced several limitations. First, their definition of medications with 
depression side effect only included medications with depression, depressive disorder, 
suicide, suicidal thoughts, suicidal ideation, or suicidal behavior listed as common or 
serious adverse effects. There are medications with other potential side effects that may 




the authors only investigated depression as an outcome without considering other 
interrelated mental disorders such as anxiety or impulse-control disorders. Third, their 
study used a cross-sectional survey, which might limit their ability to address reverse 
causation and unobservable heterogeneity. Fourth, little is known about how the use of 
these medications influenced respondents’ subsequent use of mental health services and 
the costs associated with those services. Finally, although Qato et al. (2018) significantly 
improved the previous literature by including in their study both younger adults and older 
adults, they did not investigate whether the association between medications with 
depression side effect and concurrent depression differed by age. There are conflicting 
theories and evidence on whether such association is larger among older adults or among 
young adults. On the one hand, older adults are expected to experience more adverse drug 
reactions due to decreasing hepatic metabolism and renal clearance (Leon, 2011; Shi & 
Klotz, 2011), having more chronic conditions (Ward & Schiller, 2013), and consuming 
multiple medications simultaneously (Kantor et al., 2015). On the other hand, the 
selection of young and healthy adults into taking multiple medications with depression as 
a potential side effect may signal an early onset of chronic conditions that can be more 
debilitating to health than those that occur at older ages (Huang et al., 2010). The extent 
to which theory dominates the other explains for the age-differences in adverse drug 
reactions. 
 
The present study seeks to improve the existing literature by using a longitudinal national 




medications on the U.S. market that have mental health side effects. The study has four 
aims: 
1. What is the trend in the prevalence of using medications with insomnia, 
depression, anxiety, or suicidal side effects (“mental health side effects”) 
among community-dwelling adults aged 25-84 from 1996 to 2016? 
2. What is the association between the use of medications with mental health 
side effects and subsequent nonspecific psychological distress and mental 
disorders? 
3. What is the association between medications with mental health side effects 
and subsequent use of mental health services and total costs associated with 
these services?  
4. How does the relationship differ by age? 
 
Methods 
Data comes from the 2004-2015 Medical Expenditure Panel Survey (MEPS). Although 
the MEPS has been fielded every single year from 1996 to 2016, I selected the 2004-2015 
surveys because nonspecific psychological distress was not collected until 2004. 
Moreover, data on utilization and cost of mental health services in 2016 are not yet 
available due to the replacement of the International Classification of Diseases (ICD)-9 
with the ICD-10. However, when assessing trends in the use of medications with mental 





The MEPS is a nationally representative and longitudinal survey of the civilian non-
institutionalized U.S. population, drawn from a subsample of households that participated 
in the prior year’s National Health Interview Survey (NHIS). Both MEPS and NHIS 
oversample Black, Hispanic, Asian, and low-income respondents to improve the 
precision of estimates for these subgroups. The overall MEPS response rate, after 
accounting for nonresponse rate from the NHIS, ranges from 46% to 71%. 
 
MEPS respondents enter the survey annually as members of a unique survey panel. For a 
graphical illustration of the MEPS study design, please refer to the IPUMS-MEPS’s user 
guideline: https://meps.ipums.org/meps/userNotes_MEPS_panel_design.shtml. MEPS 
then interviews participants of each panel five times over two calendar years. During 
each interview, one informant who is most knowledgeable about health and health care 
use in the household will typically report for all household members. The average recall 
period for each interview round is five months. For each calendar year, data from 
interview rounds 1, 2, and 3 are included for individuals in the first year of their panel, 
and data from interview rounds 3, 4, and 5 are included for individuals in the second year 
of their panel. Collectively, respondents from two overlapping panels in each calendar 
year provide nationally representative estimates of their health status, socio-demographic 
characteristics, chronic conditions, and medication use. Note that MEPS data in most 
years are not independent of one another because most respondents are in the survey for 
two consecutive years. However, it is still valid to pool data from multiple calendar years 
despite this lack of independence because MEPS was designed to be nationally 




structure are properly specified in all analyses (Agency for Healthcare Research and 
Quality, 2019). 
 
Following the completion of the household interview, MEPS interviewers asked 
respondents for permission to contact their medical providers (i.e. physicians, hospitals, 
home health agencies, and pharmacies) to confirm information that the respondents 
reported8. Collected information included the date of visits, diagnoses and procedures, 
charges, payments, detailed information on medications, dates when prescriptions were 
filled, sources and amounts of payments. Collected information was only used to impute 
missing data and improve the precision of estimates. Response rates vary by the types of 
medical providers, but typically range from 75% to 85%. For this reason, MEPS is one of 
the most comprehensive data sources on national-level medical utilization and 
expenditures, as well as individual characteristics such as socio-demographic 
characteristics, health behaviors, and health conditions. 
 
This study used a merged sample of respondents from 2004 to 2015, which combined the 
full year consolidated files with the medical condition files, the event files, and the 
prescribed medicine files. Information on end-of-the-year socio-demographic 
 
8 Note that MEPS only contacted medical providers to confirm information reported by respondents, and in 
many cases, asked for more information about an event reported by a respondent (i.e. cost or diagnosis for a 
reported doctor visit). Additional events reported by medical providers but not by the respondents were not 
included in the data to avoid the discrepancy in the number of events between respondents who gave 




characteristics was obtained from the full year consolidated files, while round-specific 
information on the use of medications, self-reported chronic conditions, and the use and 
costs of health services came from the remaining files. I first selected respondents aged 
25 to 84 (N = 248,741). Respondents aged 85 and older were dropped because MEPS 
censored age at 85, and unobservable characteristics of the oldest population might be 
systematically different from those of the general population. I excluded respondents who 
were under 25 years of age because all analysis models controlled for educational 
attainment. Restricting the sample to those aged 25 and older allowed respondents to 
complete their educational attainment. After excluding 33,886 respondents without 
mental health assessment9, 3,304 respondents with missing information on any of the 
covariates described shortly below, the final sample included 211,551 respondents. In a 
sensitivity analysis not reported here, I used multiple imputation with chained equations 
to handle missing data, but the interpretation of the results did not change because only 
1.5% of the sample had missing data on covariates. The results in this paper come from 
the analytic sample without missing data. 
 
Nonspecific psychological distress. MEPS measures nonspecific psychological distress 
over a 30-day recall period using a five point Likert-type scale developed by Ronald C. 
Kessler and is widely known as the Kessler 6 Scale (K6) (Kessler et al., 2002, 2003). The 
K6 scale has been successfully implemented in major epidemiological studies in various 
 
9 Respondents were not eligible for the mental health assessment if there was no record of the person in the 
interview round, if they were deceased or institutionalized, if they had moved out of the U.S. or to a 




ethnic and cultural contexts to investigate six manifestations of nonspecific psychological 
distress (Furukawa et al., 2003; Kessler et al., 2003, 2010). Interviewers asked 
respondents for the frequency with which, in the past four weeks, they felt so sad that 
nothing could cheer them up, felt nervous, felt restless or fidgety, felt hopeless, felt that 
everything was an effort, and felt worthless. Acceptable responses for all six questions 
fell into five categories, ranging from “none of the time,” “a little of the time,” “some of 
the time,” “most of the time,” to “all of the time,” and were assigned a corresponding 
value from 0 to 4. The summed responses of the K6 scale therefore ranges from 0 to 24, 
where 0 represents the lowest level of nonspecific psychological distress, and 24 
indicates the highest level of nonspecific psychological distress.  
 
I classified respondents as likely having major nonspecific psychological distress if their 
score was 13 or higher. This cutoff point has been proven to have a classification 
accuracy of 0.92 for serious mental illness, as defined by the Diagnostic and Statistical 
Manual of Mental Disorders 4th Edition (Kessler et al., 2003). I also used each individual 
K6 question as an outcome variable to investigate which aspect of nonspecific 
psychological distress was driving the result observed in the composite K6 score. For 
each question, I created a binary variable that took a value of 1 if a person reported the 
frequency of “most of the time” or “all of the time.” (scores 3 and 4).  
 
Self-reported mental disorders. To supplement the analysis using the K6 scale, I used 
self-reported information on whether a respondent had any mental disorders as a 
secondary outcome. These self-reported measures have been previously used to study the 




et al., 2017). Medical condition data were collected from household respondents during 
each round. However, only conditions indicated as being “current” were included in the 
medical condition files. MEPS defines a condition as being “current” if the person was 
currently experiencing the condition or if the condition was associated with a specific 
event that occurred during the reference period of the interview round (i.e. outpatient 
visit, inpatient visit, emergency department visit, office-based visit, prescription 
medication). Each medical condition was recorded as verbatim text, which was then 
coded to fully specified ICD-9 by professional coders. All ICD-9 codes were verified, 
and the error rates did not exceed 2.5% for any coders. ICD-9 condition codes were 
further aggregated into mutually-exclusive clinical classification codes (Elixhauser et al., 
1998). Most ICD-9 conditions within each clinical classification code are clinically 
homogenous. Mental disorders in MEPS are coded from 650 to 67010. Using these 
clinical classification codes, I created an indicator for whether a person experienced any 
new mental disorders, either treated or untreated, in each interview round relative to the 
previous round. 
 
Use and costs of mental health services were measured by linking the medical condition 
files to the event files. Most conditions recorded in the medical condition files 
corresponded to at least one event (i.e. outpatient visit, inpatient visit, emergency 
department visit, office-based visit, prescription medications used) in the event files. 
Each event included the following information: date of the visit, whether the respondent 
 





saw a doctor, type of care received, type of services received, whether medications were 
prescribed during the visit, flat fee charges, imputed sources of payments, total payments 
and total charges. Using detailed information at the visit-level, I calculated the total 
number of visits in each round regardless of the place of service (outpatient, inpatient, 
emergency department, office-based), and the total charges (including charges for visits 
and prescription medications) for all mental disorders that a respondent reported in the 
medical condition files. I adjusted all charges to reflect 2016 dollars. 
 
Previous studies have assessed the validity of events reported in MEPS. While inpatient 
stays and the number of inpatient hospital nights were accurately reported in MEPS 
compared to the linked Medicare data (Zuvekas & Olin, 2009b), office visits, emergency 
department visits, and Medicare expenditure are underreported by 12% to 34% (Zuvekas 
& Olin, 2009a). Regardless, underreporting of utilization and costs for certain events was 
unlikely to affect behavioral analyses because the magnitude of the misreport was not 
different across subgroups (Zuvekas & Olin, 2009a). 
 
Medications. MEPS documents the use of prescription medications, nonprescription 
medications, and dietary supplements for each interview round. The prescription 
medication files contain information11 on the name and national drug code of each 
medication; quantity, form, strength, and the number of days supplied; Multum 
therapeutic drug classes; the condition(s) that each medication was intended for, the date 
when respondents started using each medication; and the total cost of each medication. 
 




Interviewers asked respondents to report all medications, including all refills, that they 
consumed since the last interview round. Interviewers then entered the complete 
medication names into a computer, which were automatically matched with an existing 
drug in the database. The drug database used for the match was obtained from Lexicon 
Plus, a proprietary database of Cerner Multum that provided, on an annual basis, a 
comprehensive list of all prescription and some non-prescription medications available in 
the U.S. market.  
 
The quality of prescription medication data has been independently assessed in prior 
studies. Hill, Zuvekas, & Zodet (2011) linked MEPS prescription drug database to 
Medicare Part D claim data and found that while the number of medications and total 
expenditures were generally in accordance with those in claim data, respondents had the 
tendency of underreporting different types of medication consumed and overreporting the 
number of refills for each medication. Despite such discrepancy, these authors suggested 
that behavioral analyses were unlikely to be affected because misreport did not vary 
across socio-demographic subgroups. In this study, I removed all medication refills due 
to overreporting, and treat each distinct reported medication in each interview round as a 
course of treatment. I also created a series of binary variables that indicated whether 
respondents used any antidepressants; anxiolytics, sedatives, hypnotics; anticonvulsants; 
and antipsychotics for treatment of any mental disorders (clinical classification codes 
650-670).  
 
Medications with potential mental health side effects. Medications with depression or 




al. (2018), I used the Micromedex database to identify medications with insomnia and 
anxiety side effects. Prior studies have independently established the accuracy and 
reliability of adverse effects listed in Micromedex (Cheng et al., 2010). The database is 
based on several sources: the U.S. Food and Drug Administration’s black box warnings, 
MedWatch, post-marketing surveillance, clinical trials, and comprehensive literature 
reviews. In this study, medications with insomnia side effects were identified using a 
keyword search including the following words: insomnia and sleep disorder; medications 
with anxiety side effects were detected using the following search words: anxiety, 
anxious, and nervous. Consistent with the study by Qato et al. (2018), I classified 
medications as having insomnia and anxiety as potential side effects if their adverse 
effects are listed as common or serious in Micromedex. Note that the lists of medications 
with different mental health side effects are not mutually exclusive. A medication with 
insomnia as a side effect may also have depression as a potential side effect. 
 
I identified 98 medications with insomnia side effect, 124 medications with depression 
side effect, 41 medications with anxiety side effect, and 107 medications with suicidal 
side effect (Tables 1-4). It is important to note that these numbers do not represent the 
full set of medications with mental health side effects in the U.S market, but rather the 
number of medications with mental health side effects consumed by respondents aged 25-
84 in the analytic sample from 1996 to 2016. Using the reported number of medications 
with mental health side effects, I constructed a variable that indicated whether during the 
recall period of an interview round (usually five months on average), a respondent took 




regression models), one medication, two medications, or at least three medications with 
any mental health side effects. 
 
-Insert Tables 1 to 4 About Here- 
 
 
Chronic conditions.  Many medications with mental health side effects are intended for 
treatment of chronic conditions that have been found to be correlated with the onset of 
depression (Köhler et al., 2018). I controlled in all analysis models the number of self-
reported chronic conditions that the person was currently experiencing during interview 
round, either treated or untreated. Using the definition of chronic conditions from 
Goodman et al. (2013), I classified the following conditions as being chronic: 
hypertension, congestive heart failure, coronary artery disease, cardiac arrhythmias, 
hyperlipidemia, stroke, arthritis, asthma, cancer, chronic kidney disease, chronic 
obstructive pulmonary disease, dementia (Alzheimer’s, and other senile dementias), 
diabetes, hepatitis, human immunodeficiency virus (HIV), and osteoporosis. Using the 
number of self-reported chronic conditions, I created a variable that represented whether 
a respondent had no chronic conditions (the reference category), one conditions, two 
conditions, or at least three conditions during a round of interview. Controlling for each 
individual chronic condition as a binary variable did not alter the interpretation of the 
results. 
 
Pain. A growing number of studies has found that pain and depressive symptoms usually 
coexist and share similar biological pathways and neurotransmitters (Bair et al., 2003). 




pain also report depressive symptoms (Bair et al., 2003). In addition, pain is one of the 
leading reasons for seeking medical care (Komaroff, 1990; Kroenke, 2001), which may 
increase patients’ exposure to medication use. MEPS respondents reported the frequency 
that pain interfered with their work in the last four weeks, including both work outside of 
the home and housework. Possible responses included “none of the time,” “a little of the 
time,” “some of the time,” “most of the time,” and “all of the time.” I created a binary 
variable that indicated whether the person experienced any pain, regardless of the 
reported frequency. 
 
Other covariates. In all models, I controlled for socio-demographic variables that were 
potentially associated with one’s depression and the use of medications such as race 
(non-Hispanic white: reference category, non-Hispanic black, Hispanic, or others); age 
and age squared; gender; marital status (married or living with a partner: reference 
category, widowed/divorced/separated, or never married); educational attainment (less 
than high school: reference category, high school graduate, college or higher); whether 
the person’s household income was under the federal poverty threshold; whether the 
person has private insurance, public insurance (i.e. Medicaid or State Children's Health 
Insurance Program), Medicare, and/or any other insurance; and whether the person is 
obese (BMI is at least 30). I also included a dummy variable for each year and each 






To adjust for complex and multistage sampling, I calculated weighted prevalence 
estimate of medications with mental health side effects in each year using Taylor 
linearization methods. I used logistic regression to assess the statistical significance of 
trends of medications with mental health side effects. In each calendar year, I used 
information on the reported use of medications with mental health side effects in round 1 
(or 3) to predict subsequent mental health and use/costs of mental health services in 
round 2 (or 4) for respondents in the first (or second) year of their panel. Rounds 1 and 3 
will be referred to as the baseline, while rounds 2 and 4 will be referred to as the follow-
up hereafter. Weighted multivariate linear least-squared and logistic regression models 
were used to investigate the association between the use of medications with mental 
health side effects at baseline and mental distress (K6) at follow-up, whether a respondent 
reported any new mental disorders at follow-up, whether a respondent had more visits for 
mental health disorders at follow-up compared to baseline, and whether a respondents 
used more psychotropic medications for treatment of mental disorders at follow-up 
compared to baseline. Weighted two-part model was used to estimate the relationship 
between the use of medications with mental health side effects at the baseline and 
changes in the number of visits and total charges for mental disorders between the 
baseline and follow-up due to their zero-heavy count data. The first part of the model 
estimated the probability of having a non-zero and non-negative12 value using a logit 
regression. The second part estimated changes in the number of visits/charges associated 
 
12 Some respondents had a negative value because they had fewer visits or charges at the follow-up 




with mental disorders conditional on having any using a Gamma generalized linear model 
with log link. 
 
For analysis of the K6 and each element in the K6 scale, I controlled for whether a person 
had any mental disorders at the baseline to avoid reverse causation and reduce the threat 
of spuriousness, using an indicator for whether a person reported having any mental 
disorders (treated or untreated) or used any psychotropic medications for treatment of 
mental disorders such as antidepressants, anxiolytics, sedatives, hypnotics, 
anticonvulsants, and antipsychotics. This is because the K6 was only collected in rounds 
2 and 4 for each respondent; therefore, no information was available at the baseline 
(rounds 1 and 3). Regardless, self-reported mental disorders and the use of medications 
for treatment of mental disorders are relatively reasonable indicators for psychological 
distress at the baseline. I also controlled for changes in the number of medications with 
mental health side effects between the baseline and follow-up (decline in the number of 
medications with such side effects or no changes: reference category, an increase of one, 
two, or three of such medications). As a test for sensitivity, I included in all models the 
use of medications without any of known mental health side effects and changes in the 
reported number of these medications between the baseline and follow-up. If the 
association between medications with mental health side effects and the outcome was 
driven by any unobservable heterogeneity in health, the relationship between medications 
without mental health side effects and the outcome should be equally significant as that 
between medications with mental health side effects and the outcome. Lastly, all models 




insurance status as described above, as well as a series of dummy variables for year and 
region fixed effects. 
 
To assess whether the association between medications with mental health side effects 
and mental health outcomes varied by age, I included in the analytic models an 
interaction term between the categories of medications with/without mental health side 
effects and a categorical variable for age (25-44, 45-64, and 65-84). I then computed the 
marginal effects of medications with and without mental health side effects on the 
outcomes for each age group, while holding all other covariates constant. 
 
In several sensitivity analyses, I repeated the main analyses for three sub-samples: 
respondents with at most one self-reported chronic condition at the baseline, respondents 
without any self-reported mental disorders (either treated or untreated) at baseline, and 
respondents with at least one self-reported mental disorder at baseline. The first sub-
sample included relatively healthy respondents without comorbidity, while the second 
sub-sample consisted of respondents without any existing mental disorders at baseline. If 
the association between medications with mental health side effects and mental health 
was not mainly driven by comorbidity and existing mental disorders, I expect to observe 
similar results in the first and second sub-samples compared to those in the main analysis. 
I repeated the same analyses for the third sub-sample of respondents with pre-existing 
mental disorders in order to investigate whether the use of medications with mental 
health side effects worsened mental health for these respondents (i.e. developing new 






Figure 1 presents unadjusted (Panel A) and age/sex adjusted (Panel B) trends in the use 
of medications with any mental health side effects from 1996 to 2016 for U.S. adults 
aged 25-84. In Panel A, 55% of U.S. adults aged 25-84 in 1996 did not use medications 
with any mental health side effects. In 2016, this prevalence dropped to 49.5% (p < 
0.001). Further investigation suggests that while the prevalence of using one or two of 
these medications has been relatively stable or even slightly declining over the same 
period, the reported use of three or more medications with mental health side effects has 
increased from 21.9% to 29.8% (p < 0.001, or a relative increase of 36.2%). The increase 
in concurrent use of at least three of these medications could be in part due to factors 
such as the introduction of new medications on the market, the increase in chronic 
conditions and comorbidity in the population (Ward & Schiller, 2013), or the growing 
availability of over-the-counter medications with mental health side effects (Qato et al., 
2018).  
 
-Insert Figure 1 About Here- 
 
Figure 2 examines the unadjusted and age/sex adjusted prevalence of U.S. adults aged 
25-84 who used at least one medication with insomnia, depression, anxiety, and suicidal 
side effects, respectively. Although more adults who used medications with depression as 
a potential side effect than medications with any other side effects in every single year, 
the prevalence of using medications with depression side effect was relatively stagnant 
between 1996 and 2016 (37.3% in 2016 vs. 36.5% in 1996, p = 0.40). In contrast, the use 




increasing between 1996 and 2016 by 11.3 percentage points (p < 0.001, relative increase 
of 66.8%), 6.3 percentage points (p < 0.01, relative increase of 80.7%), and 11.2 
percentage points (p < 0.001, relative increase of 77.3%), respectively.  
 
-Insert Figure 2 About Here- 
 
Table 5 presents descriptive statistics of the outcomes and the control variables for the 
full analytic sample, and by the number of medications with potential mental health side 
effects. Overall, 68.6% of respondents reported not using medications with mental health 
side effects, while 17.7%, 7.5%, and 6.3% reported using one, two, and at least three of 
those medications. Between the baseline and follow-up, 77.3% of respondents consumed 
at most the same number of medications with mental health side effects, while 14.4%, 
5.1%, and 3.2% increased their consumption by one, two, or three of such medications, 
respectively.  
 
-Insert Table 5 About Here- 
 
Respondents who used at least three medications with mental health side effects were 
much more likely to report psychological distress (K6), mental disorders, having at least 
one visit associated with such mental disorder(s), and more visits and higher costs 
associated with mental disorders between the baseline and follow-up. For example, 
among respondents who reported using at least three medications with mental health side 
effects at the baseline, 19.6% likely had mental distress at follow-up, 9.8% had at least 
one new mental disorder at follow-up, 18.7% had more visits for mental disorders at 




follow-up compared to at the baseline, compared to 3.3%, 4.0%, 2.2%, and 3.6% among 
respondents who did not use such medications, respectively (p-value < 0.001 for all 
comparisons). Additionally, individuals who reported using at least three medications 
with mental health side effects on average had an increase of 0.63 visits and $242 in total 
charges for mental disorders between the baseline and follow-up (p-value < 0.001 for 
both comparisons) compared to individuals who did not use these medications. Note that 
there is a dose-response relationship, such that the prevalence of psychological distress 
and the use/costs of mental health services increased for every additional medication 
consumed that have mental health side effects.  
 
I also found that respondents who used more medications with mental health side effects 
tended to be white; aged 65 to 84; married or cohabiting with a partner; divorced, 
widowed, or separated; high school graduated; low-income; publicly insured; obese; had 
any pain that interfered with work or housework; and were more chronically ill (p < 
0.001 for all variables). Respondents who used more medications with mental health side 
effects were systematically sicker than non-users. Some of the most common chronic 
conditions among individuals who consumed at least three medications with mental 
health side effects were hypertension (56.4%), hyperlipidemia (46.5%), arthritis (25.2%), 
chronic obstructive pulmonary disease (17.9%), and diabetes (23.8%).  
 
Table 6 presents evidence for the association between the use of medications with mental 
health side effects and psychological distress (K6), each individual question in the K6 




the baseline. In column (1), compared to non-users, those who used one, two, or at least 
three of those medications with mental health side effects at the baseline reported a 
higher K6 score by 0.113 (p < 0.001), 0.224 (p < 0.001), and 1.318 (p < 0.001) points, 
respectively. A similar pattern was observed when investigating psychological distress 
(K6 score of at least 13) in column (2). Consuming at least three medications with mental 
health side effects was associated with an increase in the odds of psychological distress 
by 1.859 times (p < 0.001). Further investigation into each individual question in the K6 
scale in columns (3) to (8) revealed that using these medications was associated with all 
aspects of psychological distress. Finally, medications with mental health side effect are 
also significantly associated with the likelihood of reporting a new mental disorder during 
follow-up (column 9). The odds of reporting a new mental disorder increased by almost 
two times when using three or more of these medications when compared to not using 
any (p < 0.001). In all analyses, I observed a dose-response such that the incidence of 
psychological distress or self-reported mental disorder increased with every additional 
medication with mental health side effects.  
 
-Insert Table 6 About Here- 
 
If the association between medications with mental health side effects and mental health 
was driven by unobserved heterogeneity in health, then one should expect to observe 
similar results for medications without these side effects. I found that the use of 
medications without known mental health side effects was generally not associated with 
worsened mental health, and in a few cases, such use was even beneficial to mental 




everything was an effort (column 3 of Table 6). Using at least three medications without 
known mental health side effects was associated with an increase in the odds of feeling 
that everything was an effort by 1.132 times (p < 0.05). However, the magnitude of the 
coefficient for medications without known mental health side effects was significantly 
smaller than that for medications with these side effects. These findings suggest that the 
use of medications with mental health side effects at the baseline was associated with 
worsened mental health at follow-up. These associations, however, were unlikely to have 
been driven by unobservable heterogeneity in health. 
 
In Table 7, I demonstrate the association between the use of medications with mental 
health side effects at the baseline and changes in use and costs of mental health services 
between the baseline and follow-up. In columns (1) to (3), compared to nonusers, those 
who used at least three medications with mental health side effects reported higher odds 
(OR = 2.346, p < 0.001) of having at least one additional visit for mental disorders at 
follow-up relative to baseline, 0.152 more visits between the baseline and follow-up for 
mental disorders (p < 0.001), and an increase of more than $100 in total charges between 
baseline and follow-up for visits with mental health diagnoses (p < 0.001). I also found 
that respondents used more psychotropic medications for treatment of mental disorders at 
follow-up compared to at the baseline as a result of consuming medications with mental 
health side effects. For example, the odds of using at least one additional antidepressant; 
anxiolytics, sedatives, or hypnotics; anticonvulsants; and antipsychotics at follow-up 
relative to baseline increased by more than two times for individuals consuming at least 
three medications with mental health side effects compared to nonusers (columns 4 to 8 




6, I found that the associations between medications without known mental health side 
effects and the use/costs of mental health services were generally trivial and, in many 
cases, they were associated with a decline in utilization and costs. 
 
-Insert Table 7 About Here- 
 
To ensure that the associations between medications with mental health side effects and 
mental health outcomes were not driven by comorbidity or individuals who already had 
mental disorders at the baseline, I repeated all analyses for three sub-samples: 
respondents with at most one chronic condition at baseline, respondents without any 
preexisting mental disorders at baseline, and respondents with at least one pre-existing 
mental disorder at baseline.  
 
I observed similar results among respondents with at most one chronic condition at the 
baseline in Tables 8 and 9. In some cases, the associations between medications with 
mental health side effects and mental health outcomes were even slightly larger than 
those of the full analytic sample in Tables 6 and 7. This implies that the results were 
applicable to relatively more-healthy respondents and were not driven by comorbidity. I 
also found similar patterns among respondents with and without any preexisting mental 
disorders at the baseline (Tables 10 to 13). However, the associations between 
medications with mental health side effects and mental health outcomes were much larger 
among respondents with preexisting mental disorders at the baseline compared to those 
without these preexisting conditions. As such, the results observed in the full analytic 




health side effects were likely associated with an onset of mental disorders among those 
without these disorders at the baseline and worsened mental health among those who 
already had these disorders.  
 
-Insert Tables 8 to 13 About Here- 
 
In Figures 3 to 9, I present the marginal effect of medications with mental health side 
effects on mental health and use/costs of mental health services by age groups (25-44, 45-
64, and 65-84). Figures 3 and 4 demonstrate the age-profile of the association between 
medications with mental health side effects and nonspecific psychological distress (K6 
score and whether the K6 score is at least 13). Among respondents aged 25-44, 
medications with mental health side effects had significantly negative consequences on 
mental health, regardless of the number of doses taken. For middle-aged and older adults, 
the association between medications with mental health side effects and nonspecific 
psychological distress did not become statistically significant until the respondent 
consumed at least three of those medications. A similar finding has been documented in 
Huang et al. (2010). The declining association between medications with mental health 
side effects and mental health across age groups is worth noting. Among respondents 
who consumed two or at least three medications with mental health side effects, young 
adults aged 25-44 were more likely to experience psychological distress than middle-
aged and older adults.   
 






In Figures 5 to 7, I present the association between medications with mental health side 
effects and whether a respondent developed at least one new mental disorder at follow-
up, whether a respondent had more visits for mental disorders at follow-up, and whether a 
respondent used more psychotropic medications13 for treatments of mental disorders at 
follow-up compared to at the baseline. Across all age groups, respondents were much 
more likely to develop a new mental disorder, had more visits, and used more 
psychotropic medications for mental disorders when taking at least one medication with 
side effect, relative to nonusers. The association increased with every additional 
medication taken. The age differences in such associations were less significant than 
those in Figures 3 and 4. Medications with mental health side effects seemed to have 
relatively equal impacts on respondents regardless of their age.  
 
-Insert Figures 5 to 7 About Here- 
 
 
Finally, Figures 8 and 9 illustrate the marginal effects of medications with mental health 
side effects on changes in the number of visits and total costs for visits with mental 
disorder diagnoses between follow-up and baseline. Using medications with mental 
health side effects at the baseline was associated with an increase in the number of visits 
or total costs for mental disorders across all age groups. However, the association did not 
become statistically significant until a person consumed at least three of these 
medications. Moreover, the increase in visits and totals costs was larger for adults aged 
 
13 Medications used for treatment of mental disorders include antidepressant; anxiolytics, sedatives, or 




25-44 compared to adults aged 65-84, although the estimates were not significantly 
different from one another. 
 
-Insert Figures 8 and 9 About Here- 
 
Discussion 
This chapter investigated the trends in using medications with mental health side effects 
among community-dwelling adults from 1996 to 2016. It then examined the extent to 
which the use of these medications was associated with worsened mental health, as well 
as increased utilization and costs of mental health services.  
 
The findings are six-fold. First, I found that the use of medications with mental health 
side effects has increased significantly since 1996, and much of the increase was 
attributed to the use of medications with insomnia, anxiety, and suicidal side effects, 
rather than medications with depression as a potential side effect. Second, I found that the 
use of medications with any mental health side effects was detrimental to mental health 
and was associated with an increase in the onset of new mental disorders, especially 
under conditions of polypharmacy. Third, concurrent use of medications with mental 
health side effects was associated with an increase in the number of visits and costs for 
mental disorders, as well as the subsequent use of psychotropic medications for 
treatments of mental disorders. Fourth, while medications with mental health side effects 
had negative consequences on health and health care use/costs, I found that medications 




health or increased use/cost of mental health services. In some cases, taking medications 
without mental health side effects was even beneficial to mental health and reduced the 
use and costs for mental health services. Fifth, medications with mental health side 
effects were more detrimental to mental health among respondents who already had 
mental disorders at the baseline compared to those without these preexisting disorders. 
Finally, I found that young adults were equally impacted, or in some cases, they were 
more likely to be impacted by medications with mental health side effects compared to 
middle-aged and older adults. While the association between medications with mental 
health side effects and nonspecific psychological distress (K6) declined over age (Figures 
3 and 4), such age discrepancy was less significant for other outcomes (Figures 5 to 9). 
This may be due to underreporting or recall bias of psychological symptoms in the K6 
scale among older adults (Lyness et al., 1995). Underreporting or recall bias were 
alleviated for other outcomes (i.e. self-reported mental disorders, visits and costs 
associated with mental disorders, and the use of psychotropic medications for treatments 
of mental disorders) because MEPS contacted respondents’ medical providers to correct 
and impute missing information. Moreover, the large and significant association between 
the use of medications with mental health side effects and several outcomes for young 
adults may also be attributed to the selection to using multiple of these medications as a 
result of an early onset of chronic conditions that can be more detrimental to health than 
those that occur at older ages (Huang et al., 2010) 
 
These findings imply that physicians are likely to have neglected the important role of 




health side effects in this study are intended for the treatments of chronic and physical 
diseases such as antihypertensives, proton pump inhibitors, respiratory agents, and 
hormonal modifiers. While these medications may be beneficial for controlling and 
treating disease for which they are intended, many of them may induce psychological 
distress and the use/costs of mental health services. The decision to prescribe these 
medications may in part reflect physicians’ belief that physical health should be 
prioritized over mental health, and that any mental health side effects can be treated later 
by prescribing more psychotropic medications after physical conditions are under control 
(Tamblyn, 1996). In this study, I found that the use of medications with mental health 
side effects indeed induced the use of additional psychotropic medications for treatments 
of mental disorders at the follow-up. To avoid adverse consequences of medications on 
mental health, physicians may want to conduct mental health screenings before and 
during administration of medications with potential mental health side effects, especially 
when patients consume multiple of these medications simultaneously, in order to adjust 
medication doses. 
 
While many medications with mental health side effects are harmful to mental health, I 
found that medications without these known side effects did not have any adverse 
consequences, even when used in a set. This finding aligns with prior studies by Qato et 
al. (2018) and Do and Schnittker (2020). In many cases, the use of medications without 
known mental health side effects was even beneficial to mental health and reduced 
subsequent use and costs of mental health services. The results hold even after controlling 




respondents with any existing mental disorders or respondents with multiple chronic 
conditions. It is possible that the use of medications without known mental health side 
effects helps manage chronic and physical conditions that have been found to have a 
detrimental effects on mental health (Köhler et al., 2018). These findings bridge the gap 
between the literature on polypharmacy and the literature on medication side effects. 
Much of the adverse consequences of polypharmacy on health may be mainly due to 
consuming multiple medications with certain side effects. As such, any policies that aim 
to address polypharmacy should focus on reducing the inappropriate use of medications 
with adverse side effects instead of medications without known side effects.  
 
Finally, the literature on polypharmacy typically focuses on older adults because they are 
at higher risks of experiencing adverse drug reactions due to biological and medical 
reasons. As such, little is known about the role of polypharmacy or medications with side 
effects in mental health of younger adults. In this study, I found that medications with 
mental health side effects were as harmful to the mental health of younger adults as they 
were to older adults. For self-reported nonspecific psychological distress (K6 scale), I 
found that the bar was even lower for young adults. Using one, two, or at least three 
medications with mental health side effects had adverse effects on psychological distress 
for young adults, while the association was not observed among older adults until they 
consumed at least three medications with these side effects. This finding has been 
previously observed in a study by Huang et al. (2010) that investigated the association 
between polypharmacy and the risk of falls among diabetic patients. The authors found 




young adults compared to those using one or no medications. For older diabetic adults, 
the authors did not observe a significant relationship between polypharmacy and falls 
until patients consumed six to seven medications. In addition, I found that using at least 
three medications with mental health side effects was much more harmful to young 
adults’ psychological distress than it was for older adults (Figure 4). It is possible that for 
young and healthy adults, the selection into concurrently using at least three medications 
with mental health side effects may be attributed to the early onset of chronic conditions 
that can be more debilitating to health than those that occur in older ages. For other 
outcomes such as the development of new mental disorders, the use of psychotropic 
medications, and use/costs of mental health services, I found that the associations 
between these outcomes and the use of medications with mental health side effects did 
not significantly vary by age groups. Future studies should investigate the consequences 
of polypharmacy and medications with side effects among the young adult population.  
 
Conclusion 
This study presents a significant increase in the use of medications with insomnia, 
depression, anxiety, or suicidal side effects among community-dwelling U.S. adults in the 
past two decades. Exposure to these medications was associated with psychological 
distress, the development of new mental disorders, and the use/costs of mental health 
services across all age groups, especially under the condition of polypharmacy. These 
results highlight the needs for mental health screenings among patients who consume 
medications with mental health side effects. They also highlight the synergic effects of 
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Figure 1: Unadjusted and Adjusted Weighted Prevalence of U.S. Adults Aged 25-84 
Taking Medications with Any Insomnia, Depression, Anxiety, or Suicidal Side 











Figure 2: Unadjusted and Adjusted Weighted Prevalence of U.S. Adults Aged 25-84 
Taking Medications with Individual Side Effect of Insomnia, Depression, Anxiety, 








Table 1: Medications with Insomnia Side Effect Consumed by U.S. Adults Aged 25-84 in MEPS 1996-2016. 




Acamprosate Emtricitabine-Tenofovir Piperacillin-Tazobactam 
Acetaminophen Escitalopram Pramipexole 
Acetaminophen-Tramadol Exemestane Progesterone 




Amphotericin B Fexofenadine-Pseudoephedrine Quetiapine 
Anastrozole Fluoxetine Raltegravir 
Aripiprazole Fluvoxamine Ramelteon 
Armodafinil Formoterol Ribavirin 
Asenapine Guanfacine Rimantadine 
Atomoxetine Interferon Beta-1B Roflumilast 
Benzphetamine Lamivudine-Zidovudine Selegiline 
Boceprevir Lamotrigine Sertraline 
Buprenorphine-Naloxone Letrozole Sibutramine 
Bupropion Leuprolide Sildenafil 
Butorphanol Levofloxacin Tacrolimus 
Carteolol Levothyroxine Tamsulosin 
Cetirizine-Pseudoephedrine Lindane Tenofovir 
Ciprofloxacin Lisdexamfetamine Theophylline 
Citalopram Loratadine-Pseudoephedrine Thyroid 
Clomipramine Mefloquine Tiagabine 
Dalfampridine Megestrol Tramadol 
Daptomycin Methylphenidate Tranylcypromine 
Desloratadine-Pseudoephedrine Milnacipran Trazodone 
Desvenlafaxine Modafinil Valproic Acid 







Diflunisal Mycophenolic Acid Venlafaxine 
Divalproex Nabumetone Vilazodone 
Donepezil Ofloxacin Zileuton 
Duloxetine Paroxetine Zoledronic Acid 




















Table 2: Medications with Depression Side Effect Consumed by U.S. Adults Aged 25-84 in MEPS 1996-2016. 




Acetaminophen-Hydrocodone Emtricitabine Megestrol 
Acetaminophen-Oxycodone Enalapril Metaproterenol 
Acitretin Enalapril-Hydrochlorothiazide Metaxalone 
Acyclovir Esomeprazole Methocarbamol 







Anastrozole Estradiol-Levonorgestrel Metolazone 
Aspirin Estradiol-Norethindrone Metoprolol 
Atenolol Estradiol-Norgestimate Metronidazole 
Atenolol-Chlorthalidone Estropipate Montelukast 
Atropine-Diphenoxylate Estradiol Morphine 
Azathioprine Estradiol-Ethynodiol Nabumetone 
Baclofen Estradiol-Etonogestrel Nisoldipine 
Bendroflumethiazide-Nadolol Estradiol-Levonorgestrel Norethindrone 
Benzphetamine Estradiol-Norethindrone Omeprazole 
Betamethasone Estradiol-Norgestimate Oxybutynin 
Betaxolol Estradiol-Norgestrel Oxycodone 
Bicalutamide Etonogestrel Pantoprazole 
Brimonidine Exemestane Phentermine 
Brimonidine-Timolol Famotidine Pimozide 
Cabergoline Fentanyl Prazosin 
Cetirizine Flecainide Prednisolone 
Cimetidine Fluphenazine Prednisone 
Clonidine Galantamine Propafenone 










Cortisone Haloperidol Rabeprazole 
Cyclobenzaprine Homatropine-Hydrocodone Ranitidine 
Cyclosporine Hydrochlorothiazide-Metoprolol Rasagiline 
Dantrolene Hydrocodone Risedronate 
Desogestrel-Estradiol Hydrocodone-Ibuprofen Tamoxifen 
Dexamethasone Hydrocortisone Telmisartan 
Dexlansoprazole Hydroxyprogesterone Testosterone 
Dexmethylphenidate Hydroxyzine Theophylline 
Dienogest-Estradiol Ibuprofen Timolol 
Donepezil Indomethacin Tizanidine 
Dorzolamide-Timolol Lansoprazole Trandolapril 
Dronabinol Losartan Triamcinolone 















Table 3: Medications with Suicidal Side Effect Consumed by U.S. Adults Aged 25-84 in MEPS 1996-2016. 
Acamprosate Escitalopram Olanzapine 
Acetaminophen Esomeprazole Oxandrolone 
Acetaminophen-Hydrocodone Eszopiclone Oxcarbazepine 
Acetaminophen-Tramadol Ferrous Sulfate Paroxetine 
Alprazolam Finasteride Peginterferon Alfa-2A 
Amantadine Fluoxetine Phenelzine 
Amitriptyline Fluoxetine-Olanzapine Phenytoin 
Amitriptyline-Chlordiazepoxide Flurazepam Prednisone 
Amitriptyline-Perphenazine Fluticasone Pregabalin 
Amoxicillin-Clavulanate Fluvoxamine Progesterone 
Aripiprazole Gabapentin Protriptyline 
Armodafinil Haloperidol Quetiapine 
Asenapine Hydrocortisone Raltegravir 
Aspirin Iloperidone Ramelteon 
Atomoxetine Imipramine Ranitidine 
Bupropion Interferon Beta-1A Ribavirin 
Butabarbital Interferon Beta-1B Risperidone 
Carbamazepine Isotretinoin Rivastigmine 
Carbidopa-Entacapone-Levodopa Lamotrigine Roflumilast 
Carbidopa-Levodopa Leuprolide Selegiline 
Chlordiazepoxide Levetiracetam Sertraline 
Chlorzoxazone Levonorgestrel Sibutramine 
Ciprofloxacin Lorazepam Tapentadol 
Citalopram Lurasidone Topiramate 
Clomipramine Mefloquine Tramadol 
Clonazepam Memantine Trazodone 
Clorazepate Methylphenidate Triazolam 
Dapsone Metoclopramide Valproic Acid 
Desipramine Milnacipran Varenicline 
Desvenlafaxine Mirtazapine Venlafaxine 







Didanosine Montelukast Zafirlukast 
Doxepin Moxifloxacin Zaleplon 
Duloxetine Nefazodone Zolpidem 
Efavirenz Nortriptyline Zonisamide 




















Table 4: Medications with Anxiety Side Effect Consumed by U.S. Adults Aged 25-84 in MEPS 1996-2016. 
Acamprosate Estazolam Modafinil 
Amantadine Exemestane Mycophenolate Mofetil 
Aripiprazole Fentanyl Paliperidone 
Armodafinil Fluoxetine Peginterferon Alfa-2A 
Carbidopa-Levodopa Fluvoxamine Propafenone 







Dalfampridine Hydrocodone-Pseudoephedrine Tretinoin 
Desvenlafaxine Levothyroxine Triazolam 
Dexmethylphenidate Lindane Valproic Acid 
Dronabinol Lisdexamfetamine Venlafaxine 
Efavirenz-Emtricitabine-Tenofovir Mefloquine Ziprasidone 














Table 5. Descriptive Statistics for Mental Health, Medication Use, and Control Variables for U.S. Adults Aged 25-84. Data 
Source: MEPS 2004-2015. 
  All 
respondents 
  Number of medications with any insomnia, depression, suicide, or 
anxiety side effectsa 
  P-valueb 
        None 1 medication 2 medications 3+ medications     
  N = 211,551   N = 151,337 N = 33,883 N = 14,225 N = 12,106     
Binary outcomes at follow-upc, Nd (%)e 
Mental distress (K6 >= 13) 12390 (5.0)   5924 (3.3) 2187 (5.2) 1527 (8.7) 2752 (19.6)   p < 0.001 
Felt everything an effort most/all of the time 17896 (7.5)   9469 (5.4) 3095 (7.6) 1967 (11.7) 3365 (25.5)   p < 0.001 
Felt hopeless most/all of the time 9076 (3.6)   4627 (2.5) 1567 (3.5) 1034 (5.7) 1848 (13.0)   p < 0.001 
Felt nervous most/all of the time 11801 (4.9)   5821 (3.3) 2112 (5.1) 1409 (8.2) 2459 (17.6)   p < 0.001 
Felt restless most/all of the time 13902 (5.8)   7238 (4.2) 2480 (6.1) 1624 (9.3) 2560 (18.1)   p < 0.001 
Felt sad most/all of the time 7393 (2.8)   3712 (2.0) 1274 (2.7) 865 (4.6) 1542 (10.5)   p < 0.001 
Felt worthless most/all of the time 8055 (3.3)   3962 (2.2) 1394 (3.3) 960 (5.4) 1739 (12.5)   p < 0.001 
Any new mental disorders at follow-up 9775 (5.0)   5621 (4.0) 1921 (5.8) 1057 (7.4) 1176 (9.8)   p < 0.001 
Whether had more outpatient, inpatient, office-
based, emergency visits for mental disorders at 
follow-up 
8712 (4.5)   3137 (2.2) 1851 (5.6) 1423 (10.2) 2301 (18.7)   p < 0.001 
Used more of any four medications below for 
treatment of mental disorders at follow-up 
9434 (5.0)   4748 (3.6) 1978 (6.1) 1195 (8.4) 1513 (12.5)   p < 0.001 
     Used more antidepressants 7371 (4.0)   3788 (3.0) 1475 (4.6) 887 (6.3) 1221 (10.1)   p < 0.001 
     Used more anxiolytics, sedatives, or 
hypnotics 
4157 (2.2)   1617 (1.2) 862 (2.6) 656 (4.7) 1022 (8.6)   p < 0.001 
     Used more anticonvulsants 3173 (1.7)   1095 (0.8) 623 (1.9) 537 (3.8) 918 (7.7)   p < 0.001 
     Used more antipsychotics 2417 (1.2)   822 (0.6) 427 (1.3) 402 (2.9) 766 (6.4)   p < 0.001 
                            
Continuous outcomes at follow-upc, meand (standard error) 
K6 total score 3.34 (0.02)   2.81 (0.02) 3.57 (0.03) 4.59 (0.06) 6.97 (0.08)   p < 0.001 
Changes in number of outpatient, inpatient, 
office-based, emergency visits for mental 
disorders between baseline and follow-up 
0.16 (0.01)   0.09 (0.01) 0.19 (0.02) 0.33 (0.03) 0.63 (0.05)   p < 0.001 
Changes in total costs for mental disorders 
between baseline and follow-upf 







                            
Independent variablesa, Nd (%)e                           
Number of medications WITH insomnia, depression, suicidal, and anxiety side effects                 
     None 151337 (68.6)                       
     1 medication 33883 (17.7)                       
     2 medications 14225 (7.5)                       
     3+ medications 12106 (6.3)                       
Number of medications WITHOUT insomnia, depression, suicidal, and anxiety side 
effects 
                
     None 134356 (61.1)                       
     1 medication 31552 (16.2)                       
     2 medications 17849 (9.1)                       
     3+ medications 27794 (13.6)                       
Changes in number of medications WITH insomnia, depression, suicidal, and anxiety side effects between baseline and subsequent 
round 
      
     Decline or no changes 166584 (77.3)   120437 (77.7) 26061 (76.6) 10891 (76.4) 9195 (76.0)   p < 0.001 
     Increase of 1 medication 28681 (14.4)   19915 (14.2) 4932 (14.9) 2071 (14.7) 1763 (14.8)   p = 0.065 
     Increase of 2 medications 9971 (5.1)   6753 (5.0) 1737 (5.1) 759 (5.4) 722 (5.9)   p = 0.001 
     Increase of 3+ medications 6315 (3.2)   4232 (3.1) 1153 (3.4) 504 (3.4) 426 (3.3)   p = 0.048 
Changes in number of medications WITHOUT insomnia, depression, suicidal, and anxiety side effects between baseline and subsequent round     
     Decline or no changes 151197 (70.1)   111886 (72.2) 22636 (67.0) 9143 (64.6) 7532 (62.4)   p < 0.001 
     Increase of 1 medication 30248 (15.1)   19689 (14.0) 5754 (16.8) 2523 (17.8) 2282 (19.1)   p < 0.001 
     Increase of 2 medications 13902 (6.9)   9035 (6.3) 2613 (7.8) 1214 (8.4) 1040 (8.6)   p < 0.001 
     Increase of 3+ medications 16204 (7.9)   10727 (7.5) 2880 (8.4) 1345 (9.3) 1252 (9.9)   p < 0.001 
Race                           
     Non-Hispanic White 104477 (69.1)   67230 (64.9) 20005 (76.4) 9050 (79.6) 8192 (82.0)   p < 0.001 
     Non-Hispanic Black 37145 (10.8)   27582 (11.9) 5547 (8.9) 2304 (8.7) 1712 (7.4)   p < 0.001 
     Hispanic 51583 (13.1)   42009 (15.4) 5863 (9.1) 2095 (7.6) 1616 (6.9)   p < 0.001 
     Others 18346 (6.9)   14516 (7.9) 2468 (5.6) 776 (4.1) 586 (3.7)   p < 0.001 
Female 115305 (52.2)   76418 (47.2) 21345 (61.2) 9256 (63.4) 8286 (67.1)   p < 0.001 
Age groups                           
     25-44 93171 (41.9)   75536 (47.5) 11498 (34.3) 3710 (26.3) 2427 (19.6)   p < 0.001 
     45-64 83370 (40.1)   56939 (38.7) 14221 (41.6) 6260 (43.3) 5950 (48.5)   p < 0.001 
     65-84 35010 (18.0)   18862 (13.8) 8164 (24.1) 4255 (30.3) 3729 (31.9)   p < 0.001 
Marital status                           







     Divorced, widowed, or separated 47033 (21.4)   29467 (19.0) 8640 (23.2) 4433 (28.4) 4493 (34.0)   p < 0.001 
     Never married 41008 (17.8)   32192 (19.7) 5155 (14.3) 2022 (13.1) 1639 (12.1)   p < 0.001 
Educational attainment                           
     Less than high school 43595 (12.9)   32157 (13.1) 5950 (10.9) 2841 (13.1) 2647 (15.2)   p < 0.001 
     High school graduate 64726 (29.7)   45998 (29.5) 10241 (29.0) 4457 (30.7) 4030 (33.0)   p < 0.001 
     College or above 103230 (57.4)   73182 (57.4) 17692 (60.1) 6927 (56.3) 5429 (51.7)   p < 0.001 
Household income <100% federal poverty 
guideline 
32849 (9.9)   22817 (9.5) 4800 (9.0) 2485 (11.1) 2747 (15.7)   p < 0.001 
Has private insurance  126526 (69.3)   90449 (69.5) 21970 (73.6) 8257 (67.0) 5850 (57.6)   p < 0.001 
Has public insurance, Medicaid, or SCHIP 30997 (9.6)   18804 (8.0) 5426 (9.8) 3054 (13.9) 3713 (21.6)   p < 0.001 
Has Medicare insurance 41688 (20.7)   21121 (15.0) 9467 (27.0) 5312 (36.0) 5788 (46.9)   p < 0.001 
Has any other health insurance 2487 (1.2)   1486 (5.9) 507 (1.4) 246 (1.7) 248 (2.1)   p < 0.001 
Whether obese (BMI >= 30) 68727 (30.8)   45705 (28.3) 11907 (32.7) 5698 (38.4) 5417 (43.1)   p < 0.001 
Any pain that interfered with work/housework 100490 (47.2)   61739 (40.5) 18973 (53.3) 9861 (66.4) 9917 (80.1)   p < 0.001 
Number of reported/treated chronic conditions                           
     None 125484 (57.5)   105590 (68.2) 13645 (41.8) 4001 (29.3) 2248 (19.2)   p < 0.001 
     1 condition 39398 (19.5)   24686 (17.3) 8577 (25.1) 3574 (25.1) 2561 (21.4)   p < 0.001 
     2 conditions 22825 (11.2)   11912 (8.2) 5661 (16.2) 2832 (20.0) 2420 (20.0)   p < 0.001 
     3+ conditions 23844 (11.7)   9149 (6.3) 6000 (16.9) 3818 (25.6) 4877 (39.4)   p < 0.001 
Specific types of reported/treated chronic 
conditions 
                          
     Hypertension 58607 (27.7)   30198 (20.0) 14065 (38.6) 7260 (48.6) 7084 (56.4)   p < 0.001 
     Congestive heart failure 1629 (0.8)   612 (0.4) 378 (1.0) 273 (1.7) 366 (2.9)   p < 0.001 
     Coronary artery disease 9746 (5.0)   3679 (2.7) 2531 (7.5) 1565 (10.8) 1971 (16.0)   p < 0.001 
     Cardiac arrhythmias 5681 (3.2)   2296 (1.8) 1468 (4.8) 927 (7.0) 990 (8.8)   p < 0.001 
     Hyperlipidemia 43545 (22.2)   22124 (16.0) 10385 (30.6) 5436 (38.4) 5600 (46.5)   p < 0.001 
     Stroke 3381 (1.6)   1389 (0.9) 753 (2.0) 538 (3.4) 701 (5.8)   p < 0.001 
     Arthritis 14210 (7.4)   5725 (4.3) 3295 (9.8) 2162 (15.5) 3028 (25.2)   p < 0.001 
     Asthma 12041 (5.8)   5638 (3.8) 2587 (7.4) 1614 (10.6) 2202 (17.3)   p < 0.001 
     Cancer 10795 (6.3)   5179 (4.4) 2696 (9.2) 1458 (11.2) 1462 (13.1)   p < 0.001 
     Chronic kidney disease 169 (0.07)   57 (0.03) 41 (0.10) 21 (0.1) 50 (0.4)   p < 0.001 
     Chronic obstructive pulmonary disease 11438 (6.1)   5319 (4.0) 2468 (7.6) 1505 (10.8) 2146 (17.9)   p < 0.001 
     Dementia, Alzheimer’s, and other senile 
dementias) 
1185 (0.5)   419 (0.2) 261 (0.6) 211 (1.4) 294 (2.2)   p < 0.001 
     Diabetes 24671 (10.6)   13065 (7.9) 5456 (13.7) 2963 (18.1) 3187 (23.8)   p < 0.001 







     Human immunodeficiency virus (HIV) 493 (0.2)   202 (0.1) 102 (0.2) 67 (0.4) 122 (0.8)   p < 0.001 
     Osteoporosis 3443 (1.8)   1586 (1.2) 864 (2.6) 468 (3.3) 525 (4.2)   p < 0.001 
Region of residence                           
     Northeast 32740 (18.0)   23027 (18.0) 5596 (19.1) 2309 (18.2) 1808 (15.4)   p = 0.006 
     Midwest 41728 (22.1)   28170 (21.3) 7463 (23.6) 3236 (23.9) 2859 (25.2)   p < 0.001 
     South 81078 (37.1)   57684 (36.8) 12835 (36.6) 5609 (38.2) 4950 (39.8)   p = 0.001 
     West 56005 (22.8)   42456 (24.0) 7989 (20.8) 3071 (19.7) 2489 (19.5)   p < 0.001 
a: Measured in rounds 1/3 (baseline)           d: unweighted frequency.           
b: p-value for differences in the variable across categories of medications with side 
effects. 
e: weighted prevalence or mean. 
        




















Table 6. Adjusted Linear Least-Squared and Logit Regressions of Mental Health on Medication Use for Adults Aged 25-84. 
Data Source: MEPS 2004-2015. 
  (1) (2)   (3) (4) (5) (6) (7) (8)   (9) 
  




























OR       
(SE) 
  
OR            
(SE) 
OR            
(SE) 
OR            
(SE) 
OR            
(SE) 
OR            
(SE) 
OR            
(SE) 
  
OR            
(SE) 
Number of medications WITH any insomnia, depression, suicidal, or anxiety side effects at baseline b     
None (reference)                       
















  1.334*** 
(0.052) 
















  1.598*** 
(0.083) 
















  1.987*** 
(0.121) 
Number of medications WITHOUT any insomnia, depression, suicidal, or anxiety side effects at baseline b 
None (reference)                       
















  1.043 
(0.042) 
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(0.051) 
















  0.935 
(0.049) 







Mean outcome 3.301 0.049   0.074 0.035 0.048 0.057 0.028 0.032   0.050 
No. of persons 211,551 211,551   211,551 211,551 211,551 211,551 211,551 211,551   211,551 
Note: * p<0.05, ** p<0.01, *** p<0.001                   
All analyses control for changes in the number of medications with and without side effects consumed between round 1 and round 2 (for those in the 
first year of their panel) and between round 3 and round 4 (for those in the second year of their panel), race/ethnicity, gender, age and age squared, 
marital status, education, poverty, health insurance coverage, obesity, number of chronic conditions, whether had any pain that interfered with normal 
work outside the house or housework in the past 4 weeks, year and region fixed-effects. 
a: Measured in round 2 for those in the 1st year of their panel, and round 4 for those in the 2nd year.     




















Table 7. Adjusted Logit and Two-Part Model Regressions of Utilization/Cost of Mental Health Services on Medication Use for 
Adults Aged 25-84. Data Source: MEPS 2004-2015. 
  (1) (2) (3) (4) (5) (6) (7) (8) 
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Number of medications WITHOUT any insomnia, depression, suicidal, or anxiety side effects at baseline b   
None (reference)                 






















































                  
Mean outcome 0.045 0.158 76.465 0.050 0.040 0.022 0.017 0.012 
No. of persons 211,551 211,551 211,551 211,551 211,551 211,551 211,551 211,551 
Note: * p<0.05, ** p<0.01, *** p<0.001 
All analyses control for changes in the number of medications with and without side effects consumed between round 1 and round 2 (for those 
in the first year of their panel) and between round 3 and round 4 (for those in the second year of their panel), race/ethnicity, gender, age and age 
squared, marital status, education, poverty, health insurance coverage, obesity, number of chronic conditions, whether had any pain that 
interfered with normal work outside the house or housework in the past 4 weeks, year and region fixed-effects. 
a: Measured in round 2 for those in the 1st year of their panel, and round 4 for those in the 2nd year. 



















Table 8. Adjusted Linear Least-Squared and Logit Regressions of Mental Health on Medication Use for Adults Aged 25-84 
With at Most One Chronic Condition. Data Source: MEPS 2004-2015. 
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  1.392*** 
(0.069) 
















  1.745*** 
(0.118) 
















  2.249*** 
(0.184) 
Number of medications WITHOUT any insomnia, depression, suicidal, or anxiety side effects at baseline b 
None (reference)                       
















  1.072 
(0.051) 
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(0.072) 
                        







No. of persons 164,882 164,882   164,882 164,882 164,882 164,882 164,882 164,882   164,882 
Note: * p<0.05, ** p<0.01, *** p<0.001 
                  
All analyses control for changes in the number of medications with and without side effects consumed between round 1 and round 2 (for those in the 
first year of their panel) and between round 3 and round 4 (for those in the second year of their panel), race/ethnicity, gender, age and age squared, 
marital status, education, poverty, health insurance coverage, obesity, number of chronic conditions, whether had any pain that interfered with normal 
work outside the house or housework in the past 4 weeks, year and region fixed-effects. 
a: Measured in round 2 for those in the 1st year of their panel, and round 4 for those in the 2nd year.     





















Table 9. Adjusted Logit and Two-Part Model Regressions of Utilization/Cost of Mental Health Services on Medication Use for 
Adults Aged 25-84 With at Most One Chronic Condition. Data Source: MEPS 2004-2015. 
  (1) (2) (3) (4) (5) (6) (7) (8) 
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Number of medications WITHOUT any insomnia, depression, suicidal, or anxiety side effects at baseline b 
None (reference)                 






















































                  
Mean outcome 0.038 0.137 59.606 0.039 0.031 0.016 0.012 0.009 
No. of persons 164,882 164,882 164,882 164,882 164,882 164,882 164,882 164,882 
Note: * p<0.05, ** p<0.01, *** p<0.001 
All analyses control for changes in the number of medications with and without side effects consumed between round 1 and round 2 (for those 
in the first year of their panel) and between round 3 and round 4 (for those in the second year of their panel), race/ethnicity, gender, age and 
age squared, marital status, education, poverty, health insurance coverage, obesity, number of chronic conditions, whether had any pain that 
interfered with normal work outside the house or housework in the past 4 weeks, year and region fixed-effects. 
a: Measured in round 2 for those in the 1st year of their panel, and round 4 for those in the 2nd year. 


















Table 10. Adjusted Linear Least-Squared and Logit Regressions of Mental Health on Medication Use for Adults Aged 25-84 
Without Mental Disorders at Baseline. Data Source: MEPS 2004-2015. 
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  1.341*** 
(0.057) 
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(0.099) 
















  2.024*** 
(0.161) 
Number of medications WITHOUT any insomnia, depression, suicidal, or anxiety side effects at baseline b 
None (reference)                       
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(0.045) 
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(0.059) 
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(0.058) 
                        







No. of persons 176,362 176,362   176,362 176,362 176,362 176,362 176,362 176,362   176,362 
Note: * p<0.05, ** p<0.01, *** p<0.001 
                  
All analyses control for changes in the number of medications with and without side effects consumed between round 1 and round 2 (for those in the 
first year of their panel) and between round 3 and round 4 (for those in the second year of their panel), race/ethnicity, gender, age and age squared, 
marital status, education, poverty, health insurance coverage, obesity, number of chronic conditions, whether had any pain that interfered with normal 
work outside the house or housework in the past 4 weeks, year and region fixed-effects. 
a: Measured in round 2 for those in the 1st year of their panel, and round 4 for those in the 2nd year.     





















Table 11. Adjusted Logit and Two-Part Model Regressions of Utilization/Cost of Mental Health Services on Medication Use 
for Adults Aged 25-84 Without Mental Disorders at Baseline. Data Source: MEPS 2004-2015. 
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Number of medications WITHOUT any insomnia, depression, suicidal, or anxiety side effects at baseline b 
None (reference)                 






















































                  
Mean outcome 0.045 0.158 76.465 0.050 0.040 0.022 0.017 0.012 
No. of persons 176,362 176,362 176,362 176,362 176,362 176,362 176,362 176,362 
Note: * p<0.05, ** p<0.01, *** p<0.001 
All analyses control for changes in the number of medications with and without side effects consumed between round 1 and round 2 (for 
those in the first year of their panel) and between round 3 and round 4 (for those in the second year of their panel), race/ethnicity, gender, 
age and age squared, marital status, education, poverty, health insurance coverage, obesity, number of chronic conditions, whether had any 
pain that interfered with normal work outside the house or housework in the past 4 weeks, year and region fixed-effects. 
a: Measured in round 2 for those in the 1st year of their panel, and round 4 for those in the 2nd year. 


















Table 12. Adjusted Linear Least-Squared and Logit Regressions of Mental Health on Medication Use for Adults Aged 25-84 
With Mental Disorders at Baseline. Data Source: MEPS 2004-2015. 
  (1) (2)   (3) (4) (5) (6) (7) (8)   (9) 
  




























OR       
(SE) 
  
OR            
(SE) 
OR            
(SE) 
OR            
(SE) 
OR            
(SE) 
OR            
(SE) 
OR            
(SE) 
  
OR            
(SE) 
Number of medications WITH any insomnia, depression, suicidal, or anxiety side effects at baseline b     
None (reference)                       
















  1.164 
(0.121) 
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(0.173) 
















  1.837*** 
(0.249) 
Number of medications WITHOUT any insomnia, depression, suicidal, or anxiety side effects at baseline b 
None (reference)                       
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(0.092) 
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(0.104) 
















  1.016 
(0.098) 







Mean outcome 6.656 0.170   0.199 0.116 0.158 0.163 0.094 0.109   0.075 
No. of persons 35,189 35,189   35,189 35,189 35,189 35,189 35,189 35,189   35,189 
Note: * p<0.05, ** p<0.01, *** p<0.001 
                  
All analyses control for changes in the number of medications with and without side effects consumed between round 1 and round 2 (for those in the 
first year of their panel) and between round 3 and round 4 (for those in the second year of their panel), race/ethnicity, gender, age and age squared, 
marital status, education, poverty, health insurance coverage, obesity, number of chronic conditions, whether had any pain that interfered with normal 
work outside the house or housework in the past 4 weeks, year and region fixed-effects. 
a: Measured in round 2 for those in the 1st year of their panel, and round 4 for those in the 2nd year.     




















Table 13. Adjusted Logit and Two-Part Model Regressions of Utilization/Cost of Mental Health Services on Medication Use 
for Adults Aged 25-84 With Mental Disorders at Baseline. Data Source: MEPS 2004-2015. 
  (1) (2) (3) (4) (5) (6) (7) (8) 
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Number of medications WITHOUT any insomnia, depression, suicidal, or anxiety side effects at baseline b 























































                  
Mean outcome 0.232 0.810 360.470 0.206 0.167 0.101 0.084 0.069 
No. of persons 35,189 35,189 35,189 35,189 35,189 35,189 35,189 35,189 
Note: * p<0.05, ** p<0.01, *** p<0.001 
All analyses control for changes in the number of medications with and without side effects consumed between round 1 and round 2 (for 
those in the first year of their panel) and between round 3 and round 4 (for those in the second year of their panel), race/ethnicity, gender, age 
and age squared, marital status, education, poverty, health insurance coverage, obesity, number of chronic conditions, whether had any pain 
that interfered with normal work outside the house or housework in the past 4 weeks, year and region fixed-effects. 
a: Measured in round 2 for those in the 1st year of their panel, and round 4 for those in the 2nd year. 








Figure 3: Association Between Baseline Medications with Side Effects and K6 Score 











Figure 4: Association Between Baseline Medications with Side Effects and Mental 












Figure 5: Association Between Baseline Medications with Side Effects and Whether 











Figure 6: Association Between Baseline Medications with Side Effects and Whether 











Figure 7: Association Between Baseline Medications with Side Effects and Whether 
Used More Psychotropic Medications for Treatment of Mental Disorders at Follow-










Figure 8: Association Between Baseline Medications with Side Effects and Changes 












Figure 9: Association Between Baseline Medications with Side Effects and Changes 
















This dissertation investigated the causes and health consequences of polypharmacy. In 
the first chapter, I provided strong evidence that while the expansion of Medicare Part D 
increased access to affordable and life-saving medications for older adults, it had a 
substantial impact on polypharmacy. An increase at this margin introduced a potential 
moral hazard, given that the additional research conducted in my dissertation showed 
significant adverse effects for emotional and cognitive well-being associated with 
polypharmacy. To the extent that these results are generalizable to other health insurance 
programs, expanding Medicaid under the Affordable Care Act in 2014 or implementing a 
Medicare-for-All program might produce similar effects on polypharmacy. Therefore, 
policies that reduce polypharmacy by promoting proper prescribing practices following 
an insurance expansion program can potentially alleviate adverse medical outcomes 
associated with polypharmacy. In the second chapter, I showed that the concurrent use of 
three or more medications with cognitive impairment side effects among U.S. older 
adults increased three-fold in the past two decades. Further, I found that concurrent use of 
three or more of these medications was associated with reductions in the global cognitive 
score, performance on the word learning and recall assessment, and performance on the 
digit symbol substitution assessments. In contrast, medications without known cognitive 
side effects were not associated with a decline in cognitive function. Finally, in my third 
chapter, I assessed trends in the use of medications with mental health side effects and 
their consequences for mental health and the use/costs of mental health services. My 




medications among U.S. adults in the past two decades. I also found that the concurrent 
use of mediations with mental health side effects was associated with an increase in 
psychiatric symptoms and the use/costs of mental health services. Patterns in medication 
use observed in the second and third chapters were potentially due to overconfidence in 
medicine as a solution to disease, a focus on single disease outcomes rather than 
comorbidity, and the spillover effect of treating chronic physical disease to mental 
disease. The results also highlighted the impact of polypharmacy. The most significant 
side effects documented in this dissertation were limited to individuals taking three or 
more medications with cognitive or mental health side effects. Polypharmacy may 
present unique risks for side effects, amplifying the effects of each of the medications in a 
set. Further, polypharmacy also increases the risk of drug-drug interactions that may lead 
to adverse cognitive and psychiatric disorders.  
 
Given the growing prevalence of polypharmacy and its adverse consequences on 
population health, it is important to understand how people are initially exposed to 
medication use and polypharmacy, and how the overuse of medications can potentially 
lead to larger social problems. In this chapter, I use the theoretical frameworks of 
medicalization and pharmaceuticalization to better understand the potential causes of 
polypharmacy and the increasing use of medications with cognitive and mental health 
side effects. Medicalization is a process in which previously non-medical problems are 
defined as illnesses or disorders, and are treated using medical interventions (Conrad, 
1992). Pharmaceuticalization is defined as “the process by which social, behavioural or 




doctors or patients” (Abraham, 2010b). Despite the overlap, there are marked differences 
between two theories (Abraham, 2010b). Although medicalization increases patients’ 
exposure to medical interventions, the treatment does not necessarily involve the use of 
prescription medications. Moreover, some medications can be used to treat established 
medical conditions, without transforming a non-medical problem to a medical one. In 
addition, whereas studies on medicalization focus on the interactions between physicians 
and patients when defining an illness, they pay less attention to the increasingly important 
role of the pharmaceutical industry in shaping and influencing medical treatments 
(Conrad & Leiter, 2004). Although these agents remain unchanged under both theoretical 
frameworks (i.e. physicians, patients, and the pharmaceutical industry), the key player is 
different. Guided by these two interrelated theories, I first demonstrate the extent to 
which physicians, the pharmaceutical industry, and patients contribute to the rise in 
medication use. I then examine how the processes of medicalization and 
pharmaceuticalization vary across subgroups in the population, resulting in disparities in 
medication use. Finally, I discuss the implication of disparities in medication usage 
across subgroups for population-level health disparities.  
 
The roles of medicalization and pharmaceuticalization in increased medication use 
Physicians. Prior studies have emphasized the ways that medical professionals organized 
to create demand in order to generate new markets for their services (Larson & Larson, 
1979). In order to achieve professional dominance, it was crucial for medical 
professionals to become major players in the social construction of disease, including 




traced back to the medicalization of menopause in the 1930s and 1940s (Bell, 1987). A 
small number of elite physicians created a medical vocabulary for menopause and used it 
to define menopause as a deficiency disease instead of a normal process of aging 
(Moynihan, 2002). As a result, it was recommended that all menopausal women, not just 
some women, should consult physicians for appropriate treatment, making menopause a 
medical problem. The medicalization of menopause was successful in part due to the 
approval and availability of a new estrogen medication in 1938 (Bell, 1987). As a result, 
estrogen sales doubled and tripled in the mid-1960s and 1970s (Stefanick, 2005). By 
2000, approximately 25% of women aged 40 and older were current estrogen therapy 
users (Brett & Reuben, 2003). While estrogen therapy can resolve symptoms of 
menopause and lower the risk of osteoporosis, they can also increase the risks of 
depression, suicide, and anxiety, as demonstrated in the third chapter of this dissertation. 
In fact, almost half of prescription medications with depression as a common or serious 
side effect are hormone/estrogen therapies (Qato et al., 2018). In some additional 
analyses not presented in this dissertation, I found that women were more likely to use 
medications with depression or suicide as potential side effects and were more likely to 
experience polypharmacy than men, in part due to their frequent consumption of 
hormone/estrogen medications. The dominant role of medical professionals in defining 
disease has also been documented in other historical examples of mental illness, 
alcoholism, opiate addiction, homosexuality, hyperactivity, delinquency, and crime 
(Conrad, 2005; Conrad & Schneider, 2010; Moynihan, 2002). Although advances in 




preserve the central role of physicians in pushing the boundaries of disease as wide as 
possible to expand markets for their services. 
 
Pharmaceutical industry. Although previous analyses of medicalization designated 
physicians as the key drivers of the social construction of disease, recent studies of 
pharmaceuticalization have increasingly focused on the pharmaceutical industry 
(Abraham, 2010a; Conrad, 2005). Part of this shift was due to recent changes in the 
organization of medical care – including the introduction of managed care, the emphasis 
on consumer advocacy and accountability, and the advancement of pharmaceutical 
innovations (Abraham, 2010a; Conrad, 2005). Studies found that the pharmaceutical 
industry drove the process of pharmaceuticalization mainly through three channels, 
including (1) pharmaceutical detailing, (2) direct-to-consumer advertising, and (3) 
marketing diseases (Conrad, 2005; Conrad & Leiter, 2004; Williams et al., 2011). First, 
while pharmaceutical marketing varies widely in types, more than half of marketing 
expenditure directly targets physicians through detailing (Campbell, 2009). Aggressive 
detailing efforts from pharmaceutical representatives have resulted in almost 94% of 
physicians having some type of financial ties to the industry, most of which are by ways 
of free meals or gifts at the workplace (Campbell et al., 2007). Using various sources of 
exogenous shocks such as detailing regulations, drug patent expirations, or the migration 
of patients, prior studies have established a robust and positive association between 
receiving detailing payments and the quantity of drugs prescribed (Carey et al., 2017; 
Grennan et al., 2018; Manchanda & Honka, 2005; Spurling et al., 2010). Physicians with 




name medications that are clinically equivalent to other more-affordable or generic 
substitutes (Greenway & Ross, 2017). Second, the rise in direct-to-consumer advertising 
(DTCA) of prescription medications in the U.S. has generated a controversial debate on 
the extent to which DTCA has substantial effects on consumer behavior. Following a 
policy change that relaxed restrictions on DTCA in 1997, spending on DTCA has 
increased from $150 million in 1993 to $6 billion in 2016 (Dave, 2013; Schwartz & 
Woloshin, 2019). While DTCA may drive demand for expensive pharmaceutical 
treatments despite the clinical effectiveness of other existing alternatives (market 
stealing), it can also increase pharmaceutical usage and spending by getting undiagnosed 
individuals to doctor’s office (market expansion). A handful of studies supported the 
effects of DTCA on market expansion (Bradford et al., 2006; Iizuka & Jin, 2005; 
Rosenthal et al., 2003) rather than market stealing (Dave, 2013; Wosinska, 2002), 
implying that DTCA tends to increase individuals’ exposure to pharmaceutical therapies. 
Third, pharmaceutical companies are not just advertising medication, but are also selling 
sickness by reframing disease as having a pharmaceutical solution and by promoting the 
use of medication for non-medical purposes. Using a case study of erectile dysfunction, 
Lexchin (2006) demonstrated how Pfizer – one of the world’s largest pharmaceutical 
companies – turned Viagra from an effective product for erectile dysfunction due to 
organic causes, such as diabetes or prostate surgery, to a legitimate lifestyle medication14 
for almost all men. Pfizer redefined the prevalence and psychological effects of erectile 
dysfunction by extrapolating results from a non-nationally-representative study to argue 
that more than half of men aged 40 and older experienced erectile dysfunction and that 
 




erectile dysfunction led to psychological distress (Lexchin, 2006). By convincing men 
that Viagra should be the first choice of therapy for any degree of erectile dysfunction, 
regardless of the patient’s age or the sources of the problem, Pfizer pharmaceuticalized a 
normal process of aging and turned it to a medical condition that required pharmaceutical 
interventions. Prior studies have also documented similar marketing strategies for the 
cases of restless leg syndrome (Woloshin & Schwartz, 2006), excessive sleepiness 
(Kroll‐Smith, 2003), or male pattern baldness (Moynihan, Heath, & Henry, 2002). Taken 
together, aggressive marketing strategies employed by the pharmaceutical industry – 
either through detailing physicians, direct-to-consumer marketing, or redefining disease – 
can potentially contribute to patients’ reliance on medications and increase the risk of 
polypharmacy. While the pharmaceutical industry has increasingly become an important 
player in the social construction of illness, it is important to not deemphasize the role of 
physicians. In fact, physicians remain as gatekeepers to most medical resources in the 
U.S., including prescription medications. The growth of the pharmaceutical industry, if 
any, may just help physicians reinforce their ability to transform non-medical problems to 
ones that have a pharmaceutical solution. 
 
Patients. While physicians and pharmaceutical companies define or broaden the 
boundaries of illnesses to increase the demand for their services, these agents also 
respond to the markets that patients create (Conrad, 2005; Riessman, 1983). Barsky and 
Borus (1995) noted that the public’s tolerance for mild symptoms and the threshold at 
which patients seek medical interventions have lowered in recent decades. 




no pathophysiological explanation or organic causes (Burton, 2003; Escobar et al., 2010; 
olde Hartman et al., 2009). These patients tend to overuse medical care, have higher 
medical expenditures, and undergo unnecessary procedures (Barsky et al., 2005). Using 
an example of sleeplessness, Moloney et al. (2011) reported that the number of office 
visits that involved complains for sleeplessness had more than doubled between 1993 and 
2007 from 2.7 million to 5.7 million. In response, the diagnosis of sleeplessness and the 
prescription of nonbenzodiazepine sedative hypnotics increased by 7.6-fold and 30-fold, 
respectively (Moloney et al., 2011). As such, complains about mild symptoms in part 
contribute to the medicalization of physical distress in which uncomfortable bodily states 
are considered disease that require medical or pharmaceutical interventions.  
 
The roles of medicalization and pharmaceuticalization in medication use disparities 
Although the processes of medicalization and pharmaceuticalization might have 
significantly contributed to the rise in medication use and polypharmacy, these processes 
did not affect every individual equally. For instance, women’s bodies were more 
vulnerable to medicalization and pharmaceuticalization than men’s bodies due to normal 
bodily conditions such as childbirth, premenstrual syndrome, and menopause (Bell, 1987; 
Riessman, 1983). As a result, women are more likely to consume prescription 
medications and are at a higher risk of polypharmacy than men (Kantor et al., 2015). In 
the second and third chapters of this dissertation, I found that women were more likely 
than men to use medications that have cognitive impairment and mental health side 
effects. Many medications with these side effects were estrogen or hormone therapies, 




(Bell, 1987). In addition, there are substantial racial/ethnic disparities in the use of 
prescription medications and polypharmacy (Han & Liu, 2005; Kantor et al., 2015; Wang 
et al., 2007). While a majority of studies attributed the racial/ethnic gap in medication use 
to unequal access to health care and socioeconomic status (Wang et al., 2007), a growing 
literature focuses on minority patients’ reluctance to medicalization and 
pharmaceuticalization as a reason for racial/ethnic disparities in medication use (Adams 
et al., 2018; Gaskin et al., 2006; Schnittker, 2003). One study has shown that minority 
patients are more likely than non-Hispanic White patients to have concerns about the side 
effects of diabetes-related medications and the potential reliance on medication, and are 
more reluctant to adding more medications to their treatment plans (Huang et al., 2009). 
Similarly, the use of clozapine – the first-choice medication for refractory illness – is 
significantly lower among Hispanic and non-Hispanic Black patients, compared to non-
Hispanic Whites, in part due to concerns about serious side effects of the medication such 
as loss of white blood cells or instabilities of serum glucose levels (Copeland et al., 
2003). Schnittker (2003) found that neither socioeconomic status, knowledge, religion, 
nor trust in medicine explained black patients’ reluctance against the use of psychiatric 
medications, but rather their concerns towards serious side effects and efficacy of these 
medications. Minorities who are resistant to pharmaceuticals tend to adopt 
complementary and alternative medicine or healthy lifestyle changes, especially among 
less acculturated minorities (Adams et al., 2018). Therefore, even though medicalization 
and pharmaceuticalization might have increased the dependence on pharmaceutical 





Implications for population-level health disparities 
Disparities in medication use – either due to the heterogeneous effects of medicalization 
and pharmaceuticalization or other factors such as disparities in access to health care or 
socio-demographic status – can have substantial implications for population-level health 
disparities. On the one hand, medication underuse may lead to medical complications 
associated with undertreatment. For example, the underuse of diabetes-related 
medications among minority patients may in part explain for their higher rates of 
diabetes-related complications relative to non-Hispanic White patients (Huang et al., 
2009), such as renal disease, retinopathy, blindness, amputations, amputation-related 
mortality, and diabetes-related mortality (Carter et al., 1996; Emanuele et al., 2005; 
Harris et al., 1998; Lanting et al., 2005; Lustman et al., 2000; National Center for Health 
Statistics, 2008). Similarly, women’s and minorities’ underuse and non-adherence of 
medications for prevention of cardiovascular disease (Lewey et al., 2013; Qato et al., 
2010), despite growing evidence for their effectiveness (Weisman & Graham, 2002), may 
contribute to marked gender and racial/ethnic disparities in cardiovascular disease (Davis 
et al., 2007; Mensah et al., 2005; Qato et al., 2010; Sheifer et al., 2000).  
On the other hand, minorities’ resistance from medication usage, relative to non-Hispanic 
Whites, may have protective effects against certain medication side effects and may help 
explain for their lower prevalence of medical conditions associated with medication side 
effects. For instance, social scientists have found it difficult to explain the racial/ethnic 
paradox in mental health: that minorities often report better mental health than non-




mental health (Budhwani et al., 2015; McGuire & Miranda, 2008). Enormous efforts 
have attempted to uncover the sources of this paradox, including socioeconomic status, 
discrimination, social networks, and religious involvement – and for the most part – have 
been unsuccessful. Schnittker and Do (2020) argue that the minority paradox in mental 
health is in part rooted in the disparity of medication use: the more frequent use of 
medications with depression or suicidal side effects among the non-Hispanic White 
population helps explain its higher rates of psychiatric symptoms than that of minorities. 
In addition, the use of medications with side effects may also be related to the migration 
paradox in mental health. The paradox implies that migrants, especially newly arrived 
migrants, often report fewer psychiatric symptoms than native-born Americans, despite 
numerous theories suggesting their disadvantages (Budhwani et al., 2015; Foo et al., 
2018). In a preliminary analysis using the National Health and Nutrition Examination 
Survey (NHANES), I found that migrants were less likely to use medications with 
depression and suicide as side effects than native-born Americans. In analytic models that 
controlled for the use of these medications, the migrant disparity in depression was 
reduced to statistical insignificance. In addition, I found that pharmaceutical acculturation 
plays an important role in the relationship between medication usage and the migrant 
disparity in health. As migrants come to resemble the pharmaceutical culture in the U.S. 
and consume more medications with depressive or suicidal side effects, their reported 
prevalence of depressive symptoms increases and becomes similar to that of the native-
born population. Moreover, the use of medication with depression or suicidal side effects 
can also help explain the gender disparities in mental health. In additional analyses not 




women, relative to men, can be partially explained by the use of medications with 
depression and suicidal side effects. More than half of these medications are estrogen or 
hormone therapies that resulted from the medicalization of menopause in the 1930s and 
1940s (Bell, 1987; Qato et al., 2018). Collectively, these findings suggest a new 
explanation for differences in health outcomes: that much can be explained by the side 
effects of commonly used medications. 
 
Conclusion 
While the processes of medicalization and pharmaceuticalization may have improved the 
standard of medical care in the United States, they have also contributed tremendously to 
the rise in medication use and polypharmacy. These processes did not affect every 
individual equally, which in part resulted in vast disparities in medication use across 
subgroups. Although the underuse of medications among certain demographic groups 
might have led to medical complications associated with undertreatment, it also had 
protective effects against serious medication side effects. A handful of studies has 
focused on the former to explain for population-level disparities in health, whereas the 
role of medication side effect has likely been underappreciated, especially under the 
condition of polypharmacy. Therefore, the investigation of medication side effects is an 
important frontier for future social science research and could help explain important 
trends in health disparities. Moreover, conceptualizing how people are initially exposed 
to the use of medications with side effects will shed light on patterns and disparities in 
population health and speak directly to the role of broader social, economic, cultural, and 
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